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Heme Biosynthesis: Structure–Activity Studies of Murine Ferrochelatase
Zhen Shi
ABSTRACT

Ferrochelatase catalyzes the terminal step of heme biosynthesis by inserting
ferrous iron into protoporphyrin IX. The current study is aimed at understanding the
structural basis of porphyrin binding and distortion in ferrochelatase-catalyzed reaction
by functional analysis of a highly conserved active site loop motif. The loop was shown
to contact bound porphyrin based on crystallographic and molecular modelling
observations, and its role in murine ferrochelatase was assessed by random mutagenesis
and steady-state kinetic analysis.

To overcome the limitations of conventional kinetic

assay methods for ferrochelatase, a continuous assay was developed by monitoring
porphyrin fluorescence decrease using natural substrates ferrous iron and protoporphyrin
IX under anaerobic conditions. For wild-type murine ferrochelatase, the assay yielded
KmPPIX of 1.4 μM, KmFe2+ of 1.9 μM and kcat of 4.0 min-1 at 30 oC. The results of random
mutagenesis indicated that all the loop residues spanning Q248-L257 tolerated functional
substitutions. While Q248, S249, G252, W256 and L257 possessed high informational
content, the other five positions contained low informational content. Selected active
loop variants exhibited kcat comparable to or higher than that of wild-type enzyme, while
KmPPIX was increased in most variants. The kcat/KmPPIX remained largely unchanged, with

ix

the exception of a 10-fold reduction in variant K250M/V251L/W256Y.

Molecular

modeling of the active loop variants suggested that loop mutations resulted in alterations
of the active site architecture.

Distortion of porphyrin substrate, a crucial step in

ferrochelatase-catalyzed metal chelation, was examined using resonance Raman
spectroscopy. The results revealed that both wild-type enzyme and loop variants induced
saddling of substrate protoporphyrin. Further, loop mutations generally interfered with
porphyrin

saddling,

with

the

least

deformation

observed

in

variant

K250M/V251L/W256Y.
N-alkyl

porphyrins

are

potent

competitive

inhibitors

of

mammalian

ferrochelatase. The present study showed that while N-methyl protoporphyrin strongly
inhibited the wild-type enzyme with an inhibition constant in the nanomolar range, it was
less effective in inhibiting variants P255R and P255G.

These results suggest that

inhibitor binding may be associated with a protein conformational change mediated by
P255. Wild-type ferrochelatase is a homodimeric [2Fe-2S] cluster-containing protein.
Variants S249A/K250Q/V251C and S249A/K250R/G252W were found to retain
enzymatic activity in the absence of FeS cluster and form active, higher order oligomers.
These observations raise the possibility that FeS cluster and homodimeric organization
are not essential to ferrochelatase catalysis.

x

Chapter One

Introduction

The importance of heme in biological systems
Heme, an iron-containing macrocyclic tetrapyrrole compound, serves a wide
range of important physiological functions in many organisms including oxygen
transport, electron transfer, detoxification, metabolite production, biological sensing and
signal transduction. In hemoglobin and myoglobin the heme prosthetic group acts as an
oxygen carrier which is crucial to gas transport and exchange in blood and tissues
(Hardison 1996; Wittenberg and Wittenberg 2003). Interestingly, hexacoordinated heme
has been found in the newly identified vertebrate globins including neuronal specific
neuroglobin and ubiquitously expressed cytoglobin (Pesce et al. 2002). The primary
function of neuroglobin has been thought to promote heme-mediated O2 diffusion into
mitochondria, which confers protection against hypoxic-ischemic attacks in neurons
(Hankeln et al. 2005). In various forms of cytochromes associated with the electron
transport chain, heme provides a redox-active metal center and thereby promotes electron
transfer in aerobic respiration and photosynthesis to increase energy production via ATP
synthesis (Rich 2003; Gray and Winkler 2005). Enzymatic activities of a diverse set of
heme monooxygenases including cytochrome P450s and nitric oxide synthase depend
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upon protein interaction with the ubiquitous cofactor heme (Poulos 2005). By supplying
catalytically active iron, heme plays an essential role in mediating electron transfer and
O2 activation to facilitate substrate oxidation (Poulos 2005). In an increasing number of
proteins the heme moiety has been shown to play a central role in biological sensing of
small molecules including O2, carbon monoxide (CO) and nitric oxide (NO), which leads
to modulation of protein activity (Rodgers 1999; Gilles-Gonzalez and Gonzalez 2005).
For instance, for mammalian neuronal heterodimeric transcription factor NPAS2BMAL1, CO binding to heme coordinated in the PAS domain of NPAS2 has been found
to inhibit DNA binding of the transactivation domain required for circadian rhythmn
regulation (Dioum et al. 2002; Uchida et al. 2005). Recently, heme has been implicated
in regulating the activity of large-conductance calcium-dependent potassium (BKCa)
channels, which control cerebral arterial smooth muscle excitability (Tang et al. 2003).
While unliganded heme binds to the protein via a conserved heme-binding motif
(CXXCH) and blocks channel activity, CO binding to heme relieved this inhibition and
thus allowing channel activation and possibly leading to vasodilation (Tang et al. 2003).
In all heme-synthesizing organisms, the heme biosynthetic pathway consists of a
series of enzymes encoded by the nuclear genes (Dailey 1997). In eukaryotes, the
enzymes and reaction intermediates of heme biosynthesis are distributed in both the
mitochondria and cytosol (Figure 1). The first committed compound in the pathway is δaminolevulinic acid (ALA) (Dailey 1997). In animals, fungi and some photosynthetic
bacteria (α-proteobacteria), ALA is generated via a four-carbon pathway (Shemin
pathway) from the condensation of glycine and succinyl-CoA catalyzed by δaminolevulinic acid synthase (ALAS) (Shemin and Russell 1953; Avissar et al. 1989). In
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Figure 1. The heme biosynthetic pathway in animal cells.
The enzymes and the subcellular distribution of the reaction intermediates in the pathway
are shown in the diagram. Adapted from (Dailey 1997).
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plants, algae, archaea and most eubacteria, ALA is synthesized using a five-carbon
pathway which starts from the C5-skeleton of glutamate and involves the action of three
enzymes (Beale et al. 1975; Kannangara et al. 1988; Frankenberg et al. 2003). Once
ALA is formed, the subsequent reactions in the pathway are common to all organisms
(Frankenberg et al. 2003). The second step involves the condensation of two ALA
molecules to form the monopyrrole porphobilinogen (PBG) catalyzed by PBG synthase.
In the third step, a linear tetrapyrrole, hydroxymethylbilane (HMB), is formed by headto-tail condensation of four PBG molecules with concomitant deamination using PBG
deaminase.

HMB is immediately cyclized by the 4th enzyme uroporphyrinogen III

synthase to form uroporphyrinogen III, the first tetrapyrrole macrocycle in the pathway.
In the 5th step, uroporphyrinogen decarboxylase catalyzes the stepwise decarboxylation of
the four acetyl side chains in uroporphyrinogen III to methyl groups to generate
coproporphyrinogen III.

Oxidative decarboxylation of coproporphyrinogen III to

protoporphyrinogen IX is catalyzed by the 6th enzyme coproporphyrinogen IX oxidase.
Subsequently, protoporphyrinogen IX is oxidized to protoporphyrin IX by the 7th enzyme
protoporphyrinogen IX oxidase. In the last step, ferrochelatase catalyzes the insertion of
iron into the protoporphyrin macrocycle to form protoheme.

In mammals, heme

biosynthesis takes place primarily in the liver and bone marrow erythroid cells (Ponka
1997). Genetic defects in the first enzyme ALAS cause aberrant iron metabolism and
associated disorders (Alcindor and Bridges 2002). Enzymatic deficiency in any one of
the steps after ALAS results in accumulation of porphyrins or porphyrin precursors and
lead to various forms of a disease state known as porphyria (Kauppinen 2005).
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In animals, plants and some bacteria, heme catabolism involves oxidative
degradation catalyzed by heme oxygenase to yield biliverdin, ferrous iron and CO
(Figure 2). Mammalian heme oxygenase is associated with biliverdin reductase in a
microsomal enzyme system, which further reduces biliverdin to bilirubin (Kutty and
Maines 1981; Maines and Gibbs 2005). The reaction catalyzed by heme oxygenase uses
molecular oxygen and requires reducing equivalents from NADPH coupled with a redox
partner, which is served by cytochrome-P450 reductase in mammals (Colas and Ortiz de
Montellano 2003) and ferredoxin in some bacteria and plants (Cornejo et al. 1998;
Wegele et al. 2004).
In mammals, heme degradation primarily occurs in the reticuloendothelial system
and hepatic cells. Heme oxygenase plays a major role in the physiological breakdown of
hemoglobin and other hemoproteins to bile pigments (Tenhunen et al. 1969; Maines and
Gibbs 2005). While the primary catabolite bilirubin is water-insoluble and potentially
toxic, conjugation of bilirubin with glucuronic acid improves water solubility and
facilitates excretion into bile (Tukey and Strassburg 2000). In patients with excessive red
cell lysis and heptobiliary diseases, bilirubin and its precursors accumulate in the serum
leading to hyperbilirubinemia, while skin deposition of excess bilirubin gives the
appearance of jaundice (Kaplan et al. 2003).

In spite of its putative cytotoxicity,

numerous studies have shown that bilirubin can elicit potent antioxidant effects providing
cellular protection against tissue injury, oxidative stress, inflammation and apoptosis
(Otterbein and Choi 2000; Sedlak and Snyder 2004; Miralem et al. 2005). The gaseous
catabolic product CO has gained much attention as a versatile paracrine and autocrine
messenger and neurotransmitter mediating diverse physiological responses such as

5

OH

α

δ

N

+

O

Heme oxygenase

N

N

N

β

Fe
N

Heme oxygenase

N

N

H2O

NADPH/O2

N

N

Fe

Fe
N

O2

N

CO

N

γ
COOH HOOC

COOH HOOC

COOH HOOC

α-meso-hydroxyheme

Heme

Verdoeme
NADPH/O2

Heme oxygenase
Fe
HOOC

HOOC

COOH

2+

COOH

Biliverdin reductase
O

N
H

N
H

H H

N
H

N
H

O

NADP

+

NADPH

Bilirubin

O

N
H

N
H

N
H

N
H

Biliverdin

Figure 2. The heme degradation pathway in mammalian cells.
The enzymes and the reaction intermediates in the pathway are shown in the diagram.
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muscle relaxation, blood vessel dilation, pain perception and anti-inflammation (Morse et
al. 2002; Boehning and Snyder 2003). Heme oxygenase has also been found to play an
important role in mammalian iron homeostasis (Poss and Tonegawa 1997). Iron released
from heme is thought to exit cells via a microsomal Fe-ATPase pump to bind to
transferrin and to enter recycling route for instance towards hemoglobin synthesis (Ferris
et al. 1999; Hentze et al. 2004). In pathogenic bacteria, heme oxygenase allows the
organism to obtain iron from acquired host heme to enable infection under low iron
conditions and protects bacteria against heme toxicity (Schmitt 1997; Zhu et al. 2000).
In the past decade, the structures of all the enzymes in the heme biosynthesis and
degradation pathways have been determined. These high resolution crystal structures
provide many opportunities to study the structural basis of the catalytic mechanism of
each enzyme and genetic diseases resulted from enzymatic deficiency. In the following
sections, recent discoveries are described in terms of structure, function, regulation and
genetic disorder associated with each of the heme biosynthetic enzymes with an emphasis
on ferrochelatase, the focus of this dissertation.

Enzymes in the heme biosynthetic pathway

Aminolevulinic acid synthase

δ-Aminolevulinic acid synthase (ALAS) (EC 2.3.1.37) is the first enzyme in the
heme biosynthetic pathway in animal cells, fungi and α-proteobacteria including
Rhodobacter, Agrobacterium, Rhizobium and Rickettsia species (Shemin and Russell
1953; Avissar et al. 1989). ALAS catalyzes the condensation of L-glycine and succinyl-
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CoA (SCoA) to form δ-aminolevulinic acid (ALA), CO2 and coenzyme A (Gibson et al.
1958; Shemin and Kikuchi 1958). The enzymatic reaction generally requires the cofactor
pyridoxal 5’-phosphate (PLP) (Nandi 1978b; 1978a; Davies and Neuberger 1979).
Bacterial ALAS is a cytosolic soluble protein consisting of ~400 residues with a
monomeric molecular mass of ~45-60 kDa (Warnick and Burnham 1971; Tait 1973;
Nandi and Shemin 1977; Davies and Neuberger 1979; Hornberger et al. 1990). In
eukaryotic cells, ALAS is nuclear-encoded, synthesized in the cytoplasm as a precursor
and translocated to the mitochondrial matrix (Whiting and Elliott 1972; Ades and Harpe
1981; Urban-Grimal et al. 1986; Ades and Stevens 1988; Munakata et al. 1993). The
transport usually involves an N-terminal leader sequence of ~60 residues, which is
cleaved proteolytically in the mitochondria (Bawden et al. 1987; Cox et al. 1991).
Additionally, a second targeting signal involving an internal hydrophobic sequence has
also been suggested (Volland and Urban-Grimal 1988). The mature form of animal and
fungal ALAS is typically present as a PLP-containing homodimer with a subunit
molecular mass of ~50-65 kDa (Whiting and Granick 1976; Volland and Felix 1984;
Ades and Friedland 1988; Ferreira and Dailey 1993).
In mammals, there are two forms of ALAS encoded by separate genes (Bishop et
al. 1981; Watanabe et al. 1983; Yamamoto et al. 1986; Riddle et al. 1989; Bishop 1990).
The housekeeping form, ALAS-1, is present in all nonerythroid cells (Watanabe et al.
1983; Yamamoto et al. 1986; Srivastava et al. 1988; Riddle et al. 1989). ALAS-1
transcription is upregulated by various hormones, porphyrinogenic drugs and xenobiotics
(de Verneuil et al. 1983a; Srivastava et al. 1988; Podvinec et al. 2004; Handschin et al.
2005), whereas product ALA inhibits ALAS-1 expression (Granick 1966; Marks et al.
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1988; Srivastava et al. 1988). Notably, mitochondrial import and maturation of ALAS-1
are inhibited by very low levels of intracellular heme (Kikuchi and Hayashi 1981; Ades
1983; Ades and Stevens 1988; Fujita et al. 1991). The inhibitory effect is mediated by
heme binding to three heme regulatory motifs (HRM) characterized by the Cys-Pro
dipeptide in the ALAS-1 N-terminal region (Zhang and Guarente 1995; Munakata et al.
2004; Dailey et al. 2005). The second isoform, ALAS-2, is only produced in developing
erythrocytes and its expression is subject to transcriptional and translational regulation
(Cox et al. 1991; Sadlon et al. 1999). Iron has long been known to stimulate ALAS-2
translation via an iron-responsive element (IRE), a stem-loop structure found in the 5’untranslated region of all the ALAS-2 transcripts (Cox et al. 1991; Dandekar et al. 1991;
Melefors et al. 1993). While binding of the iron regulatory proteins (IRP1 and IRP2) to
the IRE typically block ALAS-2 translation, this repression is relieved at high levels of
intracellular iron, and IRP1-mediated translational regulation has been shown to be
associated with FeS cluster assembly (Melefors et al. 1993; Sadlon et al. 1999;
Cooperman et al. 2005; Wingert et al. 2005).
In spite of major differences in their regulatory mechanisms, both ALAS-1 and
ALAS-2 share a highly homologous catalytic core, which consists of the C-terminal twothirds of the enzyme (Riddle et al. 1989; Cox et al. 1991; Munakata et al. 1993). In fact,
the catalytic domain of all ALASs is remarkably conserved throughout evolution with an
overall sequence identity of ~40 % from bacterial to human enzymes (Duncan et al.
1999; Astner et al. 2005). ALAS belongs to a family of PLP-dependent enzymes, which
include 8-amino-7-oxononanoate synthase (AONS), 2-amino-3-oxobutyrate CoA ligase
(KBL) and serine palmitoyl transferase (Alexander et al. 1994; Grishin et al. 1995).
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These enzymes are members of the α-oxoamine synthase family of PLP-dependent
enzymes, which catalyze C-C bond formation or cleavage between an amino acid and an
acyl-CoA substrate with release of coenzyme A and formation of an enzyme-bound 2amino-3-ketoacid intermediate (Alexander et al. 1994; Grishin et al. 1995; John 1995).
These proteins share a large number of conserved residues, exhibit homologous folding
patterns and active site geometries, and employ similar catalytic mechanisms (Alexander
et al. 1994; Grishin et al. 1995; Alexeev et al. 1998).
For ALAS, the proposed catalytic pathway involves the initial formation of a
Schiff-base between the enzyme and cofactor PLP, followed by a transimination reaction
between the enzyme-PLP complex and glycine, subsequent condensation of glycine with
succinyl-CoA, and decarboxylation of the glycinyl carboxyl group results in release of
ALA from the enzyme (Scholnick et al. 1972; Nandi 1978c). Kinetic analysis indicated
that the enzymatic reaction is initiated upon binding of the first substrate glycine to
ALAS (Fanica-Gaignier and Clement-Metral 1973; Nandi 1978c).

Glycine forms a

Schiff-base linkage with PLP to generate an external aldimine (Scholnick et al. 1972;
Nandi 1978c; Ferreira et al. 1995; Hunter and Ferreira 1999a). Subsequently the glycineALAS external aldimine is deprotonated on glycine to yield a transient quinonoid
intermediate (Nandi 1978c; Hunter and Ferreira 1999a). This complex condenses with
succinyl-CoA to convert aldimine to α-amino-β-ketoadipate (Hunter and Ferreira 1999b).
In the subsequent decarboxylation reaction, rearrangement of the α-amino-β-ketoadipate
results in the release of CO2 and a second quinonoid intermediate (Hunter and Ferreira
1999b). Protonation of the second quinonoid intermediate yields a third external ALAaldimine (Hunter and Ferreira 1999b).

In the last step, ALA is released from the
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aldimine and the holoenzyme is regenerated (Nandi 1978c; Hunter and Ferreira 1999b).
The rate-determining step appears to be product release, or a conformational change of
the enzyme associated with ALA release (Hunter and Ferreira 1999b).
This catalytic model is consistent with the recent X-ray crystal structures of
Rhodobacter capsulatus ALAS holoenzyme and substrate-enzyme complexes (ALASrc)
(Astner et al. 2005).

As expected, ALASrc bears close resemblance to the crystal

structures of AONS and KBL (Alexeev et al. 1998; Schmidt et al. 2001) and to a R.
spheroides ALAS model previously constructed by homology modeling using AONS and
KBL as templates (Shoolingin-Jordan et al. 2003b). ALAS is a symmetrical homodimer
with each monomer folded into 3 domains, all of which contribute to the dimeric
assembly. The largest domain is the central catalytic core consisting of a seven-stranded
mostly parallel β-sheet covered on both sides by nine α-helices in alternating β/α motifs.
The catalytic core provides the most extensive contribution to the dimer interface. In the
vicinity of the dimer interface lies the C-terminal domain which comprises three-stranded
antiparallel β-sheet and three α-helices. A small N-terminal domain containing a threestranded antiparallel β-sheet and an α-helix is located more distantly from the catalytic
core. The PLP cofactor is bound to the catalytic domain near the dimer interface. The
active site is proposed to be located in an interdomain cavity between the juxtaposed
catalytic domains and the C-terminal domain of the PLP-containing monomer (Astner et
al. 2005). Glycine binding occurs in this pocket, whereas succinyl-CoA binding occurs
in a channel which connects the active site to the protein exterior (Astner et al. 2005).
The active site pocket is enriched with many conserved residues, some of which have
been found previously to be necessary for catalysis (Astner et al. 2005).
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As indicated earlier (Nandi 1978c; Ferreira et al. 1993; Ferreira et al. 1995;
Hunter and Ferreira 1999a), the initial enzyme-cofactor complex involves a Schiff-base
between PLP and an invariant, catalytically-essential lysine residue. PLP-binding is
stabilized by residues from both monomers (Astner et al. 2005). Consistent with a
common observation among many PLP-dependent enzymes, the electron withdrawl
capacity of PLP appears to be enhanced by hydrogen-bonding between its pyridinium
ring and an adjacent conserved aspartate residue; this hydrogen-bond facilitates PLP to be
held in the active site while the initial PLP-lysine Schiff-base linkage is replaced with a
new Schiff-base between PLP and substrate glycine (Gong et al. 1998; Hunter and
Ferreira 1999a).

In the enzyme-glycine complex, initial binding and orientation of

glycine is shown to involve a salt bridge between the glycine carboxylate group and a
conserved arginine, which is consistent with a previous study (Tan et al. 1998).
Succinyl-CoA binds to a hydrophobic pocket near the protein surface in an extended
conformation, and a conserved glycine-rich interface loop appears to be crucial in
positioning the succinate carboxylate group as proposed previously (Gong et al. 1996).
Both succinyl-CoA and glycine are positioned in close proximity in the active site, which
makes it feasible for the nucleophilic attack of the succinyl-CoA CS1 by the glycine Cα
atom in the first quinonoid intermediate to generate a new C−C bond (Astner et al. 2005).
In mammals, enzymatic deficiency in the erythroid isozyme ALAS-2 leads to Xlinked sideroblastic anemia (XLSA), an X chromosome-linked hypochromic and
microcytic anemia characterized by the presence of ring sideroblasts in the bone marrow
(Cotter et al. 1992; Bottomley et al. 1995). Ring sideroblasts are erythroblasts containing
iron-laden mitochondria which are generated in response to disrupted heme synthesis
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(Alcindor and Bridges 2002). In some patients progressive toxic accumulation of iron in
many tissues can have fatal consequences (Cotter et al. 1999). To date more than 40
mutations in human ALAS-2 have been known to cause XLSA (Astner et al. 2005).
They include frameshift mutations, nonsense mutations and a large number of missense
mutations involving nearly 40 highly conserved residues (Cotter et al. 1999; ShoolinginJordan et al. 2003b; Astner et al. 2005) Missense mutations are primarily located in the
catalytic domain and appear to directly interfere with PLP and substrate binding (Cotter
et al. 1999; Shoolingin-Jordan et al. 2003b; Astner et al. 2005). Some substitutions are
found in the hydrophobic core or on the enzyme surface and seem likely to destabilize the
protein fold (Shoolingin-Jordan et al. 2003b; Astner et al. 2005). Pyridoxine (vitamin
B6) supplementation has been shown to be an overall effective therapy for XLSA
particularly in patients with ALAS-2 mutations near the catalytic center (Cotter et al.
1999; Alcindor and Bridges 2002; Shoolingin-Jordan et al. 2003b) The treatment can be
combined with phlebotomy or iron chelation with desferrioxamine to correct ironoverloading and improve pyridoxine responsiveness (Cotter et al. 1999; Alcindor and
Bridges 2002).

Porphobilinogen synthase
The first step common to all tetrapyrrole biosynthetic pathways is catalyzed by
porphobilinogen synthase (PBGS), also known as ALA dehydratase (ALAD) (EC
4.2.1.24). PBGS catalyzes the condensation of two molecules of 5-aminolevulinic acid
(ALA) to form the monopyrrole porphobilinogen (PBG) (Nandi et al. 1968). PBG is an
essential metabolic building block which is incorporated into various tetrapyrrole
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compounds including heme, chlorophyll and cobalamin (Warren et al. 1998). From
bacteria to mammals, the amino acid sequence of

PBGS is highly conserved and

comprised of ~330 residues (Jaffe 2003). PBGS is a cytosolic enzyme and typically
exists in a large homo-octameric assembly with a subunit molecular mass of ~35-40 kDa
(Wu et al. 1974; Anderson and Desnick 1979; Gibbs et al. 1985; Spencer and ShoolinginJordan 1993). Metal ions are often found in the active site of PBGS and are commonly
required for enzymatic activity (Jaffe 2003), although metal-independent PBGS has also
been identified in some bacterial species (Bollivar et al. 2004).
The condensation reaction catalyzed by PBGS is initiated with an ordered binding
of two ALA molecules in the active site (Jaffe 2004b). The first ALA molecule binds to
the P-site in PBGS, which involves formation of Schiff-base linkage of ALA with an
active site lysine (Gibbs and Shoolingin-Jordan 1986; Jaffe 2004a). The first ALA
contributes the propionate side chain and the pyrrole nitrogen of PBG (ShoolinginJordan and Gibbs 1985; Jaffe 2004a). The second ALA binds to the A-site, giving rise to
the acetate side chain and the amino nitrogen of PBG (Shoolingin-Jordan and Gibbs
1985; Jaffe 2004a). The rate-limiting step of the overall reaction appears to be product
release or a conformational change of the enzyme that is coupled to product release (Jaffe
2004a). Interestingly, product formation has been found to occur with a half-of-the-sites
reactivity (Kundrat et al. 2003; Jaffe 2004a).
Metal ions typically serve as cofactors in the PBGS-catalyzed reaction, and metal
binding specificity is largely phylogenetically dependent (Jaffe 2004a).

In animals,

fungi, archaea and some bacteria, PBGS contains catalytic Zn2+ whose main function is
to enhance A-site binding of the second ALA substrate molecule possibly by acting as a
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Lewis acid or electrophile to react with the bound first ALA (Jaffe and Hanes 1986; Jaffe
1995; Spencer and Shoolingin-Jordan 1995; Erskine et al. 2001b; Erskine et al. 2003).
The catalytic Zn2+ is coordinated by three cysteine ligands in a conserved C-X-C-X7-C
motif (Jaffe 2003). In contrast, Mg2+ has been found in PBGS from photosynthetic
plants, algae and some bacteria (Boese et al. 1991; Jaffe 2003). At least some of the
bound Mg2+ appear to be allosteric rather than catalytic (Boese et al. 1991; Jaffe 2003).
Additionally, both Zn2+ and Mg2+ have been found to be associated with PBGS from
many plants and bacteria (Jaffe 2003).
The structure of PBGS has been determined for the enzyme from a variety of
organisms (Jaffe 2004b). To date the crystal structures are available for the enzyme from
human (Breinig et al. 2003), yeast S. cerevisiae (Erskine et al. 1997; Erskine et al. 2001b;
Erskine et al. 2003; Erskine et al. 2005), and a number of bacteria including E. coli
(Erskine et al. 1999; Kervinen et al. 2001), Pseudomonas aeruginosa (Frankenberg et al.
1999; Frere et al. 2002), and Chlorobium vibrioforme (Coates et al. 2004). PBGS, either
in an apo form or with bound inhibitor or reaction intermediate, exhibits homologous
overall fold and active site structure (Jaffe 2004b).

The holoenzyme is typically

assembled into a homo-octamer (Erskine et al. 1997; Erskine et al. 1999; Frankenberg et
al. 1999; Kervinen et al. 2001; Coates et al. 2004). The eight monomers are organized in
422 or D4 point group symmetry with the central cavity in each subunit oriented towards
the solvent. The holoenzyme is tightly packed into four pairs of “hugging” dimers, in
which one monomer extends an N-terminal arm to wrap around the adjacent monomer
(Erskine et al. 1997; Erskine et al. 1999; Frankenberg et al. 1999; Kervinen et al. 2001;
Coates et al. 2004). Each monomer adopts a (β/α)8 barrel fold characteristic of the triose
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phosphate isomerase (TIM) barrel proteins in the adolase superfamily. The active site is
located in a deep cavity in the center of the TIM barrel, while an extended loop at the
exposed end of TIM barrel forms a mobile lid to gate solvent access. Many conserved
residues are clustered in the active site cavity and have been shown to mediate substrate
binding, catalysis and active site conformational change (Erskine et al. 1997; Erskine et
al. 1999; Frankenberg et al. 1999; Kervinen et al. 2001; Coates et al. 2004).
Crystal structural analysis has provided further details in the PBGS reaction
mechanism (Jaffe 2004b). The initial step of catalysis involves Schiff-base formation of
the P-site ALA substrate with an invariant lysine located at the bottom of active site
cavity (Gibbs and Shoolingin-Jordan 1986; Erskine et al. 1997; Erskine et al. 1999;
Erskine et al. 2001b; Frere et al. 2002; Coates et al. 2004). This first step is conserved for
all of the PBGS investigated to date and does not require metal ions (Jaffe 2004b). The
next step involves the second ALA binding to A-site, which consists of a solvent-filled
hydrophilic pocket (Erskine et al. 1999; Erskine et al. 2001b). It is possible that this
ALA forms a second Schiff-base linkage with another invariant lysine in the active site
(Erskine et al. 2001a; Kervinen et al. 2001).

In Zn-dependent PBGS, this step is

facilitated by the presence of solvent-coordinated catalytic Zn2+ (Erskine et al. 1999;
Erskine et al. 2001a; Erskine et al. 2001b; Kervinen et al. 2001). It has been proposed
that active site closure is promoted by the second ALA binding (Frankenberg et al. 1999;
Kervinen et al. 2001). The final steps have been shown to proceed via a five-membered
ring intermediate held at the active site, and PBG formation and release is facilitated by
added ALA substrate (Erskine et al. 2003). Alternatively, a reciprocating motion model
suggests that a covalently bound almost-product intermediate is transferred to the
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adjacent active site, which opens the lid and releases a PBG molecule (Jaffe 2004b). This
latter hypothesis is consistent with the observation of half-site reactivity in PBGS
(Kundrat et al. 2003).
Important features of metal-binding in PBGS have also been revealed by
structural analysis (Jaffe 2003). While Zn2+-dependent PBGS requires active site Zn2+ in
catalysis, Mg-containing PBGS uses Mg2+ for allosteric regulation of enzymatic activity
(Jaffe 2003). The binding of Mg2+ has been shown to occur at a remote location near the
active site flap and is likely to play a role in stabilizing the closed lid conformation
(Frankenberg et al. 1999; Coates et al. 2004). Interestingly, an analogous allosteric
Mg2+-binding site is occupied by a second Zn2+ in E. coli PBGS, which provides a
structural explanation for the observation that Mg2+ stimulates E. coli PBGS activity
(Mitchell and Jaffe 1993; Spencer and Shoolingin-Jordan 1993; Erskine et al. 1999;
Kervinen et al. 2001). Mammalian PBGS has long been known as a target for lead
poisoning (Warren et al. 1998).

Human PBGS activity is inhibited by very low

concentrations of Pb2+ (Simons 1995) (Jaffe 2001). Structural analysis suggests that this
inhibition is caused by Pb2+ replacement of the catalytically important, tri-cysteinecoordinated Zn2+, which leads to alteration of the active site environment and thereby
interferes with substrate binding and catalysis (Jaffe et al. 2001).
Hereditary PBGS deficiency, or Doss porphyria, is the most uncommon form of
all the porphyrias (Doss et al. 1979). The disease is autosomal recessive and fewer than
10 cases have been reported to date (Maruno et al. 2001; Doss et al. 2004). Doss
porphyria belongs to the acute hepatic porphyrias with characteristic clinical features of
acute neurovisceral attacks and neuropathy (Nordmann and Puy 2002). Patients
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generally show elevated urinary excretion of ALA and coproporphyrin, which can be
used for diagnosis (Nordmann and Puy 2002; Doss et al. 2004). Only ~10 mutations in
PBGS have been associated with Doss porphyria including predominantly missense
mutations and a few frameshift mutations (Maruno et al. 2001; Doss et al. 2004). Most
patients are compound heterozygous for the genetic defects (Maruno et al. 2001; Doss et
al. 2004). Missense mutations primarily occur near the catalytic zinc-binding site or
substrate-binding site and result in markedly diminished enzymatic activity (Maruno et
al. 2001). A few substitutions are located distant from the active site and appear to
disrupt protein structure and stability (Maruno et al. 2001). Intravenous heme arginate
infusion has been shown to be an effective therapy for the disease leading to reduction of
urinary ALA and porphyrins and correction of polyneuropathy (Doss et al. 2004).

Porphobilinogen deaminase
Porphobilinogen deaminase (PBGD), also known as hydroxymethylbilane
synthase (HMBS) (E.C.4.3.1.8) catalyzes the stepwise head-to-tail condensation of four
porphobilinogens to form the linear tetrapyrrole, hydroxymethylbilane (HMB) or preuroporphyrinogen (Bogorad 1958b). PBGD contains ~310-370 residues and exhibits an
exceedingly high degree of sequence conservation with ~40% sequence identity between
the E. coli and human sequences (Brownlie et al. 1994; Louie et al. 1996). The protein is
a monomer of ~34-39 kDa (Anderson and Desnick 1980; Raich et al. 1986; Grandchamp
et al. 1987; Louie et al. 1996). In plants PBGD is localized in the plastid chloroplast
(Bogorad 1958a; Witty et al. 1996). Human PBGD is encoded by a single gene, which
contains two distinct promoters to generate housekeeping and erythroid-specific
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transcripts by alternative splicing (Grandchamp et al. 1987). This gives rise to two
isoforms of PBGD, i.e. the erythroid form and the slightly larger non-erythropoietic form
(Grandchamp et al. 1987).
An interesting feature of the PBGD catalytic mechanism is that the reaction is
primed using a dipyrromethane cofactor that the enzyme assembles from two molecules
of porphobilinogen (Hart et al. 1987; Shoolingin-Jordan and Warren 1987; Warren and
Shoolingin-Jordan 1988). The cofactor is covalently linked to a cysteine residue (Hart et
al. 1988; Miller et al. 1988). Polymerization of four PBGs is initiated by linking one
pyrrole ring to the cofactor, followed by stepwise addition of three pyrroles (Anderson
and Desnick 1980; Shoolingin-Jordan and Warren 1987; Warren and Shoolingin-Jordan
1988). This results in an enzyme-bound hexapyrrole, which is hydrolyzed to release the
tetrapyrrole product, thus regenerating the holoenzyme (Shoolingin-Jordan and Warren
1987; Warren and Shoolingin-Jordan 1988).
The three-dimensional structure of PBGD has been determined for the E. coli
enzyme (Louie et al. 1992; Louie et al. 1996; Helliwell et al. 2003).

The crystal

structures reveal a flexible multidomain polymerase with a single active site (Louie et al.
1992; Louie et al. 1996; Helliwell et al. 2003). The protein is folded into three domains
(Louie et al. 1992; Louie et al. 1996; Helliwell et al. 2003). The active site is located in a
deep interdomain cleft and contains a dipyrromethane cofactor (Shoolingin-Jordan and
Warren 1987; Warren and Shoolingin-Jordan 1988; Louie et al. 1992; Louie et al. 1996).
Domains 1 and 2 exhibit similar folds which resemble transferrins and
periplasmic binding proteins (Louie et al. 1992; Louie et al. 1996). Domain 1 contains
the substrate-binding site and is enriched with catalytically important residues (Louie et
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al. 1992). Domain 2 has most of the cofactor-binding residues providing extensive saltbridges and hydrogen-bonds to hold the cofactor within the cleft between domain 1 and
2 (Louie et al. 1992; Louie et al. 1996). Domain 3 supplies an invariant cysteine residue
which forms a covalent link with the dipyrromethane cofactor (Louie et al. 1992; Louie et
al. 1996). It also appears to shield domain 1 and 2 from solvent exposure (Louie et al.
1996). The multi-domain organization of PBGD thus provides intrinsic flexibility to the
active site to facilitate substrate entry, cofactor attachment, chain elongation and product
release (Louie et al. 1996). Many conserved residues are found in the hydrophobic core
and are important for protein stability (Brownlie et al. 1994).

Conserved residues

clustered in the active site cleft have been shown to be catalytically essential (Brownlie et
al. 1994; Louie et al. 1996). A group of conserved arginine residues have been found to
be necessary for binding and positioning of the mono- and poly-pyrrole substrates,
cofactor binding, chain elongation and product release (Lander et al. 1991; ShoolinginJordan and Woodcock 1991; Louie et al. 1992; Louie et al. 1996; Shoolingin-Jordan et al.
2003a; Solis et al. 2004). Significantly, an invariant active site aspartate residue has been
hypothesized to play a key role in facilitating substrate interaction with the cofactor
(Woodcock and Jordan 1994). The carboxylate side chain of this aspartate is found at a
position suitable for hydrogen-bonding with the pyrrole nitrogen groups of both the
cofactor and substrate and in this manner, allows stabilization of the reaction intermediate
(Louie et al. 1992; Woodcock and Jordan 1994; Louie et al. 1996).
Partial deficiency of PBGD causes one of the most common of the porphyrias,
acute intermittent porphyria (AIP) (Meyer et al. 1972; Tschudy et al. 1975). AIP is an
autosomal dominant disease with very low penetrance (Nordmann et al. 1997; Nordmann
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and Puy 2002). Patients typically have acute episodes of neuropathic symptoms, most
frequently with abdominal pains, and at times also with psychiatric manifestations
(Anderson et al. 2005). The neurovisceral attacks are often precipitated and sometimes
exacerbated by alcohol, low caloric intake, sex hormones and porphyrinogenic drugs
such as barbiturates and sulfonamides (Jover et al. 2000; Anderson et al. 2005; Fraunberg
et al. 2005). AIP is usually diagnosed by elevated concentrations of urinary porphyrin
precursors ALA and PBG during a symptomatic relapse (Tschudy et al. 1975; Anderson
et al. 2005). Neurologic impairment is often attributed to toxicity of the accumulated
porphyrin precursors including ALA, although the mechanism is still not very well
understood (Brennan et al. 1980; Lindberg et al. 1999; Solis et al. 2004).
Currently more than 240 genetic lesions in PBGD have been described for AIP
(Kauppinen 2005). They include splice site mutations, frameshifts, small insertions,
nonsense mutations, and nearly half of all, missense mutations (Brownlie et al. 1994;
Floderus et al. 2002; Nordmann and Puy 2002; Fraunberg et al. 2005). While the
molecular defects for AIP are highly heterogeneous, a few mutations have been found
with high prevalence in Sweden, Holland, Canada, Switzerland and France suggesting a
founder effect (Lee and Anvret 1991; Puy et al. 1997; Schneider-Yin et al. 2000a;
Cappellini et al. 2002; Nordmann and Puy 2002; Schneider-Yin et al. 2002). PBGD
mutations generally lead to low residual enzymatic activity, poor protein expression or
instability or retention of the enzyme-intermediate complexes (Desnick et al. 1985;
Brownlie et al. 1994; Solis et al. 2004; Fraunberg et al. 2005; Pischik et al. 2005). Many
single amino acid substitutions occur in conserved residues located in the interdomain
active site cleft and conserved hydrophobic core (Brownlie et al. 1994; Puy et al. 1997;
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Floderus et al. 2002; Shoolingin-Jordan et al. 2003a). They have been shown to disrupt
protein fold and stability, cofactor assembly, substrate binding and polypyrrole formation
and release (Brownlie et al. 1994; Puy et al. 1997; Floderus et al. 2002; ShoolinginJordan et al. 2003a).
Two conventional therapeutic methods have been found to benefit some patients
which involve high carbohydrate intake and intravenous hematin administration
(Tschudy et al. 1975; Anderson et al. 2005). Nonetheless, recurrent severe AIP attacks
are difficult to treat and can lead to high mortality rate. Liver transplantation has been
shown to be curative for some severe cases (Soonawalla et al. 2004). The first gene
therapy trial based on recombinant adenoviral transduction of functional PBGD has
successfully increased enzymatic expression in hepatic tissues and restored metabolism
of porphyrin precursors ALA and PBG in an AIP mouse model (Johansson et al. 2004).
This approach points to the potential for effective gene therapy in human AIP.

Uroporphyrinogen III synthase
The fourth enzyme in the heme biosynthetic pathway is uroporphyrinogen III
synthase (UROS) (EC 4.2.1.75). UROS catalyzes cyclization of hydroxymethylbilane
with concurrent D ring flipping to form uroporphyrinogen III (Bogorad 1958b; 1958c;
Shoolingin-Jordan et al. 1979). Uroporphyrinogen III is the first tetrapyrrole macrocycle
in the heme biosynthetic pathway and a ubiquitous precursor of all other tetrapyrrole
compounds including chlorophyll, siroheme, F430 and vitamin B12 (Schubert et al. 2002).
While non-enzymatic cyclization of HMB produces uroporphyrinogen I isomer, D ring
inversion is exclusive to the enzymatic cyclization of linear bilane (Battersby 1978).
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Asymmetry of the D ring thus serves as a hallmark of all biosynthetic porphyrins
(Battersby 1978).
From bacteria to human, UROS has been found as a small cytosolic protein
comprising ~250-300 residues (Tsai et al. 1988; Alwan et al. 1989; Mathews et al. 2001).
The protein sequence is highly diverged throughout evolution and retains only a small
number of conserved residues scattered in the central portion of the sequence. (Mathews
et al. 2001). UROS has been purified from bacteria, plant and mammals, and it is
typically present as a monomer of ~30 kDa (Higuchi and Bogorad 1975; Clement et al.
1982; Hart and Battersby 1985; Tsai et al. 1987; Shoolingin-Jordan et al. 1988; Smythe
and Williams 1988; Tsai et al. 1988; Alwan et al. 1989; Omata et al. 2004). Interestingly,
both prokaryotic and eukaryotic UROS have been shown to be extremely thermolabile
(Tsai et al. 1987; Alwan et al. 1989). For purified human erythrocyte UROS, the half life
at 37, 45, and 60 °C was around 30, 4 and 1 min, respectively (Tsai et al. 1987). E. coli
UROS was completely inactivated at 60°C in 1 min (Alwan et al. 1989). Another
interesting feature of human UROS is that although there is only a single enzyme in all
tissues, distinct housekeeping and erythroid-specific transcripts are generated by
alternative promoter elements (Aizencang et al. 2000a; Aizencang et al. 2000b). While
expression of the housekeeping form is driven by a TATA-less promoter, the erythroid
promoter contains binding sites for erythroid-specific transcription factors GATA-1 and
NF-E2 (Aizencang et al. 2000a; Aizencang et al. 2000b).
According to a widely accepted catalytic model, the reaction pathway of UROS
involves a spiro mechanism to allow D ring rearrangement (Battersby and Leeper 1990;
Leeper 1994). In this scheme, enzymatic reaction is initiated with rearranging the A ring
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of HMB to remove the C20 hydroxyl group, followed by electrophilic attack of C16 of the
D ring by C20 carbon-cation to generate a spirocyclic pyrrolenine (Battersby and Leeper
1990; Leeper 1994). This intermediate is resolved in the opposite direction yielding an
azafluvene, which cyclizes to form uroporphyrinogen III concomitant with D ring
inversion (Battersby and Leeper 1990; Leeper 1994). This model is in agreement with
the observation that UROS is inhibited by spirolactam with a Ki of 1-2 μM (Stark et al.
1986; Cassidy et al. 1991).
To date the structure of UROS has only been determined for the human enzyme
(Mathews et al. 2001). The crystal structure shows that human UROS is an elongated bilobed monomer (Mathews et al. 2001). The protein is folded into two separate domains
with similar topology and

interconnected via a two-stranded anti-parallel β-ladder

(Mathews et al. 2001). Each domain comprises a parallel β-sheet surrounded by αhelices (Mathews et al. 2001). Domain 1 contains the N- and C-terminal sequences and
belongs to a flavodoxin-like fold family, while domain 2 adopts a DNA glycosylase-like
fold (Mathews et al. 2001). The active site is proposed to be located in a large open cleft
between the two domains on the basis of structural modeling of a putative product-UROS
complex and clustering of conserved residues along the lining of the interdomain cleft
(Mathews et al. 2001). While mutational analysis indicated that the conserved residues
are not absolutely required for activity, substrate binding is thought to involve a large
number of weaker interactions in the active site and enzymatic reaction may not require
acid/base catalysis (Mathews et al. 2001). Opening and closing of the cleft appears to be
mediated, at least in part, by movement of the bridging β-ladder residues (Mathews et al.
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2001). This intrinsic flexibility of the interdomain cleft is likely to play a key role in
substrate recognition and product release (Mathews et al. 2001).
The first porphyria ever described, congenital erythropoietic porphyria (CEP), or
Gunther’s disease, is caused by enzymatic deficiency of UROS (Romeo and Levin 1969).
CEP is a rare autosomal recessive disease with variable clinical severity (Desnick and
Astrin 2002). Characteristic symptoms include severe cutaneous photosensitivity, red
urine and red teeth (Desnick and Astrin 2002). Hemolytic anemia and splenomegaly are
observed in some patients (Desnick and Astrin 2002). Cutaneous lesions often begin in
early childhood, and the disease can be fatal without treatment (Desnick and Astrin
2002). CEP is usually diagnosed by elevated concentrations of urinary uroporphyrin I
and coproporphyrin I (Desnick and Astrin 2002). The disease symptoms develop as a
result of marked decrease of UROS activity usually to <1% normal level (Desnick and
Astrin 2002). UROS deficiency leads to accumulation of hydroxymethylbilane, which
undergoes non-enzymatic conversion to yield isomer I porphyrinogens, including the
non-enzymatically cyclized uroporphyrinogen I and its decarboxylation product
coproporphyrinogen I (Desnick and Astrin 2002). Because isomer I porphyrinogens
cannot be further metabolized towards heme synthesis, they undergo autoxidation to yield
uroporphyrin I and coproporphyrin I (Desnick and Astrin 2002).

Excess type I

porphyrins are cytotoxic to the developing erythrocytes in bone marrow, cause skin
photosensitivity and give the bright red color in urine and deposited tissues (Desnick and
Astrin 2002).
To date nearly 40 mutations in UROS have been attributed to CEP pathogenesis
(Desnick and Astrin 2002). They include more than 20 missense mutations, and a small
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number of deletions, insertions, splicing defects and erythroid-specific promoter
mutations (Desnick and Astrin 2002). Most of the missense mutations occur at conserved
residues in UROS (Desnick and Astrin 2002). Only a few residues affected are mapped
close to the active site cleft, most substitutions are scattered throughout the tertiary
structure making it possible that the primary mutational effect results from disruption of
protein fold (Mathews et al. 2001). The majority of mutant enzymes are inactive or show
very low residual activity at less than 2% normal level (Xu et al. 1995; Fontanellas et al.
1996; Shady et al. 2002). Only a few mutants have been found to retain up to 1/3rd
normal level activity, although they also become less thermostable (Xu et al. 1995; Shady
et al. 2002). Further, these less severe mutations also seem to produce milder clinical
expression (Xu et al. 1995; Shady et al. 2002). The invariant residue C73 has been found
to be a mutational hotspot (Xu et al. 1995). C73R is the most commonly found CEP
allele with an observed frequency of ~30% (Desnick and Astrin 2002). C73R mutant
enzyme retains less than 1% residual activity (Boulechfar et al. 1992). Among all CEP
alleles, C73R homozygotes manifest the most severe clinical symptoms (Desnick and
Astrin 2002). Structural mapping indicates that C73 residue is buried in the second
domain hydrophobic core and does not appear to be catalytically essential (Mathews et al.
2001). Instead, loss of activity in C73R is most likely due to destabilization of the
enzyme structure (Omata et al. 2004).
CEP patients generally need to avoid sun and require skin protection (MathewsRoth 1998). More severe cases may require treatment which reduces bone marrow
erythropoiesis and thereby decreases porphyrin production, and these therapies include
frequent blood transfusions, hydroxyurea treatment and splenectomy (Desnick and Astrin
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2002). Bone marrow transplant has proved curative for severely affected young patients
resulting in correction of enzymatic deficiency in the bone marrow and marked reduction
of porphyrin levels and cutaneous lesions (Dupuis-Girod et al. 2005). Current efforts are
focused on developing hematopoietic stem cell-mediated gene therapy towards an
effective cure (Desnick and Astrin 2002).

This method is becoming feasible with

progress in viral transduction of hematopoietic stem cells with functional UROS and
murine model studies (de Verneuil et al. 2003; Géronimi et al. 2003; Bishop et al. 2005).

Uroporphyrinogen III decarboyxlase
The fifth enzyme, uroporphyrinogen III decarboyxlase (UROD) (EC 4.1.1.37),
catalyzes

four

successive

decarboxylation

reactions

on

acetate

groups

of

uroporphyrinogen III to yield the four corresponding β-pyrrole methyl groups of
coproporphyrinogen III (Mauzerall and Granick 1958; Romeo and Levin 1971).
Although uroporphyrinogen III is the normal physiological substrate, both naturally
occurring uroporphyrinogen isomers (I and III) may serve as substrates (Mauzerall and
Granick 1958; de Verneuil et al. 1983b; Elder et al. 1983; Straka and Kushner 1983).
The decarboxylation product of isomer I, coproporphyrinogen I, cannot be processed by
the next enzyme coproporphyrinogen oxidase, but undergoes autoxidation to
uroporphyrin I (Bogorad 1958a).
UROD has been identified in many species. The proteins typically contain 300400 residues and the sequence is considerably conserved throughout evolution with the
highest degree of identity found in the N-terminal region (Romeo et al. 1986; Jones and
Jordan 1993; Nishimura et al. 1993; Mock et al. 1995; Wyckoff et al. 1996; Whitby et al.

27

1998) In most species, UROD has an apparent monomeric molecular weight of 40-50
kDa (Jones and Jordan 1993; Wyckoff et al. 1996). In bacterial, yeast and animal cells,
UROD is a cytosolic enzyme (Romeo and Levin 1971; Elder et al. 1983; Felix and
Brouillet 1990). In plants, UROD is synthesized in the cytosol as a precursor form and
imported into the chloroplast using a N-terminal sequence of ~40 residues, and the transit
peptide is cleaved in the mature protein (Mock et al. 1995). While purified UROD is
commonly monomeric (de Verneuil et al. 1983b; Elder et al. 1983; Straka and Kushner
1983; Romeo et al. 1986; Juknat et al. 1989; Felix and Brouillet 1990; Jones and Jordan
1993), dimeric UROD has also been shown in solution and in crystal structure
(Kawanishi et al. 1983; Phillips et al. 1997; Whitby et al. 1998; Phillips et al. 2003). The
human UROD gene shows enhanced transcription and abundant expression in
erythropoietic cells, whereas non-erythroid expression is constitutive but occurs at a low
level (Romeo et al. 1986).
In contrast to most decarboxylases, UROD does not require cofactors for
catalysis, and its enzymatic activity is inhibited by divalent metal ions (de Verneuil et al.
1983b; Elder et al. 1983; Kawanishi et al. 1983; Straka and Kushner 1983; Felix and
Brouillet 1990). It is known that the UROD-catalyzed decarboxylation produces three
intermediates, the hepta-, hexa- and penta-carboxyporphyrinogens (Mauzerall and
Granick 1958). This reaction sequence appears to proceed via a preferred route that starts
at the acetate side chain on the D ring pyrrole and proceeds around the macrocycle in
alphabetical order (Jackson et al. 1976). The rate-limiting step in the conversion of
uroporphyrinogen III to coproporphyrinogen III is the decarboxylation of the first
reaction intermediate heptacarboxylate porphyrinogen III (Straka and Kushner 1983;
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Felix and Brouillet 1990). While kinetic analysis of mammalian UROD suggested the
possibility of multiple catalytic sites. (de Verneuil et al. 1980; Straka and Kushner 1983;
Chaufan et al. 2005), an alternative model proposed that there is only a single active site
which contains conserved residues for substrate binding (Chelstowska et al. 1992; Garey
et al. 1992).

Decarboxylation may involve the protonated pyrrole ring of

uroporphyrinogen substrate to function as an electron sink to promote electron withdrawl
in a manner similar to the pyridine ring of PLP, e.g. in ALAS-catalyzed reaction (Barnard
and Akhtar 1979). This latter model is consistent with the crystal structures (Whitby et
al. 1998; Martins et al. 2001; Phillips et al. 2003).
The X-ray crystal structure of UROD has been solved for the human and tobacco
enzymes, revealing a high degree of conservation in the overall topology (Whitby et al.
1998; Martins et al. 2001; Phillips et al. 2003). The protein crystallized as a homodimer
with a globular tiertiary structure (Whitby et al. 1998; Martins et al. 2001; Phillips et al.
2003). Each monomer contains one domain consisting of a distorted (β/α)8 TIM (triose
phosphate isomerase) barrel (Whitby et al. 1998; Martins et al. 2001; Phillips et al.
2003). A single active site is proposed to be located in a deep cleft which extends from
the hydrophobic β-barrel core to the dimer interface (Whitby et al. 1998; Martins et al.
2001; Phillips et al. 2003). Highly conserved residues are clustered around the active site
cleft (Whitby et al. 1998; Martins et al. 2001; Phillips et al. 2003).
Most recently, the structure was determined for the complex between human
UROD and product coproporphyrinogen (Phillips et al. 2003). Both coproporphyrinogen
I and III isomers were found at the same position in the active site cavity in each
monomeric subunit and both active sites in the UROD dimer were occupied (Phillips et
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al. 2003). Specificity for the I and III isomers appears to involve differential localization
of the D-ring propionate side chain which is mediated by interaction with adjacent
residues including conserved arginines (Phillips et al. 2003). Most interestingly, the
bound coproporphyrinogen was found to adopt a distorted conformation, i.e. a domed
macrocycle, and one face of the macrocycle was aligned against a hydrophobic surface of
the active site formed by a ring of conserved residues centrally located in the β-barrel
core (Phillips et al. 2003). An invariant aspartate (human D86), which provides the only
acidic side chain in the active site, was shown to approach the center of the bound
macrocycle and its carboxylate side chain was situated in an optimal position for
hydrogen-bonding with all four pyrrole nitrogens (Phillips et al. 2003). The active site
geometry is consistent with a previous proposal suggesting that a hypothetical protonated
intermediate serves as an electron sink to accept the electrons retained when the acetyl
side chain is released as CO2 (Barnard and Akhtar 1979; Akhtar 1994). Further, the
invariant active site aspartate (D86) seems very likely to function in substrate binding by
coordinating the four pyrrole nitrogens in a domed conformation, and it might also
directly promote catalysis by electrostatic stabilization of a protonated intermediate
(Phillips et al. 2003). Kinetic and structural analysis of the site-directed D86 mutants
provided additional support for the proposed catalytic model (Phillips et al. 2003).
The most common form of porphyria in humans, porphyria cutanea tarda (PCT),
is associated with subnormal UROD activity (Kushner et al. 1976). Clinically PCT is
characterized by cutaneous hyperpigmentation (Fritsch et al. 1998).

The patients

typically exhibit severe photosensitivity associated with skin lesions as a result of the
deposition of uroporphyrin and partially decarboxylated porphyrins (Fritsch et al. 1998).
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Excessive uroporphyrins are generated and accumulated in the liver, circulate in plasma
and excreted in the urine (Fritsch et al. 1998). The disease is classified as either familial
or sporadic (Kushner et al. 1976). Familial PCT (F-PCT) is transmitted as an autosomal
dominant trait (Kushner et al. 1976). F-PCT patients are heterozygous for mutant UROD
alleles and typically exhibit half-normal UROD activity in all tissues (Phillips et al.
2001). Most carriers of mutant UROD alleles do not have clinical expression unless
additional factors are present that further reduce UROD activity in the liver (Bulaj et al.
2000). In sporadic PCT (S-PCT) patients, deficiency of UROD activity is restricted to
the liver, although no mutation in UROD has been identified (de Verneuil et al. 1978;
Elder et al. 1978b; Garey et al. 1993). To date more than 30 mutations in UROD have
been associated with F-PCT, and a majority of them are single amino acid substitutions
scattered throughout the protein scaffold (Whitby et al. 1998; Phillips et al. 2001). None
of the residues affected is directly involved in catalysis in the active site (Whitby et al.
1998; Phillips et al. 2001). Most mutations are located near the dimer interface or
regions remote from the active site (Whitby et al. 1998; Phillips et al. 2001). They are
likely to disrupt protein fold or stability resulting in activity decrease or rapid degradation
of the enzyme (de Verneuil et al. 1986; Whitby et al. 1998; Phillips et al. 2001).
An

interesting

aspect

of

PCT

is

its

well-known

association

with

hemochromatosis, an autosomal recessive disease characterized by hepatic iron overload
(Berlin and Brante 1962). Hereditary hemochromotosis is most commonly caused by
mutations in the HFE locus (Feder et al. 1996). In many clinical studies, mutant HFE
alleles, primarily with the single substitution C282Y, have been shown to occur at
increased frequencies in overt PCT patients compared to the general population (Roberts
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et al. 1997; Bygum et al. 2003; Harper et al. 2004; Mehrany et al. 2004). It has been
widely accepted that inheritance of the hemochromatosis gene is a primary risk factor for
PCT (Elder and Worwood 1998; Bulaj et al. 2000). Other susceptibility factors include
hepatitis C viral infection, alcohol consumption, heavy metal exposure and estrogen use,
although the mechanism by which PCT pathogenesis is promoted by these risk factors is
not yet clear (Bulaj et al. 2000; Egger et al. 2002; Sams et al. 2004). PCT can usually be
treated with sunscreen for skin protection and phlebotomy therapy for iron removal
(Thunell and Harper 2000; Sarkany 2001; Nordmann and Puy 2002).

Repeated

phlebotomies deplete hepatic iron stores and thereby lead to clinical and biochemical
remission (Lundvall and Weinfeld 1968).

Coproporphyrinogen III oxidase
The sixth enzyme in the pathway, coproporphyrinogen III oxidase (CPO) (EC
1.3.3.3), converts coproporphyrinogen III to protoporphyrinogen IX. CPO catalyzes the
oxidative decarboxylation of two propionate side chains on pyrrole rings A and B in
coproporphyrinogen III to yield two vinyl groups in protoporphyrinogen IX (Sano and
Granick 1961; Sano 1966). There are two distinct CPOs, oxygen-dependent and oxygenindependent. These enzymes share no sequence or structural similarity (Dailey 2002).
In eukaryotes and some aerobic prokaryotes, there is a single, oxygen-dependent
CPO (odCPO) (Dailey 2002).

The odCPOs use molecular oxygen to convert

coproporphyrinogen and releases CO2 (Dailey 2002).

In contrast to many other

decarboxylases, odCPO-catalyzed reaction does not require any cofactor or metal ions
(Yoshinaga and Sano 1980; Camadro et al. 1986a; Medlock and Dailey 1996; Dailey

32

2002). odCPO is highly conserved throughout evolution and contains a large number of
invariant residues (Martasek et al. 1994; Medlock and Dailey 1996; Lamoril et al. 2001;
Phillips et al. 2004).

From bacteria to human, the protein typically occurs as a

homodimer of 70-80 kDa (Yoshinaga and Sano 1980; Camadro et al. 1986a; Bogard et al.
1989; Kohno et al. 1993; Kruse et al. 1995; Martasek et al. 1997; Macieira et al. 2003).
While odCPOs from yeast S. cerevisiae and E. coli are cytosolic proteins
(Camadro et al. 1986b; Zagorec et al. 1988; Macieira et al. 2003), odCPO is present in
the intermembrane space between the inner and outer mitochondrial membranes in higher
animal cells (Elder and Evans 1978a; Grandchamp et al. 1978).

This results from

translocation of a cytosolic precursor into mitochondria, mediated by a N-terminal leader
sequence which is then proteolytically removed (Kohno et al. 1993; Delfau-Larue et al.
1994; Martasek et al. 1994; Susa et al. 2003).

An unusually long bipartite signal

sequence consisting of ~120 N-terminal residues is found to be essential for mammalian
CPO targeting (Susa et al. 2003; Dailey et al. 2005).
Kinetic studies of odCPO suggest that the rate-limiting step for the overall
reaction is the first decarboxylation with transient formation of the tricarboxylic
intermediate, harderoporphyrinogen (Elder and Evans 1978b; Elder et al. 1978a).
Although deprotonation of the pyrrole ring and peroxide formation have been implicated,
the catalytic mechanism is not well understood (Seehra et al. 1983; Colloc'h et al. 2002).
Recently, new insights have begun to develop with the structural determination of odCPO
(Phillips et al. 2004; Lee et al. 2005).
Crystal structures have been solved first for the yeast S. cerevisiae enzyme
(hem13p), and most recently, for the human protein revealing a homologous folding
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pattern (Phillips et al. 2004; Lee et al. 2005).
homodimer of ~70 kDa.

The yeast odCPO crystallized as a

Each monomer contains a single domain consisting of a

relatively flat 7-stranded anti-parallel β-sheet flanked on both sides by α-helices (Phillips
et al. 2004). There is one active site in each subunit, which is located in a deep cavity
sandwiched between one face of the β-sheet and a C-terminal helical surface (Phillips et
al. 2004). The crystal structures revealed two conformations, an open form and a more
closed form. Active site closure appears to be mediated by movement of two short αhelices positioned above the opening. Possibly, substrate binding induces the closed
conformation, which allows sequestration of the active site from the bulk solvent and
leaves a cavity with a size and shape comparable to the substrate molecule (Phillips et al.
2004). As indicated by a structural model of coproporphyrinogen III docking into the
CPO open conformer, the substrate fits tightly into the active site and is surrounded by
many conserved residues possibly involved in coproporphyrinogen binding (Phillips et al.
2004).

Interestingly, an invariant aspartate (D274) which belongs to a short,

conformationally mobile helix covering the pocket is found directly above the center of
the macrocycle. This led to the suggestion that D274 plays a crucial role in substrate
binding by interacting with the four pyrrole nitrogen groups via its carboxylate side
chain.
An updated catalytic model has been proposed based on the structural features of
odCPO (Lash 2005). It emphasizes the importance of substrate straining in the oxidative
reaction, e.g. by bending coproporphyrinogen macrocycle into a domed conformation
(Lash 2005). Distortion of the substrate facilitates interaction with an adjacent acidic
residue, which deprotonates the pyrrole nitrogens (Lash 2005).
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The deprotonated

pyrrolic ring favors reaction with molecular oxygen to generate an anionic peroxide
intermediate (Lash 2005).

This intermediate is resolved to yield a vinyl pyrrole

derivative concomitant with the release of CO2 and peroxide (Lash 2005). Indeed,
peroxide formation has been observed in the reaction catalyzed by E. coli odCPO
(Breckau et al. 2003).
Oxidative decarboxylation of coproporphyrinogen in anaerobic organisms is
catalyzed by an oxygen-independent CPO encoded by the hemN gene (Dailey 2002).
Although both hemF and hemN genes are present in facultative bacteria such as E. coli
and Salmonella typhimurium, the hemN product is selectively upregulated during growth
under low oxygen tension or anaerobic conditions, while the hemF product (odCPO) is
synthesized only aerobically (Xu et al. 1992; Troup et al. 1995). Unlike odCPO, the
reaction catalyzed by the hemN-encoded CPO requires Mg2+, ATP, NAD(P)+, methionine
and an FeS cluster (Coomber et al. 1992; Layer et al. 2002). Also, the enzyme is entirely
unrelated to odCPO on a structural level. The crystal structure of the E. coli hemN
product reveals features common to the radical SAM enzymes (Layer et al. 2003). The
protein is a monomer of ~53 kDa (Layer et al. 2002; Layer et al. 2003). It is folded into
two domains featuring a curved parallel β-sheet and contains a [4Fe-4S] cluster and Sadenosylmethionine (SAM) which are necessary for enzymatic activity (Layer et al.
2002; Layer et al. 2003).
Partial enzymatic deficiency of CPO causes two distinct forms of porphyria
hereditary coproporphyria and harderoporphyria (Lamoril et al. 2001; Nordmann and Puy
2002). Hereditary coproporphyria (HCP) is a rare acute hepatic porphyria (Delfau-Larue
et al. 1994).

The disease is transmitted as an autosomal dominant trait with low
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penetrance (Martasek 1998; Nordmann and Puy 2002). Clinical symptoms are primarily
acute neurovisceral attacks commonly associated with abdominal pain, hypertension and
peripheral neuropathy (Martasek 1998; Kuhnel et al. 2000; Nordmann and Puy 2002).
The symptoms are often provoked by drugs, alcohol consumption or fasting (Nordmann
and Puy 2002; Anderson et al. 2005; Kauppinen 2005). Urinary and fecal excretion of
coproporphyrin III is elevated (Kuhnel et al. 2000; Gross et al. 2002a). Sometimes
patients also exhibit photosensitive skin lesions (Kuhnel et al. 2000). Enzymatic activity
of CPO is reduced, typically to half-normal in heterozygous patients (Gross et al. 2002a;
Nordmann and Puy 2002). Harderoporphyria is a rare erythropoietic variation of HCP
(Nordmann et al. 1983). While the patients do not have acute attacks of neurological
dysfunction, their clinical manifestations are characterized by fecal excretion of a large
amount of harderoporphyrin and hemolytic anemia associated with iron overload
(Nordmann et al. 1983; Lamoril et al. 1995; Lamoril et al. 1998; Schmitt et al. 2005).
Currently nearly 40 mutations in human CPO have been described including
small insertions, deletions, splice site mutations and missense mutations (Rosipal et al.
1999; Lamoril et al. 2001; Wiman et al. 2003a; Schmitt et al. 2005). More than half of
the defects are single amino acid substitutions which occur mostly in the conserved
residues spread throughout the protein, and they are likely to disrupt protein fold or
dimerization (Lamoril et al. 2001; Phillips et al. 2004; Lee et al. 2005). While active site
mutations are very rare, CPO defects identified in harderoporphyria patients are restricted
to K404E and R401W substitutions (Lamoril et al. 1995; Lamoril et al. 1998; Schmitt et
al. 2005). Both residues are located in a short mobile α-helix (D400-K404), which
covers the active site cavity (Phillips et al. 2004). The mutant enzymes are thermolabile,
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and exhibit markedly decreased binding affinities for substrate coproporphyrinogen and
the first reaction intermediate harderoporphyrinogen (Nordmann et al. 1983; Lamoril et
al. 1995; Schmitt et al. 2005). Structural analysis suggests that the mutations may
interfere with active site closure, and thus promote diffusion of the harderoporphyrinogen
intermediate out of the substrate-binding pocket (Phillips et al. 2004). Intravenous hemin
arginate infusion has been shown to effectively alleviate acute porphyric attacks and
remains a preferable therapy for severely affected HCP patients (Kuhnel et al. 2000;
Gross et al. 2002b; Nordmann and Puy 2002).

Protoporphyrinogen IX oxidase
Protoporphyrinogen IX oxidase (PPO) (EC 1.3.3.4), the penultimate enzyme in
heme biosynthesis, catalyzes the six-electron oxidation of protoporphyrinogen IX to form
fully conjugated macrocyclic protoporphyrin IX (Porra and Falk 1964). PPO utilizes
three molecules of molecular oxygen, reducing them to three molecules of H2O2 and
generating the protoporphyrin product. The oxidation reaction requires a noncovalently
bound cofactor flavin adenine dinucleotide (FAD) (Shoolingin-Jordan 1991).

PPO has

been widely identified in bacteria, yeast, plants and higher animals (Dailey and Karr
1983; Dailey et al. 1994b; Nishimura et al. 1995b; Camadro and Labbe 1996; Dailey and
Dailey 1996a; Dailey and Dailey 1996b; Narita et al. 1996; Wang et al. 2001). Although
its sequence became significantly diversified during evolution, the protein generally has a
monomeric molecular mass of ~50-60 kDa and contains a highly conserved N-terminal
dinucleotide-binding motif G-X-G-X2-G which mediates the coordination of a FAD
cofactor (Dailey and Karr 1983; Proulx and Dailey 1992; Dailey et al. 1995; Dailey and
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Dailey 1996b; Wang et al. 2001). Plant PPO has two isozymes, with PPO1 found in the
plastid chloroplast and PPO2 in the mitochondrion (Narita et al. 1996; Lermontova et al.
1997). Eukaryotic PPO is tightly bound to the inner mitochondrial membrane (Dailey
and Karr 1983) (Deybach et al. 1985; Nishimura et al. 1995b). It is typically found as a
homodimer of ~100 kDa (Dailey and Dailey 1996b).

Interestingly, the monomeric

subunit exhibits a highly protease-resistant, compact domain structure (Arnould and
Camadro 1998; Arnould et al. 1999). A block of ~60 conserved residues near the Nterminal region has been implicated to serve as a membrane anchor for the enzyme
(Arnould and Camadro 1998; Koch et al. 2004; Morgan et al. 2004), although a short
conserved N-terminal sequence appears sufficient for mitochondrial import (Fraunberg et
al. 2003; Dailey et al. 2005). It is possible that the two regions interact to optimize the
efficiency of mitochondrial targeting.
In prokaryotes, as with CPO, PPO has two forms, but only a single form is present
in a given cell (Dailey 2002). One is the oxygen-dependent form encoded by the hemY
gene; the other is the oxygen-independent form encoded by the hemG gene (Dailey
2002). In most bacteria, oxygen-dependent PPO is associated with the plasma membrane
as a monomer or homodimer (Dailey and Dailey 1996a; Wang et al. 2001). However, B.
subtilis PPO (hemYp) is water soluble and exists in a monomeric form of ~51 kDa
(Hansson and Hederstedt 1992; Dailey et al. 1994b). In addition to protoporphyrinogen,
this enzyme can efficiently oxidize coproporphyrinogen to coproporphyrin (Hansson et
al. 1997). An interesting feature of B. subtilis PPO is that it is only very weakly inhibited
by diphenyl ether herbicides (Dailey et al. 1994b). This family of herbicides are known
as potent inhibitors of eukaryotic PPOs and cause light-dependent phytotoxicity in plants
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as a result of substrate protoporphyrinogen accumulation in the inappropriate cellular
compartment (Matringe et al. 1989; Camadro and Labbe 1996; Narita et al. 1996).
Overexpression of B. subtilis PPO in the plastids of transgenic plants has been achieved
and conferred resistance to the herbicide oxyfluorfen

(Li and Nicholl 2005).

In

anaerobic and facultative bacteria, protoporphyrinogen oxidation is catalyzed by the
hemG-encoded PPO, which belongs to a multimeric protein complex in the cellular
respiratory chain (Klemm and Barton 1987; Dailey 2002). E. coli PPO (hemGp) product
is a small, cytosolic soluble, monomeric protein of ~21 kDa containing 181 residues
(Sasarman et al. 1993; Nishimura et al. 1995a).
The structure of PPO was recently determined for the mitochondrial isozyme
(PPO2) from common tobacco Nicotiana tabacum (Koch et al. 2004). The X-ray crystal
structure of PPO2 was solved at 2.9 Å resolution with the inhibitor 4-bromo-3-(5'carboxy-4'-chloro-2'-fluoro-phenyl)-1-methyl-5-trifluoromethyl-pyrazol bound in the
active site (Koch et al. 2004). The protein is a homodimer of ~110 kDa and contains one
non-covalently attached FAD cofactor in each subunit. Each monomer consists of three
domains, which are proposed for binding to FAD, substrate and the mitochondrial
membrane, respectively.

Detergent Triton X-100 used for solubilization and

crystallization was found in the interdomain cleft. While PPO has long been known to
possess a FAD-binding motif commonly found in a superfamily of flavoproteins
including monoamine oxidases and some phytoene dehydrogenases (Dailey and Dailey
1996b), the FAD-binding domain of PPO2 also exhibits significant overall structural
resemblance to this family of flavin-dependent enzymes. The substrate-binding domain,
suggested by the orientation of the bound inhibitor, contains mostly β-strands (Koch et al.
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2004).

The active site is thought to lie in a narrow cavity between the FAD and

substrate-binding domains of each monomer (Koch et al. 2004). The docking model of
protoporphyrinogen binding to PPO2 indicated that the vinyl groups of pyrrole rings A
and B are buried deeply in the interior of the active site cavity, while the propionyl
groups of pyrrole rings C and D are directed outwards to the solvent-exposed end (Koch
et al. 2004). Since the reactive group of FAD lies adjacent to pyrrole rings A and D, the
methylene bridge between rings A and D is proposed to be the site of initial oxidation
(Koch et al. 2004). This arrangement appears to be required for protoporphyrinogen
binding and catalysis, as macrocycle rotation is unlikely due to steric constraint within
the active site. The putative membrane-binding domain protrudes from the globular core
and consists primarily of a group of α-helices formed by a consecutive N-terminal
sequence of ~100 residues (Koch et al. 2004). As was found with monotopic membrane
proteins (Binda et al. 2004), a conserved helical region forms a hydrophobic surface at
the base of PPO and probably mediates membrane insertion in a monotopical manner.
The domain structure of PPO2 lends support to a previous model which suggested
that the active site of PPO faces the cytosolic side of the inner mitochondria membrane
and substrate channeling might occur between the terminal heme synthetic enzymes
(Ferreira et al. 1988). Spatially, it seems possible that the product protoporphyrin can be
translocated to the next enzyme ferrochelatase via a U-shaped channel which connects
the active site cavity to the membrane (Koch et al. 2004).
Enzymatic deficiency in PPO causes the disease variegate porphyria (VP)
(Brenner and Bloomer 1980; Deybach et al. 1981; Meissner et al. 1986). VP is an
autosomal dominant disease with low penetrance (Nordmann and Puy 2002). Patients
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typically exhibit skin photosensitivity, or less commonly have acute episodes of
neuropathy, or sometimes show both symptoms (Bales et al. 1980; Whatley et al. 1999;
Fraunberg et al. 2002; Wiman et al. 2003b; Hift et al. 2004). Neurovisceral attacks are
often precipitated by porphyrinogenic drugs (Hift and Meissner 2005). PPO activity is
approximately half-normal in all tissues of the clinically overt patients as well as
asymptomatic carriers (Brenner and Bloomer 1980; Deybach et al. 1981; Da Silva et al.
1995). Currently about 130 mutations of PPO have been associated with VP (Kauppinen
2005).

They include splice site mutations, exon deletions, frameshifts, non-sense

mutations, and half of all are missense mutations (Deybach et al. 1996; Whatley et al.
1999; Frank et al. 2001; Fraunberg et al. 2001; Morgan et al. 2002; Wiman et al. 2003b).
Single mutations are spread throughout the protein, and many occur at conserved
residues. Most VP mutations cause total or near complete (<10%) loss of enzymatic
activity, thus exhibiting complete haplodeficiency (Deybach et al. 1996; Meissner et al.
1996; Fraunberg et al. 2001; Morgan et al. 2002). Recently, the first case report has been
described for a patient recovery from VP after liver transplantation (Stojeba et al. 2004).
Interestingly, one of the best known PPO mutations R59W gives a prime example
of the founder gene effect. VP is highly prevalent in the Afrikaner population of South
Africa, which can be traced back to an ancestral PPO allele with R59W substitution
(Meissner et al. 1996; Hift et al. 2004). Only minimal activity is retained in R59W
mutant, probably because the R59 residue is required for catalysis and active site integrity
(Manelia et al. 2003). Modeling based on the tobacco PPO2 crystal structure indicates
that the equivalent residue (N67 in tobacco enzyme) occupies an active site position
between FAD and substrate-binding site, which implies that a single mutation can
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interfere with FAD-substrate interaction and disturb the active site geometry (Koch et al.
2004).

Ferrochelatase
The last enzyme in heme biosynthesis pathway is ferrochelatase (FECH) (E.C.
4.99.1.1). Ferrochelatase catalyzes the insertion of ferrous iron into protoporphyrin IX to
form protoheme (Figure 3). Ferrochelatase activity was first described by Goldberg’s
group in 1956 using crude preparations of avian erythrocytes (Goldberg et al. 1956).
Subsequently, its enzymatic role in biological porphyrin metallation was further
examined in a variety of cell types and organisms (Porra and Jones 1963a; 1963b;
Neuberger and Tait 1964; Porra and Ross 1965; Jones 1969; 1970).

With the

identification of ferrochelatase-deficient, heme auxotrophic mutants in the bacterium
Spirillum itersonii and yeast S. cerevisiae, ferrochelatase was recognized as the genetic
basis for iron chelation in heme biosynthesis (Dailey and Lascelles 1974; Gollub et al.
1977). Ferrochelatase was first successfully cloned from S. cerevisiae in 1990 (LabbeBois 1990), followed with the cloning of human and murine genes (Nakahashi et al.
1990; Taketani et al. 1990; Brenner and Frasier 1991). As high yield bacterial expression
systems for recombinant mammalian ferrochelatases became available, purified enzymes
were given extensive biophysical and biochemical examination (Ferreira 1994; Sellers
and Dailey 1997; Dailey et al. 2000). Significantly, the X-ray crystal structure was
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Figure 3. The reaction catalyzed by ferrochelatase.
Adapted from (Al-Karadaghi et al. 1997).
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determined first for B. subtilis ferrochelatase in 1997 (Al-Karadaghi et al. 1997),
followed by the human (Wu et al. 2001) and yeast proteins (Karlberg et al. 2002) In the
past decade, the ease of cloning, expression and purification of ferrochelatase and the
extent to which they have been characterized have grown rapidly and expanded to diverse
organisms, thus a more complete understanding of ferrochelatase evolution has emerged
(Dailey and Dailey 2003).
In most organisms, ferrochelatase is found as a membrane protein (Dailey and
Dailey 2003). In animal cells and yeast, ferrochelatase is synthesized in the cytoplasm as
a nuclear-encoded precursor protein and translocated into the mitochondria using a Nterminal leader sequence consisting of ~50 residues (Camadro and Labbe 1988; Karr and
Dailey 1988; Taketani et al. 1990; Dailey et al. 2005). The mature form, typically
consisting of 400-500 residues, is associated with the matrix side of the inner
mitochondrial membrane, and the enzymatic reaction it catalyzes takes place in the
mitochondria (Jones and Jones 1968; Jones 1969; Harbin and Dailey 1985; Prasad and
Dailey 1995). Prokaryotic ferrochelatases are smaller, and while most of them are bound
to the plasma membrane, some are soluble (Hansson and Hederstedt 1994; Wang et al.
2001; Dailey and Dailey 2002).
Biochemical characterization of ferrochelatase from different species has revealed
that the reaction mechanism is conserved (Dailey and Dailey 2003). The catalytic model
was initially proposed nearly two decades ago, and has been advanced to incorporate a
multitude of details (Dailey and Dailey 2003). During catalysis the enzyme transiently
binds the iron (II) and porphyrin substrates. Metal chelation occurs only when the
porphyrin ring is distorted from planarity, concomitant with proton release from the
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pyrrole nitrogen atoms. The product heme is flat and exits the active site once formed.
An important feature of ferrochelatase-catalyzed metallation is the distortion of porphyrin
macrocycle. The original proposal drew on the observation that porphyrin analog, Nmethyl-protoporphyrin, acts as a tight-binding competitive inhibitor of ferrochelatase
with a Ki in the nanomolar range (Dailey et al. 1989). N–alkyl porphyrins have an
alkylated pyrrole ring bent 20-30o out of the otherwise planar porphyrin core, and this
nonplanar conformation has been thought to yield high affinity binding in the active site
(Dailey and Fleming 1983; Dailey et al. 1989).

Based on quantum mechanical

calculation of porphyrin binding to B. subtilis ferrochelatase, tilting of a pyrrole ring
induced by the enzyme significantly lowers the energy required for metal insertion,
suggesting that macrocycle distortion may be a thermodynamically favorable process
(Sigfridsson and Ryde 2003). Actually, antibodies made against N–methylmesoporphyrin were found to catalyze metal chelation into porphyrins and thus possess
ferrochelatase-like activity (Cochran and Schultz 1990).

Resonance Raman

spectroscopic studies revealed that murine ferrochelatase is able to induce formation of a
saddled porphyrin even in the absence of metal substrate (Franco et al. 2000), whereas
yeast ferrochelatase binds and distorts porphyrin into a domed or ruffled conformation in
the presence of the inhibitor Hg2+ (Blackwood et al. 1997; Blackwood et al. 1998). A
direct observation comes from the crystal structure of B. subtilis ferrochelatase with
bound N-methyl-mesoporphyrin, which clearly showed that a distorted macrocycle is
held tightly in the active site (Lecerof et al. 2000). In comparison, deformation of
porphyrin in the binding sites of catalytic antibodies has also been demonstrated using
resonance Raman spectroscopy and crystal structure analysis, which lends additional
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support that macrocycle distortion is a crucial step in enzymatic metallation (Yin et al.
2003; Venkateshrao et al. 2004).
Although the importance of porphyrin deformation was widely recognized, little
was known about the porphyrin substrate binding site and residues responsible for
porphyrin distortion in the enzyme (Dailey and Dailey 2003).

With the structure

determination of ferrochelatase, it became possible to address this important question so
as to understand the structural basis of porphyrin-enzyme interaction. The X-ray crystal
structure first solved was that of the small, cytosolic soluble, monomeric enzyme from
the Gram-positive bacterium B. subtilis (Al-Karadaghi et al. 1997).

Secondly, the

structure of human ferrochelatase was determined (Wu et al. 2001). This structure
revealed a homodimer with one [2Fe-2S] cluster associated with each subunit, which is
characteristic of animal ferrochelatases (Wu et al. 2001). More recently, the structure of
yeast S. cerevisiae ferrochelatase was solved, showing a homodimeric protein without the
FeS cluster (Karlberg et al. 2002). Although the overall sequence identity is only ~20%
for these proteins, they exhibit remarkably similar folds and active site geometries (AlKaradaghi et al. 1997; Wu et al. 2001; Karlberg et al. 2002). A monomeric unit of the
enzyme comprises two structurally-related domains, each of which consists of a
Rossmann-type fold, which is characterized by a four-stranded, parallel β-sheet flanked
by α-helices on both sides. The active site is situated in a deep cavity between the two
domains. The cavity is enriched with many conserved residues, some of which have been
shown to play important roles in catalysis (Al-Karadaghi et al. 1997; Lecerof et al. 2000;
Wu et al. 2001; Karlberg et al. 2002).
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The opening of the active site cleft consists of two sides, with one side composed
of residues from the first two N-terminal α-helices, α1, α2, and an intervening loop. The
opposite side is formed by a short loop connecting a β-strand and an α-helix in the
second domain (Al-Karadaghi et al. 1997; Lecerof et al. 2000; Wu et al. 2001; Karlberg
et al. 2002). The ferrochelatase loop shows a high degree of sequence identity across a
wide taxonomic range (Shi and Ferreira 2004). It was located in close proximity to the
porphyrin macrocycle in the crystal structure of inhibited B. subtilis ferrochelatase
(Lecerof et al. 2000). Consistent with this observation, the loop was predicted to contact
the porphyrin based on molecular dynamics-based docking of nickel-protoporphyrin in B.
subtilis ferrochelatase (Franco et al. 2000).

Thereby, it was hypothesized that the

conserved loop residues are involved in substrate porphyrin binding and distortion during
enzymatic reaction. In agreement with this proposal, structural features of human and
yeast ferrochelatases indicate that the active site opening defines the membrane-facing
side of ferrochelatase and provides an entry site for substrate porphyrin (Gora et al.
1996a; Wu et al. 2001; Karlberg et al. 2002). The experiments described in the following
chapters were aimed at detailed characterization of the loop motif in order to gain further
understanding of the structural basis of the ferrochelatase-catalyzed reaction.
Metal substrate binding to ferrochelatase has been studied in detail over the past
decade. Current models suggest that a channeling mechanism is involved in the transfer
of metal ions from the protein exterior into the internal reaction center near the distorted
porphyrin (Sellers et al. 2001; Lecerof et al. 2003). This notion received support from
studies of bacterial and yeast ferrochelatases (Karlberg et al. 2002; Lecerof et al. 2003).
In the active site, an invariant catalytic histidine residue (H183 in B. subtilis enyzme) has
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been found necessary for metal chelation (Kohno et al. 1994; Gora et al. 1996b; Lecerof
et al. 2000; Lecerof et al. 2003; Shipovskov et al. 2005), while an invariant glutamate and
a conserved serine can also serve as metal ligands (Karlberg et al. 2002; Lecerof et al.
2003). These residues constitute an interior site for metal-coordination; and possibly, this
site may interact with a second, surface-exposed metal-binding site, which is likely to
play a regulatory role (Karlberg et al. 2002; Lecerof et al. 2003). Transport of metal ions
between the two sites is mediated by a group of conserved acidic residues aligned along a
π-helix on an exposed surface inside the active site cavity (Karlberg et al. 2002; Lecerof
et al. 2003). Further, recent studies have provided evidence that accelerating the rate of
ligand exchange for metal ions is an important element of the catalytic mechanism
(Shipovskov et al. 2005). Examination of human ferrochelatase has led to the proposal
that iron binding involves the conserved arginine and tyrosine residues in the interior
active site cavity, whereas a conduit formed by a group of conserved, mostly aromatic
residue shuttles the iron substrate from an external location into the catalytic center
(Sellers et al. 2001).
In eukaryotic cells, the iron substrate is thought to be supplied by the
mitochondrial membrane (Taketani et al. 1986; Lange et al. 1999; Napier et al. 2005).
Recently, the iron chaperone frataxin and additional carrier proteins have been implicated
as iron donors for ferrochelatase (Lesuisse et al. 2003; He et al. 2004; Yoon and Cowan
2004; Zhang et al. 2005). Frataxin, a small, evolutionarily conserved, mitochondrial
protein, is known for its role in iron homeostasis by sequestering iron and making iron
available for FeS cluster biogenesis and heme synthesis inside the mitochondria (Lesuisse
et al. 2003; Park et al. 2003; Yoon and Cowan 2003).
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In yeast and human

ferrochelatases, frataxin is shown to recruit ferrous iron and mediate its delivery to
ferrochelatase by binding to the enzyme surface (Lesuisse et al. 2003; He et al. 2004;
Yoon and Cowan 2004).

Additionally, other carrier proteins including the yeast

mitochondrial membrane proteins Mrs3p and Mrs4p have been suggested to cooperate
with frataxin in a rapid transport system to move iron into mitochondria and direct its
utilization in heme synthesis (Zhang et al. 2005).
One of the least understood aspects of ferrochelatase concerns the role of the FeS
cluster. Although it is not present in ferrochelatases from some species including B.
subtilis (Hansson and Hederstedt 1994), E. coli (Miyamoto et al. 1991) and S. cerevisiae
(Labbe-Bois 1990; Gora et al. 1996b), cluster-containing ferrochelatases are commonly
found in evolution and a [2Fe-2S] cluster is associated with the enzyme in animals
(Dailey et al. 1994a; Ferreira et al. 1994; Sellers et al. 1998b), yeast
Schizosaccharomyces pombe (Medlock and Dailey 2000) and bacteria Caulobacter
crescentus and Mycobacterium tuberculosis (Dailey and Dailey 2002). In mammalian
ferrochelatase, the [2Fe-2S] cluster is bound to a 30-50 residue long C-terminal tail,
which constitutes a domain distinct from the structurally conserved catalytic core (Dailey
et al. 1994a). The cluster is coordinated by four cysteine residues, with three ligands
provided by a conserved C-X2-C-X4-C motif in the C-terminal tail and one much further
removed in the N-terminal region (Crouse et al. 1996; Sellers et al. 1998b; Wu et al.
2001). In human ferrochelatase, the cluster is labile, and is rapidly destroyed upon
exposure to nitric oxide concomitant with loss of enzymatic activity (Furukawa et al.
1995; Sellers et al. 1996). It is known that the cluster iron does not serve as substrate iron
and its redox state does not affect enzymatic activity (Dailey et al. 1994a; Ferreira et al.
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1994). Although mutations in the cysteine ligands can abolish catalytic activity (Sellers
et al. 1998b; Schneider-Yin et al. 2000b), the cluster does not appear to be indispensable
for enzymatic function (Medlock and Dailey 2000; Najahi-Missaoui and Dailey 2005;
Ohgari et al. 2005). Instead, it may help to enhance protein stability in mammalian
ferrochelatases (Medlock and Dailey 2000; Najahi-Missaoui and Dailey 2005; Ohgari et
al. 2005). Further, FeS cluster assembly has been implicated in regulating overall heme
production by modulating ferrochelatase activity (Taketani et al. 2003; Lange et al.
2004). In human ferrochelatase, the C-terminal cluster-containing region is involved in
binding ABC7, a member of the mitochondrial half-type ATP-binding cassette (ABC)
transporters (Taketani et al. 2003). This interaction is thought to mediate an increase in
heme synthesis during erythroid differentiation, which contributes to elevated
hemoglobin production in erythropoiesis (Taketani et al. 2003).
In mammals, naturally occurring genetic defects cause decrease in ferrochelatase
activity leading to the disease erythropoietic protoporphyria (EPP) (Magnus et al. 1961;
Todd 1994).

Typical symptoms of EPP include skin photosensitivity beginning in

childhood which results from accumulation of free protoporphyrin primarily generated in
the erythropoietic tissues (Todd 1994). Although EPP is generally not life threatening,
retention of excessive porphyrins in the liver can cause hepatobiliary diseases and entails
liver transplantation in a small fraction of patients (Bloomer 1988). In humans, EPP is
primarily transmitted as an autosomal dominant trait with incomplete penetrance and
variable clinical expression (DeLeo et al. 1976). A puzzling feature of clinical EPP is
that the patients exhibit ferrochelatase activity at only ~10-30% of the normal level,
lower than the expected, 50% residual activity (Bonkowsky et al. 1975; Norris et al.
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1990).

One explanation based on the multiallelic inheritance model is that clinical

manifestations of EPP require the inheritance of a low expression wild-type allele in
combination with a defective ferrochelatase allele (Gouya et al. 1996; Gouya et al. 1999).
In support of this model, an intronic polymorphism mapped to the intron/exon splice
acceptor site, i.e. an IVS3-48C/T allele, was shown to cause rapid degradation of
aberrantly spliced transcripts and significantly reduce the steady-state mRNA levels, thus
resulting in decreased expression from an otherwise functional ferrochelatase allele
(Gouya et al. 2002). Indeed, the low expression IVS3-48C allele is prevalent in families
with overt EPP from diverse human populations (Risheg et al. 2003; Wiman et al. 2003a;
Whatley et al. 2004; Bloomer et al. 2005). Additional factors including individual
genetic background have also been implicated in modulating ferrochelatase expression
level and EPP pathogenesis (Chen et al. 2002; Gouya et al. 2004; Abitbol et al. 2005;
Cooperman et al. 2005; Navarro et al. 2005; Zhou et al. 2005).
While the size (45 kb) of the human FECH gene locus (chromosome 18q21.31)
precludes the use of a comprehensive analysis of gene defects as routine examination for
EPP most patients exhibit mutations in the protein coding region (Rufenacht et al. 1998).
To date ~80 deleterious mutations have been identified in human ferrochelatase (Whatley
et al. 2004). Exon skipping, frameshifts and nonsense mutations are common and result
in inactive enzymes (Gouya et al. 1996; Rufenacht et al. 1998; Sellers et al. 1998a;
Schneider-Yin et al. 2000c). Over 30 missense EPP mutations have been identified, and
they typically occur in conserved residues and result in large reduction of enzymatic
activity (Rufenacht et al. 1998; Schneider-Yin et al. 2000b; Schneider-Yin et al. 2000c;
Rufenacht et al. 2001; Whatley et al. 2004). Structural mapping indicates that relatively
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few mutations are located in the active site, and the majority are scattered throughout the
protein scaffold (Najahi-Missaoui and Dailey 2005). Interestingly, mutations near the
dimer interface or FeS cluster are highly detrimental to residual enzymatic activity
(Schneider-Yin et al. 2000b; Najahi-Missaoui and Dailey 2005; Ohgari et al. 2005).
A common treatment for EPP consists of preventing or lessening photosensitivity
by β-carotene ingestion, but this method is refractory to some patients and does not
protect against liver damage (Mathews-Roth 1993; Todd 1994). Long-term intake of Lcysteine has also been shown to ameliorate photosensitivity (Mathews-Roth and Rosner
2002). Bone marrow transplantation and hematopoietic stem cell gene therapy offer the
potential of more effective cures (Pawliuk et al. 1999; Fontanellas et al. 2000; Richard et
al. 2004). In an EPP mouse model, it has been feasible to correct photosensitization by
transplanting bone marrows containing hematopoietic stem cells transduced with human
ferrochelatase (Pawliuk et al. 1999; Fontanellas et al. 2001; Richard et al. 2004).
Recently, localized skin graft has been demonstrated to effectively protect against dermal
photosensitivity (Pawliuk et al. 2005). However, liver damage remains difficult to cure
(Bloomer et al. 1996; Bloomer et al. 2005). Bone marrow transplantation in young
patients has been suggested as an option to prevent hepatobiliary complications
(Fontanellas et al. 2000).

In summary, with the availaibility of crystal structures for all the heme
biosynthetic enzymes, it has become increasingly possible to carry out extensive
structure-activity characterization for each protein. Altogether, these studies shall lead to
a better comprehension of the driving forces underlying the biological process of heme
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synthesis. More importantly, extending molecular analysis into clinical settings offers
promise toward improving the diagnosis and treatment of porphyria and anemia.
The experimental investigation presented in this dissertation focuses on the
terminal enzyme, ferrochelatase. As described above, although enzymatic studies of
ferrochelatase have been carried out for decades and encompass a wide range of
biochemical and biophysical characterization, only in the past few years have the crystal
structures been solved for ferrochelatase isolated from different organisms (Dailey and
Dailey 2003). This opens up the possibility of conducting structure-based functional
assays to probe ligand-protein interactions and to infer the enzymatic reaction
mechanism. The primary purpose of this study is to explore the structural basis of
substrate porphyrin binding and distortion with regard to ferrochelatase catalysis. This
investigation was initiated based on crystallographic observation and molecular modeling
that a highly conserved loop motif was located in the active site and appeared to interact
with bound porphyrin. The loop was subjected to random mutagenesis and the properties
of the active variants were characterized. This study revealed a number of important
results regarding the molecular details of ferrochelatase function. In support of the initial
proposal, the loop residues are shown to play a role in substrate porphyrin binding. The
loop also regulates active site conformation resulting in modulation of reaction rate and
substrate interaction.

The loop residues are directly involved in distortion of the

porphyrin macrocycle into a non-planar conformation, which contributes to the catalytic
efficiency of ferrochelatase. Structural changes in the loop are also found to play a role
in determining the sensitivity to the inhibitor N-methyl-protoporphyrin. One unexpected
finding is that loop mutations allow the enzyme to retain activity even without FeS
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cluster assembly and adopt an alternative oligomeric states. Overall, the results described
here provide new insights into the structural basis of porphyrin metallation catalyzed by
ferrochelatase.
Ferrochelatase is present at the convergence of the intracellular tetrapyrrole
biosynthetic and iron supply pathways.

Because accumulation of unmetallated

porphyrins and ferrous iron are cytotoxic, integration of both pathways by ferrochelatase
is crucial for cellular metabolism, especially in the process of erythroid cell development
(Ponka 1999).

While enzymatic deficiency of ferrochelatase leads to the disease

erythropioetic protoporphyria (Gouya et al. 2002), growing evidence indicates that
ferrochelatase function is also intimately related to iron metabolism (Taketani 2005).
Therefore, it is hoped that ferrochelatase shall contribute to a better understanding of its
physiological importance, for instance, towards the pathogenesis mechanism and therapy
of erythropoietic porphyria as well as diseases associated with aberrant iron metabolism.
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Chapter Two

Materials

Plasmid pGF42 contains the mature form of wild-type murine ferrochelatase
subcloned into the pCASS3 vector (Ferreira 1994). Plasmid pGF47 contains the mature
form of wild-type murine ferrochelatase with a N-terminal 5X-His-tag (Franco et al.
2000). Plasmid pGF23 contains the murine erythroid 5-aminolevulinate synthase cDNA
cloned into the pCASS3 vector (Ferreira and Dailey 1993). E. coli strain Δvis was a kind
gift of Dr. H. Inokuchi at Kyoto University (Nakahigashi et al. 1991). E. coli strains
PK4331 (iscS-) and RZ4500 were from Dr. P. Kiley at the University of Wisconsin
(Schwartz et al. 2000).
Oligonucleotides were synthesized by Cybersyn, IDT Integrated Technologies
and Invitrogen.

Protoporphyrin IX, Ni-protoporphyrin, zinc-protoporphyrin and N-

methyl protoporphyrin were obtained from Frontier Scientific and were used without
further purification.

Hemin, tris(hydroxymethyl)amino-methane carbonate (Trizma

base), MOPS, tricine, thiamine, cholic acid, sodium citrate, polyethylene glycol sorbitan
monooleate (Tween-80), polyethylene glycol sorbitan monolaurate (Tween-20), agarose,
bovine serum albumin standard solution ampules, the bicinchonic acid protein
determination reagents, gel filtration molecular weight markers, CelLytic B II bacterial
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cell lysis extraction reagent, ExtrAvidin-peroxidase, palmitic acid, stearic acid, oleic acid,
linoleic acid, arachidonic acid and N-(biotinoyl)-1,2-dihexadecanoyl-sn-glycero-3phosphoethanolamine triethyl-ammonium salt (biotin-DHPE) were obtained from Sigma
Chemicals. Bacto agar, Bacto tryptone, yeast extract, vitamin assay casamino acids,
dextrose and ferrous ammonium sulfate were from Fisher Scientific.

Restriction

enzymes, DNA ligase and DNA polymerases were from New England Biolabs. Plasmid
purification kit, QiaQuick gel extraction kit and Ni-NTA agarose resins were from
Qiagen. Talon metal chelate affinity resins and Talon HT 96-well plate were from BD
Biosciences. Blue-sepharose CL-6B, PD-10 columns and Microspin S200-HR columns
were from Pharmacia. Amicon stirred cells, centricon, microcon, Amicon Ultra-4 and
Ultra-15 centrifugal filter units were from Millipore. Chelex-100 resins, sodium dodecyl
sulfate-polyacylamide gel electrophoresis reagents and silver staining kit were from BioRad Laboratories. Superdex-200 gel filtration matrix, T7 sequenase version 2.0 DNA
sequencing kit, ECL chemiluminescent Western blotting detection reagents and
Hyperfilm ECL were from GE Healthecare. Superblock blocking buffer and Gelcode
blue stain were from Pierce.
from

Schleicher

and

phosphatidylethanolamine

Protran BA85 nitrocellulose membrane (0.45 μm) was
Schuell.

(bovine

Phosphatidylcholine
liver),

phosphatidylinositol

(bovine
(bovine

liver),
liver),

phosphatidylserine (porcine brain), lysophosphatidylcholine (soy), lysophosphatidylethanolamine (chicken egg), cardiolipin (bovine heart), cholesterol, diacylglycerol and
sphingomyelin (porcine brain) were from Avanti Polar Lipids. Microtiter and gas-tight
syringes were from Hamilton. Screw-cap fluorescence cuvettes and magnetic stir bars
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were from Starna Cells. Septum caps were from Supelco. All reagents were of the
highest purity available.

Experimental Methods

Media preparation for bacterial cultures
All the media for bacteria growth were prepared and stored aseptically.
LB medium (for routine growth of E. coli cells) contains 1% Bacto tryptone, 0.5%
yeast extract, 1% NaCl.
LB/agar plate contains: 1% Bacto tryptone, 0.5% yeast extract, 1% NaCl., and
1.5% agar.
Terrific broth (enriched medium for growing E. coli cells) contains: 1.2% Bacto
tryptone, 2.4% yeast extract, 0.4% glycerol, 0.17 M KH2PO4, and 0.72 M K2HPO4.
SOB media (for recovery of transformed E. coli DH5α and BL21 cells) contains:
2% Bacto tryptone, 0.5% Bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2
and 10 mM MgSO4.
SOC media (for recovery of transformed Δvis cells) contains: 2% Bacto tryptone,
0.5% Bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and
20 mM glucose.
MOPS media (for induced protein expression in E. coli cells) consists of the
following components: 1 liter complete medium is prepared by mixing 200 mL M
solution (described below), 2 mL O solution (described below), 0.1 mL P solution
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(described below), 1 mL S solution (described below), 0.5 mL 0.2% thiamine, 40 mL
3.75% vitamin assay casamino acids, 20 mL 20% glucose, and supplemented with sterile
H2O to a final volume of 1 liter.
200 mL M solution is composed of 4.2 % (w/v) MOPS, 0.4% (w/v) tricine, 0.8%
(w/v) KOH, 1.46% (w/v) NaCl, 0.26% (w/v) NH4Cl and 0.42% (w/v) NaHCO3. M
solution is sterilized by autoclaving and kept at 4 oC.
50 mL O solution is prepared by dissolving 0.1g FeCl2·4H2O in 10 mL HCl and
10 mL H2O, mixing with 1 mL T solution (described below), adding 2.68 g MgCl2·H2O,
and filled with H2O to a final volume of 50 mL. O solution is filter-sterilized and kept at
4 oC.
100 mL P solution is prepared by dissolving 13.6 g KH2PO4 in 100 mL H2O. P
solution is sterilized by autoclaving and kept at 23 oC.
100 mL S solution is prepared by dissolving 4.81 g K2SO4 in 100 mL H2O. S
solution is sterilized by autoclaving and kept at 23 oC.
100 mL T solution is prepared by dissolving 184 mg CaCl2·2H2O, 64 mg H3BO3,
40 mg MnCl2·4H2O, 18 mg CoCl2·6H2O, 4 mg CuCl2·2H2O, 340 mg ZnCl2 and 605 mg
Na2MoO4·2H2O in 8 mL concentrated HCl, and filled with H2O to a final volume of 100
mL. T solution is filter-sterilized and kept at 23 oC.

Competent cell preparation and bacterial transformation
The procedures described here were used to prepare competent cells for
electroporation for the bacterial strain BL21(DE3) and DH5α. All reagents used were
prepared sterilely. LB medium was inoculated with E. coli cells stored as a frozen
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glycerol stock and the inoculum was grown on a LB/agar plate at 37 oC for 16 hr.
Bacterial cells from a single colony were used as an inoculum to grow a 20 mL culture in
LB medium at 37 oC overnight with shaking at 220 RPM on a platform shaker. The
saturated bacterial culture was diluted 50-fold into 1 liter LB medium. The freshly
diluted culture was incubated at 37 oC with shaking at 220 RPM, until OD600 reached
~0.6 when measured using a 1 cm path-length cuvette, which usually took ~1-2 hr. The
cells were pelleted by centrifuging at 6000 RPM in a Beckman JA-10 rotor for 10 min at
4 oC. Cell pellets were washed twice in ice-cold H2O, followed by two washes in icecold 10% glycerol. After the washes, cells were resuspended in 10% glycerol to a total of
~6 mL and aliquoted in ~200 μL to pre-chilled microfuge tubes. The aliquots were
quickly frozen in liquid N2 and stored at -80 oC. For electro-transformation, typically, 40
μL competent cells were incubated on ice with 1-2 μL solution containing a total of ~1
ng to 1 μg DNAs. The mixture was transferred to a pre-chilled 0.1 cm electroporation
cuvette and electroporated using a Bio-Rad Gene Pulser under the setting of 1.8 KV and
25 μF. The mixture was grown in 1 mL SOC medium for 1-3 hr at 37 oC in a platform
shaker at 220 RPM. 100-200 μl of the transformation was spread on an agar plate and
incubated at 37 oC overnight. Transformants were obtained from colonies developed on
the plate.

Glycerol stock preparation for bacterial cells
An individual colony developed on an agar plate was inoculated into ~5 mL
growth media and the culture was incubated at 37 oC overnight with shaking at 220 RPM.
The next day, the culture was collected and mixed with glycerol to make a stock solution
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containing 10% glycerol. Aliquots of ~1 mL were transferred to microfuge tubes and
stored at –80 oC.

Plasmid DNA purification
Plasmids from bacterial cultures were isolated using Qiagen Tip-20 or Tip-100
according to the manufacturer’s protocol. For small-scale preparation, colonies of BL21
or DH5α cells were inoculated into ~10 mL growth media. The culture was grown
overnight at 37 oC, and the plasmids were extracted usually at a yield of ~1 μg/mL
culture. Concentration of double-stranded DNA was determined by measuring OD260 in
a 1 cm path-length cuvette using an extinction coefficient of 1OD = 50 μg/mL DNA. An
aliquot of the preparation, usually 0.2-0.5 μg, was run on agarose gel, typically 0.8%, to
assess purity of the plasmid.

Sodium dodecyl sulfate-polyacylamide gel electrophoresis and protein concentration
determination
SDS-polyacrylamide gel electrophoresis was run as described by LaemmLi
(Laemmli 1970). Typically, 1-10 μg of denatured protein samples were run on 15%
acrylamide and 0.75-mm thick mini-gels. The denatured protein sample was prepared by
mixing proteins with loading buffer containing 50 mM TrisCl pH 6.8, 2% SDS, 0.1%
bromophenol blue and 10% glycerol, along with 0.1 M dithiothreitol dissolved in 1 mM
NaAcetate pH 5.2. The mixture was boiled at 95 oC for 2-3 min, and an aliquot of ~1015 μL was loaded onto a gel. Usually, gels were run at 100-120 V for 2-3 hr at 23 oC.
Protein bands were visualized using Coomassie Brilliant blue (R-250) staining by
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incubating gels in 0.25% Coomassie blue solution in 45% methanol and 10% acetic acid
for a few hours, followed by destaining in 30% methanol and 10% acetic acid for
overnight. Alternatively, gels were stained using Gelcode blue stain (Pierce). Gels were
rinsed in ddH2O several times, followed by overnight incubation in Gelcode solution and
destained in ddH2O for a few hours. Both methods allow ~1 μg or more proteins to be
shown. For improved sensitivity, gels were silver stained, which allows visualization of
~ 10 ng or more proteins.
Protein concentrations were determined by the bicinchoninic acid assay. In a 2
mL reaction, bicinchoninic acid and 4% (w/v) CuSO4 solution were mixed at a 50:1 ratio,
and the mixture was incubated with 100 μl protein sample. The reactions were allowed
to proceed for 30 min at 37 oC, or 2 hr at 23 oC. At the end, the absorbance of each
sample at 562 nm was measured using 1 cm path-length cuvette on a UVPC-2100U dualbeam spectrophotometer. A standard curve was generated using dilutions of 1 mg/mL
bovine serum albumin (BSA) stock solution in the reaction.

Construction of a random library and genetic selection of functional ferrochelatase
loop variants
Electro-competent cells of the E. coli strain Δvis were prepared following a
standard procedure. To complement deficiency in the endogenous ferrochelatase activity,
LB medium was supplemented with 10 μg/mL hemin and 0.4 % (w/v) glucose to allow
growth of Δvis cells. To eliminate background from wild-type ferrochelatase in library
construction, a mock vector was generated by replacing the segment in the murine
ferrochelatase expression plasmid pGF47 which spans the ten codons for the loop motif
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Figure 4. Random mutagenesis of the ferrochelatase active site loop motif and
biological selection of the functional variants.
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with a stuffer sequence derived from the murine ALAS expression plasmid pGF23 via
two unique restrictions sites BstEII and PspOMI (Figure 4). The ferrochelatase random
library was constructed based on previously described protocols (Munir et al. 1992; Gong
and Ferreira 1995; Landis and Loeb 1998) (Figure 4). Two single-stranded DNA oligos
with 15 complementary base pairs at their 3’ ends were annealed. Oligo 1 (5’-ATG GAA
AAG CTG GGT TAC CCC AAC CCC TAC CGA CTG GTT TGG-3’) is a 42mer
corresponding to the sense strand nucleotides and contains a BstEII site (italics) for
cloning. Oligo 2 (5’-AGC GTC ATC TGT CTG AGG GCC CAA CCA GGG TAC TGG
ACC AAC CTT GGA CTG CCA AAC CAG TCG GTA-3’) is a 66mer spanning the
antisense strand nucleotides with a PspOMI restriction site (italics) for cloning. Oligo 2
contains degenerate nucleotides (underlined) corresponding to codons 248-257 of the
mature murine ferrochelatase loop residues. Each of the ten loop codons was randomized
using 85% wild-type nucleotides and 15% mixture of the other three nucleotides. A 60
μL annealing reaction, containing 0.5 nmole of each oligo, 200 mM Tris-HCl, pH 7.5,
100 mM MgCl2 and 250 mM NaCl, was incubated at 80 °C for 5 min, followed by 55 °C
for 15 min, 37 °C for 15 min and finally at 23 °C for 30 min. The hybrid was extended
using the Klenow fragment of E. coli DNA polymerase I (5 units) in a 40 μL mixture
containing 50 pmole of annealed oligos, 62.5 µM of each of the four dNTPs and EcoPol
buffer (10 mM Tris-HCl, pH 7.5, 5 mM MgCl2 and 7.5 mM dithiothreitol). The extension
reaction was carried out at 37 °C for 2 hr. The generated double-stranded mutagenic
DNA was then amplified by the polymerase chain reaction (PCR) using two primers
corresponding to the 5’ termini of oligos 1 and 2. The two primers used were: FC-66, 5’ATG GAA AAG CTG GGT TAC CCC AA-3’, which covers the first 23 nucleotides of
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the 5’ terminus of oligo 1 and FC-R67, 5’-AGC GTC ATC TGT CTG AGG-3’, which
corresponds to the 18 nucleotides of the 5’ terminus of oligo 2. The PCR reactions were
performed in 100 µL reaction volumes consisting of 20 pmole of primers FC-66 and FCR67, 3-50 pmole of the extended double-stranded DNA as template, 50 µM each of the
four dNTPs, 1 unit of VentR DNA polymerase, and ThermoPol reaction buffer (20 mM
Tris-HCl, pH 8.8, 10 mM KCl, 10 mM (NH4)2SO4, 2 mM MgSO4 and 0.1% Triton X100). The reaction mixture was subjected to temperature cycling in a MJ Research
programmable thermal controller by running 1 cycle of 95 °C for 2 min, followed by 30
cycles of 95 °C for 1 min, 45 °C for 2 min, and 72 °C for 1 min, and a final extension at
72 °C for 10 min. The PCR product of 93 bp was purified using Microspin S200-HR
columns, and subsequently digested with BstEII and PspOMI. The ~60 bp digested
fragment was isolated from an agarose gel using GLASSFOG matrix and buffers in the
MERmaid kit and subcloned into the mock vector previously digested with the same
enzymes.
The 20 μL reaction ligation contained the randomLy mutagenized insert and
vector at a 5:1 molar ratio, 1 mM ATP, 7 units of T4 DNA ligase, ligase buffer (50 mM
Tris-HCl, pH 7.5, 10 mM MgCl2, 10 mM dithiothreitol, 1 mM ATP, and 25 µg/mL
bovine serum albumin), 100 mM NaCl and 10% PEG 6000. After 16-20 hr incubation at
16 °C, the ligation reaction was purified by passing through Microspin S200-HR columns
(Pharmacia), and used to transform competent Δvis cells with an Electroporator II
(Invitrogen). Aliquots of 1-2 μL of the ligated products were electroporated into 40 μL

Δvis cells, using 0.1 cm cuvettes (Invitrogen) at 1.5 KV, 50 μF and 150 Ω. After the
pulse, transformants were resuspended in 1 mL SOC medium (2% Bacto tryptone, 0.5%
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Bacto yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM MgSO4 and 20
mM glucose) supplemented with 10 μg/mL hemin, and incubated at 37 0C for 4 hr with
continuous shaking.

To assess transformation efficiency, a small portion of the

transformed cells was spread onto LB plates containing 50 μg/mL ampicilin, 0.4 % (w/v)
glucose and 10 μg/mL hemin.

The remaining transformed cells were plated onto

LB/ampicilin plates to allow selection of the active variants.
Only Δvis cells expressing functional ferrochelatase can form colonies on heminfree media. Aliquots of Δvis cells transformed with the random library ligation products
were plated on LB/agar medium containing 50 μg/mL ampicilin and 0.4 % (w/v) glucose,
and incubated at 37 °C for 24-30 hr. Plasmids were isolated from all of the surviving
colonies, and the randomized regions were sequenced to determine the permissible amino
acid substitutions. To prepare double-stranded DNA templates, ~20 mL of Δvis culture
for each clone was grown overnight in terrific broth containing 50 μg/mL ampicilin and
0.4 % (w/v) glucose, and plasmids were purified using Qiagen Tip-20 (Qiagen).
Sequences were determined for the sense strand using the primer MFC-73: 5’-AGA GGG
GAC CCC TAT CCC CAA GAG GTA-3’, which is 63 bp 5’ to the randomized loop
region. 166 clones were sequenced by the dideoxynucleotide chain termination method
using a T7 sequenase 2.0 DNA sequencing kit and 35S-dATP. The remaining 48 clones
were sequenced by the ABI automated DNA sequencers at the University of Florida.

Large-scale purification of the wild-type ferrochelatase and loop variants
The wild-type murine ferrochelatase and the functional loop variants were
expressed under the E. coli alkaline phosphatase promoter phoA in BL21(DE3) cells or
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DH5α cells as described previously (Ferreira 1994). Bacterial colonies were used to
inoculate ~100 mL LB/amp media and the culture was grown overnight at 37 oC with
shaking at 220 RPM.

Approximately 10 mL of the overnight culture was used to

inoculate 1 liter of MOPS medium containing 50 mg/liter ampicilin. The MOPS culture
was grown at 37 oC for 4 hr with shaking at 220 RPM in a Beckman platform shaker, and
the growth was continued at 25-30 oC for 16-20 hr. Typically, 8 liters of MOPS culture
were grown. Bacterial cells were pelleted at 6,000 RPM for 10 min at 4 oC in a Beckman
JA-10 rotor. Cells were resuspended in ~30 mL solution containing 20 mM TrisCl pH 8
and 10% glycerol. Cells were homogenized, and ruptured using a French press with 3-4
passages at 14,000 psi. To reduce proteolysis, 0.0017% (w/v) phenylmethylsulfonyl
fluoride was included in the lysate. Lysate was resuspended in a solution containing 0.6
M NaCl, 0.5% cholate, 20 mM TrisCl pH 8 and 10% glycerol under constant stirring at 4
o

C for 30 min. The solubilized lysate was centrifuged at 44,000 RPM using a 50.2Ti

rotor in a Beckman ultracentrifuge for 1 hr at 4 oC. The supernatant fraction was saved
and used for loading onto the affinity columns.
For protein purification using blue sepharose resins, the supernatant from
ultracentrifugation was mixed with 35% (NH4)2SO4 and stirred at 4 oC for 20 min. The
mixture was centrifuged at 11,000 RPM for 30 min.

The pellet fraction was

homogenized in ~20 mL equilibration buffer containing 20 mM TrisCl pH 8, 10%
glycerol, 0.5 M NaCl and 0.5% NaCholate. The homogenate was loaded onto a 15 x 2.5
cm gravity column packed with ~20 mL blue sepharose resins. The column was washed
in ~150 mL equilibration buffer until A280 < 0.1. Subsequently, the column was washed
with ~100 mL wash buffer containing 20 mM TrisCl pH 8, 10% glycerol, 1 M NaCl and
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0.5% NaCholate until A280 < 0.1. Proteins were eluted in elution buffer containing 20
mM TrisCl pH 8, 10% glycerol, 1.5 M NaCl and 1% NaCholate. Elution fractions, ~50
mL total, were pooled and concentrated in a 50 mL Amicon stirred cell to ~1-5 mL.
Aliquots of ~200 μL of purified concentrated proteins were stored in liquid N2 until use.
For purification of ferrochelatase with N-terminal His-tag using metal chelate
affinity resins, the supernatant fraction obtained from ultracentrifugation was loaded onto
a 17 x 1.5 cm gravity column packed with ~10 mL Talon resins equilibrated in buffer
containing 20 mM TrisCl pH 8, 10% glycerol, 150 mM NaCl and 0.5% NaCholate. The
column was first washed with ~200 mL equilibration buffer until A280 < 0.1. It was
further washed in ~100 mL equilibration buffer supplemented with 10 mM, 20 mM and
30 mM imidazole. Proteins were eluted using equilibration buffer containing 100 mM
imidazole. The protein in the elution fractions in a total of ~100 mL was pooled and
concentrated in an Amicon stirred cell. To remove imidazole, purified samples were
loaded onto a 100 x 2 cm HPLC column packed with ~150 mL Superdex-200 resins in
equilibration buffer. The proteins were eluted at a flow rate of 0.4 mL/min and elution
fractions were collected and concentrated.

UV-visible absorbance spectra of purified ferrochelatase
UV-visible absorption spectra of purified ferrochelatase and variants were
recorded using a UVPC-2100U dual-beam spectrophotometer (Shimadzu) with 1 cm
path-length cuvette at 23 oC. Typically, a protein solution at ~20 μM was added to the
cuvette, and the absorption spectrum was collected across the wavelength range of 250700 nm.
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Metal content analysis of purified ferrochelatase
The metal ion content of purified ferrochelatase was determined using plasma
emission spectroscopy. His-tagged wild-type ferrochelatase was purified using bluesepharose affinity column chromatography and variant S249A/K250Q/V251C was
purified using Talon metal chelate affinity column chromatography followed by gel
filtration chromatography.

The proteins were concentrated in a centricon (MWCO

10,000 Da). The sample for plasma emission spectroscopy was prepared in 1 mL assay
buffer containing 20 mM TrisCl pH 8, 10% glycerol and 150 mM NaCl. Metal ion
concentrations in 60 μM solution of His-tagged wild-type ferrochelatase, 40 μM and 23
μM solutions of variant S249A/K250Q/V251C and the assay buffer alone, were
determined using 20-element analysis at the Chemical Analysis Laboratory at the
University of Georgia.

Pyridine-hemochromogen assay
A conventional method to measure ferrochelatase activity is by quantifying heme
production using the pyridine-hemochromogen assay. A 2 mM protoporphyrin IX stock
solution was prepared by dissolving protoporphyrin in 100 mM NH4OH and 0.5% (v/v)
Tween-80. A 4 mM ferrous iron stock solution was prepared anaerobically by dissolving
15.7 mg Fe(NH4)2(SO4)2·6H2O and 27 mg Na3Citrate in 10 mL deaerated H2O. A
mixture containing the enzyme incubated with a solution containing 100 μM
protoporphyrin and 100 mM TrisCl pH 8 was deareated under Argon flow. Reaction was
initiated by adding the ferrous iron solution to a final concentration of 100 μM. The
68

entire reaction was incubated at 23 oC for 20 min. At the end of incubation, 0.5 mL of 1
N NaOH and 0.5 mL pyridine were added to the mixture. Half of the sample was
reduced with dithionite, and the other half was used as reference.

The difference

spectrum of the reduced sample versus the oxidized sample was collected at 23 oC using
a UVPC-2100U dual-beam spectrophotometer in 1 cm path-length cuvette. Wavelength
scan was run between 500 nm and 600 nm. The absorbance differential between the
maximum at 557 nm and minimum at 541 nm was recorded and used to calculate the
amount of pyridine-hemochromogen formed using the extinction coefficient Δε(A557A541) of 20.7 mM-1 cm-1 (Porra and Jones 1963a).

Continuous assay of ferrochelatase activity
An initial rate assay was developed for ferrochelatase by monitoring the decrease
of porphyrin fluorescence using protoporphyrin IX and ferrous iron as substrates. Caution
was taken in preparing the assay reagents in order to minimize trace metal ion
contamination. All of the buffers and solutions including 1 M Tris-acetate pH 8.1 and
10% (v/v) Tween-80 were made in HPLC-grade H2O and further purified using Chelex100 resins. Protoporphyrin IX was prepared as 200 μM stock solution by dissolving
porphyrin solid in 100 mM NH4OH and 0.5% (v/v) Tween-80. The solution was adjusted
to pH 8.1 with acetic acid, and kept in 0.1 M Tris-acetate pH 8.1. Ferrous iron was
prepared under anaerobic conditions as a 2 mM ferrous ammonium citrate stock by
dissolving equimolar amounts of ferrous ammonium sulfate and sodium citrate, i.e. 7.8
mg Fe(NH4)2(SO4)2·6H2O and 13.6 mg Na3Citrate in 10 mL H2O (Taketani and
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Tokunaga 1981). All glassware used in the assays was soaked in HCl overnight to
remove traces of iron.
Protoporphyrin fluorescence was monitored on a Shimadzu RF-5301PC
fluorimeter equipped with a red-sensitive photomultiplier tube. The thermostatically
controlled cell holder was maintained at 30

o

C.

A 2 mL solution containing

protoporphyrin IX in 0.1 M Tris-acetate pH 8.1 and 0.5 % (v/v) Tween-80 was deaerated
in a fluorescence cuvette sealed with a septum cap and containing a micro-magnetic
stirring bar. Deaeration continued for at least 30 minutes by applying repeated cycles of
vacuum and purging with ultra-high purity argon gas. The cuvette was then placed in the
fluorimeter cell holder. Purified ferrochelatase was added to the mixture by injection
using a fixed-needle syringe, and the mixture was equilibrated for 5 min at 30 oC under
constant stirring. The reaction was initiated by injecting ferrous iron, and the progress of
the reaction was monitored continuously by recording the emitted light through an
emission monochromator set at 635 nm (5-nm slit width) upon excitation at 505 nm (3nm slit width). The rate of change in fluorescence intensity (arbitrary unit min-1) was
converted to velocity (nmol of protoporphyrin min-1) using a standard curve of
fluorescence intensity versus protoporphyrin concentration. The time course for each
reaction was collected using the Shimadzu software RF-5301PC and the initial rates were
calculated from the linear portion of the progress curves.
The steady-state kinetic parameters KmFe2+, KmPPIX and kcat of wild-type
ferrochelatase were determined at 30 oC using the continuous fluorimetric assay as
described above. The data were analyzed in matrices of five protoporphyrin and five
Fe2+ concentrations by fitting the initial velocities to Equation 1:
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Vmax [PPIX][Fe 2+ ]
v = Fe2+
K i [PPIX] + K mPPIX [Fe 2+ ] + K mFe2+ [PPIX] + [Fe 2+ ][PPIX]

(Eq.1)

where KmPPIX and KmFe2+ are the Michaelis constants for protoporphyrin and Fe2+, KiFe2+ is
the dissociation constant for Fe2+, v is the initial velocity, and Vmax is the maximal
velocity of the reaction. Equation 1 describes the steady-state velocity equation for a bireactant system in the absence of products (Segel 1975). The kinetic constants and
standard deviations were calculated from regression analysis using the statistical program
DATAFIT (Oakdale Engineering).

Steady-state kinetic analysis of the loop variants
Ferrochelatase activity was determined by monitoring the consumption of
substrate protoporphyrin using ferrous iron as the metal substrate in a continuous
spectrofluorimetric assay conducted under strictly anaerobic conditions as described
previously (Shi and Ferreira 2003). Typically, a mixture containing 100 mM Tris-acetate
pH 8.1, 0.5% (v/v) Tween-80 and protoporphyrin IX was incubated with ferrochelatase
for ~5 min at 30 °C, and the enzymatic reaction was initiated by ferrous ammonium
citrate injection. Activities are expressed as nmole protoporphyrin consumed per minute
per mg of enzyme. The steady-state kinetic parameters were determined from matrices of
five protoporphyrin and five Fe2+ concentrations. The reported values and the standard
deviations were obtained from the nonlinear least squares fit of the data to the MichaelisMenten equation for bi-reactant systems using the software DataFit.
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Homology modeling of murine ferrochelatase
Comparative protein modeling of the three-dimensional structures of wild-type
murine ferrochelatase and selected loop variants was performed using the amino acid
sequence and coordinates for human ferrochelatase (PDB code 1hrk) as the template.
Sequence alignments, molecular modeling, energy minimization and PROCHECK model
analyses were performed on the Geno3D servers provided by the Institute of Biology and
Chemistry of Proteins (IBCP) in Lyon, France (Combet et al. 2002). The monomeric
models for wild-type ferrochelatase and the loop variants were visualized using the
program VMD version 1.7 (Humphrey et al. 1996). The secondary structures in the
protein models were identified by the STRIDE algorithm included in VMD.

Resonance

Raman

spectroscopy

of

porphyrin

binding

to

the

wild-type

ferrochelatase and loop variants
Stock solutions of protoporphyrin, hemin and Ni-protoporphyrin were prepared
by dissolving porphyrins in 100 mM NH4OH and 0.5% (v/v) Tween-80. Typically,
porphyrin stocks were made as 2 mM solutions, and further diluted in equilibration buffer
containing 20 mM TrisCl pH 8, 150 mM NaCl and 10% glycerol prior to incubation with
proteins. Wild-type ferrochelatase and the variants were purified by Talon metal chelate
affinity column without adding detergent sodium cholate during the entire purification
procedure. Aliquots of ~200 μL of purified proteins (typically at 100-150 μM) in
equilibration buffer were stored in liquid N2 until use. To prepare samples for resonance
Raman spectroscopy, porphyrins (typically 6 μM) were incubated with ferrochelatase
(typically 60 μM) in equilibration buffer on ice and the final concentration of detergent
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Tween-80 was adjusted to 12 μM. Each sample, in a final volume of ~100 μL, was
transferred to a stoppered 3 x 3 mm cross-section optical cell (NSG Precision Cells) for
spectra collection. The spectra were routinely recorded at 26 oC for 2-10 min using 20
mW laser power. The spectra were recorded on a Raman spectrometer by applying the
406.7-nm line of an INNOVA 304 Kr+ laser (Coherent) as previously described (Lu et al.
2002).

Briefly, the spectrometer consists of a 0.75m monochromator with a 2048-

channel liquid N2-cooled CCD detector (Instruments, SA). Position mode was used for
CCD detection, with each section covering about 500 cm-1 of the Raman spectrum
without moving the grating.
The resonance Raman spectra were exported as even-X ASCII files for plotting
with SigmaPlot (SPSS). Lorentzian decomposition of the spectra was performed using
the program PeakFit (SYSTAT). Curve-fitting was used to obtain the frequencies for the
centers of the structure-sensitive bands. For the region near the saddling-symmetry (B2u)
mode γ15, the spectral fitting procedure was adjusted to take into account the varying
signal-to-noise characteristics of the low-frequency Raman spectra for protoporphyrin
binding to the proteins.

First, the spectra of protoporphyrin bound to wild-type

ferrochelatase and the quadruple mutant Q248P/S249G/K250P/G252W, which exhibited
the highest signal-to-noise level, were fit with all parameters free, including the center,
width and amplitude of each Lorentzian band, as well as the slope and intercept of a
linear baseline. Eight lines were used to fit the frequency region from 580 to 780 cm-1,
and the average half-width at half maximum of γ15 was determined to be 2.814 cm-1.
This value for the width was then fixed and the data were refit. These parameters were
used for the constrained fits to yield the simulation results.
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Profiling the active variants by high-throughput protein purification
Plasmids encoding all the active loop variants were transformed into BL21 cells
and the variant proteins were purified using a TALON HT 96-well plate. BL21
transformants were inoculated into ~10 mL LB/ampicilin media and grown at 37 oC
overnight. Typically, ~5 mL culture was inoculated into 150 mL MOPS media, and the
culture was grown at 37 oC for 4 hr and then at 25 oC overnight. Bacterial cells were
pelleted at 4,000 RPM in an Eppendorf centrifuge, resuspended in a 10 mL solution
containing 20 mM TrisCl pH 8 and 10% glycerol. The cells were lysed by passing
through the French press twice. The lysate was solubilized in 20 mM TrisCl pH 8
containing 0.6 M NaCl, 0.5% NaCholate and 10% glycerol with stirring for 1 hr at 4 oC.
The mixture was centrifuged at 15,000 RPM for 30 min and the supernatant fraction was
saved. In a TALON 96-well plate, each well contained 200 mg BD Talon Superflow
resin and the resin was equilibrated with a buffer of 20 mM TrisCl pH 8 containing 10%
glycerol, 150 mM NaCl and 0.5% NaCholate. The supernatant was loaded into each
well. The wells were then washed with ~15 mL equilibration buffer until A280 < 0.1.
Further washes were in ~5-10 mL equilibration buffer supplemented with 10 mM and 20
mM imidazole. Ferrochelatase was eluted using 2 mL equilibration buffer supplemented
with 100 mM imidazole. The eluate was collected in a 96-well plate. Eluate for each
sample was concentrated to ~100 μL in an Amicon Ultra-4 centrifugal filter unit (MWCO
10,000). Imidazole in the sample was removed by exchanging the proteins into a storage
buffer of 20 mM TrisCl pH 8 containing 10% glycerol and 150 mM NaCl. UV-visible
absorbance scan was taken for each purified variant.

74

Liposomal binding assays of ferrochelatase variants
Liposomes were formulated with a lipid composition similar to that found in the
inner mitochondrial membranes of mouse liver cells (Ardail et al. 1990). Biotinylated
liposomes were prepared following a previously described procedure (Zhu et al. 2001).
Each lipid was weighed and suspended in chloroform to make a 1 mg/mL stock solution.
The lipid stocks were mixed in a glass tube at ratios (w/w) of 1% biotin-DHPE, 35%
phosphatidylcholine,

26.5%

phosphatidylethanolamine,

18%

cardiolipin,

5%

phosphatidylinositol, 2.3% cholesterol, 2.8% diacylglycerol, 0.7% sphingomyelin, 0.5%
phosphatidylserine, 0.5% lysophosphatidylcholine, 0.3% lysophosphatidylethanolamine,
2.2% palmitic acid, 1.2% stearic acid, 1.3% oleic acid, 1.8% linoleic acid and 0.9%
arachidonic acid. The mixture was dried under N2, resuspended in 25 mM TrisCl pH 7.6
and 150 mM NaCl (TBS). The resuspension was sonicated to obtain a 100 μg/mL
solution for use as a 1000X liposome stock for protein-binding assay. Liposome size
distribution was determined by dynamic light scattering at 26 oC using a submicron
particle size analyzer (Beckman Coulter) at the University of New Mexico.
Purified ferrochelatase was diluted to 1 μg/μL in equilibration buffer containing
20 mM TrisCl pH 8, 10% glycerol, 150 mM NaCl and 0.5% NaCholate. A serial dilution
by 70% was made for each protein stock. 10 μL of the diluted samples were spotted onto
nitrocellulose membrane (~10 x 15 cm) and air-dried for 30 min. The blot was then
wetted in H2O followed by TBS. For binding assay, the blot was first blocked with 50
mL Superblock buffer (Pierce) for 2 hr at 23 oC, followed by washing in TBS with 0.05%
(v/v) Tween-20 (TBST) 3 times for 10 min each. The blot was then transferred to a
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hybrization bottle (Amersham), and incubated with 50 μL liposome stock solution diluted
in 50 mL TBS. The hybridization bottle was placed on a rotor in a hybridization oven
(Fisher Scientific) at 30 oC for 1 hr. Subsequently, the blot was washed in TBST three
times for 15 min each at 23 oC. For biotin detection, the blot was incubated with 1 μL
peroxidase-conjugated extravidin (Sigma) at 2 mg/mL diluted in 50 mL TBS for 30 min,
at 23 oC. Final washes were in TBST twice for 15 min each, and in TBS three times for
15 min each. In the last step, the blot was treated with chemiluminescence substrate
solutions (Amersham Biosciences) according to the manufacturer’s instructions and
exposed to a Hyperfilm (Amersham Biosciences). The bound liposomes were quantified
using the densitometry program supplied with ChemiImager 4400 (Alpha Innotech). The
relative binding affinity was calculated from the intensity of chemiluminescent signals
plotted against the amount of protein spotted onto the nitrocellulose membrane. Wildtype ferrochelatase was run as the standard, and a variant (G252D/V254I) was used as an
internal control; essentially G252D/V254I was included in every single blot to ensure that
the ratio between the chemiluminescent signal intensity for wild-type protein and the
variant remained constant from blot to blot.

Inhibition assay of ferrochelatase by N-methyl protoporphyrin on agar plates
A 2 mM stock solution of N-methyl protoporphyrin (NMPP) was made by
dissolving NMPP in 20 mM NH4OH containing 2% (v/v) Tween-20. The solution was
filter-sterilized and kept at 4 oC. The stock solution was diluted 100-, 1000- and 10,000fold to prepare plates containing 20 μM, 2 μM and 0.2 μM NMPP. All plates were kept
at 4 oC in the dark. Δ vis cells transformed with wild-type ferrochelatase and functional
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variants were grown in LB medium containing 50 μg/mL ampicilin and 0.4 % (w/v)
glucose at 37 oC overnight with shaking at 220 RPM. Each of the overnight cultures was
diluted 20-fold into fresh media, and grown at 37 oC for ~1 hr until OD600 reached ~0.40.5. Subsequently, these cultures were diluted with LB medium by 106-fold and 100 μL
aliquots of the diluted stock were spread on plates containing LB/ampicilin only or with
added NMPP at 0.2 μM, 2 μM and 20 μM, respectively. The plates were incubated at 37
o

C for 16 hr, and the number of colonies developed on each plate was counted.

Quantification

of N-methyl

protoporphyrin

binding to ferrochelatase by

fluorescence quenching measurements
Purified wild-type ferrochelatase and variants P255R and P255G were diluted into
a 3 mL solution containing 10 mM Tris-acetate and 0.05% (v/v) Tween-80 at pH 8.
Protein fluorescence was excited at 283 nm and monitored at 331 nm at 23 oC using a
Shimadzu RF-5301PC fluorimeter. Equilibrium binding of N-methyl protoporphyrin to
the protein was monitored by quenching the intrinsic protein fluorescence. A stock
solution of NMPP at 200 μM was made by dissolving NMPP in 100 mM NH4OH
containing 0.5% (v/v) Tween-80. Aliquots were added to the protein solution. After
incubating on ice for 1 hr, fluorescence of the mixture was measured as described above.
The fluorescence intensity was plotted against NMPP concentration and the dissociation
constant of NMPP for ferrochelatase was determined using the least-squares fit of each
data set to Equation 2 by nonlinear regression (Anderson et al. 1988):
ΔF ⎡(Et +L +K d ) −
⎢⎣
F = F0 −

(Et + L + K d )2 − 4 Et L ⎤⎥
⎦

2 Et

77

(Eq.2)

where Kd is the dissociation constant, F is the measured fluorescence, F0 is the
fluorescence in the absence of NMPP, ΔF is the quenched fluorescence, Et is the total
protein concentration, and L is the total NMPP concentration.

Transient kinetic analysis of ferrochelatase activity
The kinetic steps involved in NMPP binding to ferrochelatase were assessed using
stopped-flow absorption spectroscopic analysis by monitoring the enzymatic reaction in
the presence of various concentrations of the inhibitor NMPP. The reactions were run on
an OLIS model RSM-1000 stopped-flow spectrophotometer equipped with a stoppedflow mixer and observation chamber of 4 mm optical path-length. The dead time of the
instrument is ~2 ms. Wavelength scans spanning 347 nm to 574 nm were collected at
1000 scan/sec. The syringes containing the reaction components and the stopped-flow
cell were maintained at 30 °C using an external water-bath. The concentrations of
reagents loaded into each syringe were twice the final concentrations in the observation
chamber upon mixing, which were reported as the actual values. Enzymatic activity was
monitored by following the increase in absorbance at 420 nm for zinc-protoporphyrin
production using Zn2+ and protoporphyrin as substrates.
The enzyme and substrate stock solutions were diluted in a buffer of 100 mM
Tris-acetate pH 8 containing 0.5% (v/v) Tween-80. A 3 mM zinc-acetate stock solution
was made by dissolving zinc-acetate in ddH2O. A 200 μM protoporphyrin stock solution
was prepared by dissolving protoporphyrin in 50 mM NH4OH and 0.5% (v/v) Tween-80.
A 2 mM N-methyl protoporphyrin stock solution was prepared by dissolving NMPP in
100 mM NH4OH containing 0.5% (v/v) Tween-80.
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Typically, a 2 mL solution

containing 1 μM ferrochelatase, 10 μM protoporphyrin and various amounts of NMPP
was pre-incubated on ice for 30 min. The mixture was subsequently transferred to one of
the stopped-flow syringes. The other stopped-flow syringe was loaded with ~2 mL
reaction buffer containing 30 μM zinc-acetate. The enzymatic reaction was initiated by
mixing the contents from both syringes.

Reaction progression was monitored by

following the increase in absorbance at 420 nm. The data were analyzed by fitting the
absorbance values to Equation 3:

A = A0 + vst +

v0 − vs
1 − e − kt
k

(

)

(Eq.3)

where A is the observed absorbance, A0 is the initial absorbance, νs is the steady-state
velocity, ν0 is the initial velocity, and k is the pseudo-first order rate constant for inhibitor
binding. Equation 3 describes the progress of enzymatic reactions in the presence of
tight-binding competitive inhibitors (Williams and Morrison 1979).

Ligand binding pocket size measurement

Structural models of wild-type ferrochelatase and variants P255R and P255G
were generated using the amino acid sequence and coordinates for human ferrochelatase
(PDB code 1hrk) as a template. Sequence alignments, molecular modeling, energy
minimization and PROCHECK model analysis were performed on the Geno3D servers at
the Institute of Biology and Chemistry of Proteins (IBCP) in France (Combet et al. 2002).
Dimensions of the porphyrin binding pocket in the monomeric models of wild-type
protein and the variants were calculated on the CASTp server (Liang et al. 1998). Values
for the area and volume of Connolly’s surface of the active site cavity were determined
using the CAST program (Liang et al. 1998).
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Enzymatic activity of ferrochelatase in the absence of FeS cluster synthesis

RZ4500 cells (iscS+) developed large colonies on LB/agar plates, whereas small
colonies of PK4331 cells (iscS-) were formed on LB/agar plates containing 30 μg/mL
kanamycin after overnight incubation 37 oC upon inoculating the cells stored as frozen
glycerol stock (Schwartz et al. 2000). Competent cells of both strains were prepared for
electroporation following previously described procedures. RZ4500 cells from a single
colony were inoculated into 10 mL LB medium and grown overnight at 37 oC with
shaking at 220 RPM. The saturated culture was diluted 100-fold into 1 liter LB medium,
and grown at 37 oC with shaking at 220 RPM until OD600 reached ~0.6, which usually
took ~2 hr. Cells were washed twice in H2O, then twice in 10% glycerol. Cells were
resuspended in 5 mL of 10% aqueous glycerol. Aliquots of 0.5 mL suspension were
rapidly frozen and stored at -80 oC. PK4331 cells from a single colony were inoculated
into 40 mL LB medium containing 30 μg/mL kanamycin and grown overnight at 37 oC.
The saturated culture was diluted 100-fold into 4 liter LB/kanamycin medium, and grown
at 37 oC with shaking at 220 RPM until OD600 reached ~0.6, which took ~6 hr. Cells
were washed twice in H2O, then twice in 10% glycerol. Cells were resuspended in 20
mL 10% glycerol. Aliquots of 0.5 mL suspension were rapidly frozen and stored at -80
o

C.
Aliquots of 40 μL electro-competent RZ4500 cells and 100 μL electro-competent

PK4331 cells were mixed separately with plasmids encoding wild-type ferrochelatase,
single mutant C341A, triple mutants S249A/K250Q/V251C and S249A/K250R/G252W.
The mixtures were transferred to pre-chilled 0.1 cm electroporation cuvettes and

80

electroporated at 1.8 KV, 25 μF using a Bio-Rad Gene Pulser.

Transformation of

RZ4500 cells was grown in SOB medium at 37 oC for 1 hr and plated onto LB/ampicilin
plates. Transformation of PK4331 cells was grown in SOB medium at 37 oC for 5 hr and
plated onto LB/ampicilin/kanamycin plates. Subsequently, 50 mL MOPS culture was
grown for each transformant. The culture was pelleted, and the pellet was resuspended in
20 mM TrisCl pH 8 and 10% glycerol. The resuspension was passed through French
press twice, and the lysate was solubilized by incubating with 0.6 M NaCl and 0.5%
NaCholate with stirring at 4 oC for 30 min. 10 mL total lysate was obtained for each
transformant. Enzymatic activity was measured using a zinc-chelatase assay as described
previously (Shi and Ferreira 2004). A 2 mL reaction mixture was set up by adding 200
μL cell lysate, 3 μM ZnCl2 and 2 μM protoporphyrin in a buffer of 100 mM TrisCl pH
7.6, and the mixture was incubated for 1 hr at 37 oC. The amount of ZnPP formed was
measured by monitoring fluorescence at 592 nm upon excitation at 421 nm.

Molecular mass assessment of purified ferrochelatase

The molecular mass of purified ferrochelatase was assessed using size exclusion
column chromatography. A 100 x 2 cm HPLC column packed with ~150 mL Superdex200 resin was equilibrated with 20 mM TrisCl pH 8 containing 150 mM NaCl and 5%
glycerol. The flow rate was 0.4 mL/min. Purified wild-type ferrochelatase and variants
S249A/K250R/G252W and S249A/K250Q/V251C were injected in 100-200 μL aliquots
at a protein concentration of 240-800 μM. Elution fractions were collected at 1 mL
intervals, and absorbance at 280 nm of each fraction was measured using a Shimadzu
UVPC-2100U dual-beam spectrophotometer with 1 cm path-length cuvette at 23 oC. The
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column was calibrated using marker proteins of known molecular masses which included
amylase (200 kDa), alcohol dehydrogenase (150 kDa), albumin (66 kDa), carbonic
anhydrase (29 kDa) and cytochrome c (12.4 kDa). Enzymatic activity of the eluted
protein was determined using a zinc-chelatase assay as described previously (Shi and
Ferreira 2004).
Dynamic light scattering was used as an alternative method for molecular size
measurement. Approximately 1 mg each of the purified wild-type ferrochelatase and
variants S249A/K250Q/V251C and S249A/K250R/G252W was diluted into a 4 mL
buffer of 20 mM TrisCl pH 8 containing 150 mM NaCl, 0.5% NaCholate and 10%
glycerol. The molecular mass distribution in each sample was analyzed at 23 oC on a
particle size analyzer at the Particle Engineering Research Center at the University of
Florida.

Electron paramagnetic resonance spectroscopy of purified ferrochelatase

EPR spectra were collected for wild-type ferrochelatase and variants
S249A/K250R/G252W and S249A/K250Q/V251C.

Wild-type protein was purified

using blue-sepharose affinity resin (Ferreira 1994; Shi and Ferreira 2003) or Talon metal
chelate affinity resin (Shi and Ferreira 2004), while the variants were purified using
Talon resin as described previously (Shi and Ferreira 2004). X-band EPR spectra were
collected in collaboration with Dr. David Tierney at the University of New Mexico.
Purified proteins were reduced by titrating with dithionite at an equal molar ratio.
Samples in the concentration range of 190-400 μM were analyzed by spectroscopy.
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Chapter Three

Results

Purification of recombinant ferrochelatase

Large-scale purification of wild-type ferrochelatase and loop variants

In order to obtain large quantities of purified ferrochelatase for characterization,
recombinant wild-type protein and variants were isolated from an overexpression system
by growing the BL21 cells or DH5α transformants in complete MOPS media. Wild-type
protein and selected variants were typically purified by affinity column chromatography
using blue-sepharose resins or metal chelate resins. Interestingly, while certain variants,
including triple mutant K250M/V251L/W256Y, were difficult to purify by either bluesepharose or Ni-NTA agarose resins following the standard procedures, the problem was
circumvented by applying cobalt-based metal chelate affinity resins (Talon resins).
Subsequently, Talon resins were used routinely to purify His-tagged ferrochelatase. On
average, 1-2 mg purified proteins could be obtained from 1 liter culture. The yield was
lower

for

some

variants

including

K250M/V251L/W256Y

and

Q248P/S249G/K250P/G252W by 2-3 fold compared to wild-type ferrochelatase.
Typically, purified proteins were concentrated to 1-10 mg/mL (20-200 μM) and stored in
liquid N2.
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The UV-visible absorption spectra of purified ferrochelatase exhibit distinct
features derived from the FeS cluster (Figure 5).

In wild-type ferrochelatase, one

monomeric unit is associated with one [2Fe-2S] cluster, giving rise to the characteristic
absorbance band at 330 nm and shoulders at 440 nm and 525 nm. Typically, for wildtype protein, the absorbance ratio A330/A278 is 3 and A440/A278 is 6.
exhibited

UV-visible

spectra

similar

to

wild-type

Most variants

ferrochelatase.

Variants

S249A/K250R/G252W and S249A/K250Q/V251C showed absorption features with
some alterations and were further analyzed. Purity of the proteins was checked by SDSPAGE. Similar to wild-type ferrochelatase, purified variants migrated on the SDS-PAGE
gel with an estimated molecular mass of 42 kDa (Figure 6).

Small-scale purification of ferrochelatase loop variants

All of the 33 active variants generated in the random library were over-expressed
and purified from BL21 cells using a Talon-HT 96-well plate. The yield of purified
proteins obtained by the plate method was similar to that obtained from large-scale
cultures. Typically, 1-2 μg ferrochelatase could be isolated from 1 mL MOPS culture.
Purified proteins, 20-200 μg in total, were concentrated to 200 μL for use in the
concentration

range

of

0.1-1

mg/mL

(2-20

μM).

The

triple

mutant

S249A/K250R/G252W was produced at a lower yield of ~0.3 μg/mL culture. The lowest
yield was observed in the double mutant V254I/L257K, which could only be obtained at
~0.01 μg/mL culture.
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Figure 5. The UV-visible absorbance spectra of purified wild-type murine
ferrochelatase and selected loop variants.
The recombinant wild-type ferrochelatase and variants were over-produced in E. coli
DH5α or BL21(DE3) cells and purified using blue-sepharose or metal chelate affinity
column chromatography. The absorption spectra are shown for: (a) wild-type protein
(8.8 μM), (b) single mutant V251L (15.2 μM), (c) triple mutant
S249A/K250Q/V251C (18.8 μM), (d) triple mutant K250M/V251L/W256Y (10.5
μM), (e) quadruple mutant Q248P/S249G/K250P/G252W (19.4 μM). Similar to
wild-type ferrochelatase, most variants exhibited the electronic absorption features
characteristic of [2Fe-2S] cluster-containing proteins, including absorption bands at
330 nm, and shoulders at 440 nm and 525 nm. Variant S249A/K250Q/V251C lacked
the absorption shoulder at 440 nm.
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Figure 6. SDS-polyacrylamide gel electrophoresis of purified ferrochelatase.
Migration of purified murine ferrochelatase with N-terminal 5X-His-tag on 15% SDSpolyacrylamide gel is shown. The estimated apparent molecular mass for wild-type
protein (10 μg) was 42 kDa (lane 2). Variant Q248P/S249G/K250P/G252W (5 μg)
exhibited a similar size (lane 3).
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Developing a continuous assay for steady-state kinetic analysis of ferrochelatase

A continuous assay was developed to determine ferrochelatase activity based on
the fluorescence properties of porphyrin. The substrate protoporphyrin IX is fluorescent,
whereas the reaction product protoheme does not fluoresce. Thereby, it was possible to
monitor the progress of the ferrochelatase-catalyzed reaction with ferrous iron and
protoporphyrin IX as substrates by following the decrease of protoporphyrin
fluorescence. To minimize inner filter effect associated with excitation in the Soret band
at 406 nm, porphyrin fluorescence was monitored using λex= 505 nm and λem = 635 nm
(Figure 7). Strictly anaerobic conditions were imposed during the assay in order to
maintain iron substrate in the reduced state. Reactions were conducted at the optimal pH
of 8, and 0.5% (v/v) Tween-80 was included in the medium to optimize solubilization of
protoporphyrin. Under these conditions, the initial rate of the reaction was obtained from
the slope of the progress curve by monitoring the disappearance of substrate porphyrin
fluorescence (Figure 8). The rate of porphyrin disappearance was found to be linearly
dependent on the concentration of wild-type enzyme in the range of 25-150 nM (Figure
9). Thus, the assay allows enzymatic activity to be determined for ferrochelatase in the
nM concentration range, in contrast to the conventional pyridine-hemochromogen
method, which requires a relatively large amount of protein (>100 nM). Steady-state
kinetic analysis of wild-type ferrochelatase indicates that the enzymatic activity exhibited
hyperbolic dependence on protoporphyrin concentration at various ferrous iron
concentrations (Figure 10). The calculated Km values for protoporphyrin IX and ferrous
iron are 1.4 ± 0.2 μM and 1.9 ± 0.3 μM, respectively, while kcat is 4.0 ± 0.3 min-1.
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A

B

Figure 7. The fluorescence spectra of protoporphyrin.
The spectra were shown for protoporphyrin IX (1 μM) in assay buffer containing 100
mM Tris-acetate pH 8 and 0.5% (v/v) Tween-80. (A) The excitation spectrum
displayed four distinct bands at 406 nm, 505 nm, 541 nm and 576 nm (λem = 635 nm).
(B) The emission spectrum exhibited a maximum at 635 nm (λex = 505 nm).
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Fe2+ injection

Figure 8. Time course for the disappearance of protoporphyrin in the
ferrochelatase-catalyzed reaction.
Wild-type murine ferrochelatase (176 nM) was pre-incubated with protoporphyrin (2.7
μM) at 30 oC under strictly anaerobic conditions. Reaction was initiated by addition
of ferrous iron (5 μM). The decrease in fluorescence intensity at 635 nm (λex = 505
nm) was continuously monitored over the course of the reaction. The initial rate was
determined from the slope of the tangent to the initial, linear part of the progress
curve.
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Figure 9. Dependence of the initial rate of protoporphyrin consumption on
ferrochelatase concentration.
Initial rates were determined for enzymatic reactions by the continuous assay using
protoporphyrin (2 μM), Fe2+ (4 μM) and purified wild-type ferrochelatase at various
concentrations.
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Figure 10. Determination of the steady-state kinetic parameters of wild-type
murine ferrochelatase.
Enzymatic activity was measured using a continuous assay conducted at 30 oC under
strictly anaerobic conditions. The reactions contained purified ferrochelatase (70 nM),
protoporphyrin and ferrous iron. The hyperbolic curves represent the best fits to the
Michaelis-Menten equation by plotting initial velocity against protoporphyrin
concentration at constant Fe2+ concentrations of 0.5 μM (▲), 1 μM (□), 2 μM (●), 3
μM (∇) and 4 μM (■). The steady-state kinetic parameters of the wild-type
ferrochelatase were determined to be KmPPIX = 1.4 ± 0.2 μM, Km Fe2+ = 1.9 ± 0.3 μM,
and Vmax = 97.4 ± 7.9 nmol min-1 mg-1 enzyme.
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Characterization of the functional ferrochelatase loop variants

Crystal structural analysis of ferrochelatase reveals that the enzymes exhibit
similar folding patterns and active site structures throughout evolution. Each monomeric
unit consists of two domains, with each domain folded into a Rossmann-type fold. The
active site is located in a deep cleft between the two domains. One side of the cleft is
formed by the first two N-terminal α-helices, α1, α2, and a loop between them, and the
other side consists of a short loop sequence (Al-Karadaghi et al. 1997; Lecerof et al.
2000; Wu et al. 2001; Karlberg et al. 2002). The loop motif exhibits a high degree of
sequence identity among all known ferrochelatases (Figure 11). The loop has been
proposed to be directly involved in porphyrin interaction based on molecular dynamics
calculations of B. subtilis ferrochelatase with bound nickel-protoporphyrin (NiPP)
(Franco et al. 2000) and crystal structural analysis of ferrochelatase with the heme analog
N-methyl mesoporphyrin bound in the active site (Lecerof et al. 2000). To test this
hypothesis, random mutations were introduced to the ten consecutive loop residues
Q248-L257 in murine ferrochelatase and functional variants were further characterized.

Biological selection of the active loop variants

By incorporating a mixture of four nucleotides at each of the 30 bases in the target
sequence, random substitutions were generated simultaneously in all the residues. Using
a combination of 85% of the wild-type nucleotides and 15% of the other three nucleotides
at each position, the bias was set towards the wild-type sequence, thus increasing the
probability of recovering active ferrochelatase variants. Under these conditions, a full
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Figure 11. Sequence alignment of the loop motif in ferrochelatase.
A representative subset illustrates high degree of identity in the loop motif among all
known sequences of ferrochelatase. The amino acid sequences were obtained from NCBI
using BLAST search and aligned using CLUSTAL W (Thompson et al. 1994).
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spectrum of permissible substitutions at each position was drawn.

To eliminate

background activity from wild-type enzyme, a mock vector was constructed by replacing
a segment of wild-type ferrochelatase plasmid with a nonfunctional stuffer sequence, and
it was used as the cloning vector for the random nucleotide sequences. In order to select
the functional variants, E. coli strain Δvis was chosen as the host for the plasmid library
containing the randomized loop sequences. Because Δvis cells need hemin in the growth
media for survival, transformants of Δvis cells carrying the mock vector with inactivated
ferrochelatase could not grow in hemin-free media, while Δvis cells transformed with a
functional ferrochelatase expression plasmid could override the requirement for hemin
and form colonies on hemin-free plates. Screening of the unselected library by genetic
complementation showed that 90% of the random mutants were inactive.

This is

consistent with the hypothesis that the loop motif is important for enzymatic function,
and also demonstrates that the biological selection procedure was efficient. From a total
of 2,210 Δvis transformants harboring randomized loop mutations, 214 clones were able
to grow in hemin-free medium, and the plasmids were sequenced to identify nucleotide
changes in the loop region. Most of them were single, double and triple mutants, with an
average of 2.2 amino acid changes (Figure 12A). For a relatively quick assessment of the
active library, all of the functional Δvis transformants were assayed for enzymatic activity
by monitoring zinc-protoporphyrin production using crude cell extracts. Most variants
showed zinc-chelatase activity reduced to less than 60% of the wild-type level, whereas a
subset of triple mutants displayed activities comparable to, or even higher than, wild-type
ferrochelatase (Figure 12B).
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A

B

Figure 12. Activity assessment and distribution of the number of the functional loop
variants.
(A) Distribution of the number of the functional variants relative to the number of amino
acid changes. Random substitutions were introduced into the ten residues encoding the
murine ferrochelatase loop motif.
Active variants were recovered by genetic
complementation in the E. coli strain Δvis, and mutations were identified by DNA
sequencing. (B) Zinc-chelatase activity of the variants relative to the number of amino
acid substitutions.
Zinc-chelatase activity was assayed by monitoring zincprotoporphyrin formation using cell extracts prepared from Δvis cells transformed with
the active variants. Enzymatic activity of each variant was normalized to the activity
level of wild-type enzyme.
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Distribution of the functional amino acid substitutions

The spectrum and frequency of substitutions observed in the active variants are
shown in Figure 13. Functional mutations were detected at every residue in the loop
motif. However, single mutants were only recovered at five positions, i.e., K250, V251,
P253, V254 and P255, and they are grouped as low informational content residues.
Changes were mostly conservative at K250 and V251, while P253, V254 and P255
tolerated a diverse set of alterations. Mutations in any of the remaining five residues
were rare and only occurred in conjunction with substitutions at other positions, and
thereby they contain high informational content. Permissible replacements at Q248,
S249, G252, W256 and L257 were very restricted, with the exception of G252, which
could be converted to residues of various sizes and charges in the context of double,
triple, quadruple and penta mutants.

Steady-state kinetic analysis of the active loop variants

Five active variants were purified to homogeneity and characterized by steadystate kinetic analysis. The single mutant V251L was selected because it was the only
point mutation allowed at the low information content residue V251 and was also coselected in a number of double, triple and quadruple mutants. The single mutant P255R
was selected because, although P255 has low information content, arginine replacement
was a drastic amino acid alteration and was observed in single, double and quadruple
mutants (Figure 13). Due to the lack of single substitutions at the high information
content positions, multiply-substituted variants were chosen for further analysis (Figure
13). By characterizing the triple mutants S249A/K250Q/V251C, K250M/V251L/W256Y
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Figure 13. Spectrum and frequency of amino acid substitutions in functional loop
variants.
Mutations at each residue are listed along with the number of times each substitution was
observed. The wild-type loop sequence is shown on the bottom of each mutant category.
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and the quadruple mutant Q248P/S249G/K250P/G252W, attempts were made to examine
the mutational effects of Q248, S249, G252 and W256 in combination with changes at
other positions.
Steady-state analysis indicated that, with exception of the triple mutant
K250M/V251L/W256Y, all of the variants had kcat values comparable to or higher than
that of wild-type ferrochelatase (Table 1). There was a 2-fold increase in kcat for the
single mutants V251L and P255R, 4.5-fold increase for the triple mutant
S249A/K250Q/V251C,

and

Q248P/S249G/K250P/G252W.

3.5-fold

increase

for

the

quadruple

mutant

Relative to wild-type enzyme, the Km values for

protoporphyrin (KmPPIX) were elevated ranging from a 2-fold increase for the single
mutant P255R to 8-fold for the triple mutant K250M/V251L/W256Y, suggesting that the
interaction with the porphyrin substrate was disrupted due to the loop mutations (Table
1). The Km values for ferrous iron (KmFe2+) in the single mutants V251L and P255R and
triple mutant K250M/V251L/W256Y were of the same order of magnitude as that in
wild-type enzyme.

The KmFe2+ value was 2.5-fold higher for the triple mutant

S249A/K250Q/V251C, while a 4-fold decrease was observed for the quadruple mutant
Q248P/S249G/K250P/G252W (Table 1).

Homology modeling of wild-type murine ferrochelatase and selected loop variants

To assess how loop mutations could possibly affect the three-dimensional
structure of ferrochelatase and the active site architecture, structural models of the
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Table 1. Steady-state kinetic parameters of wild-type ferrochelatase and selected
loop variants.
Ferrochelatase activity was determined by a continuous assay using protoporphyrin and
2+
o
Fe as substrates (Shi and Ferreira 2003). The assays were conducted at 30 C under
strictly anaerobic conditions. Steady-state kinetic parameters were determined using
matrices of concentrations for both substrate protoporphyrin and Fe2+ (Shi and Ferreira
2004).

kcat

KmPPIX

kcat / KmPPIX

KmFe2+

kcat / KmFe2+

(min-1)

(μM)

(min-1 μM-1)

(μM)

(min- 1 μM-1)

Wild-type ferrochelatase

4.1 ± 0.3

1.40 ± 0.20

2.93

1.90 ± 0.30

2.16

V251L

8.3 ± 1.2

1.82 ± 0.35

4.56

1.13 ± 0.53

7.35

P255R

7.8 ± 0.8

2.65 ± 0.44

2.94

1.46 ± 0.38

5.34

S249A/K250Q/V251C

18.0 ± 2.5 6.84 ± 1.74

2.63

5.15 ± 1.44

3.50

K250M/V251L/W256Y

3.0 ± 0.4 11.25 ± 2.45

0.27

1.08 ± 0.48

2.78

Q248P/S249G/K250P/G252W 14.1 ± 0.9 10.34 ± 1.14

1.36

0.48 ± 0.21

29.40

Proteins
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wild-type protein and loop variants were generated using the crystal structure of human
ferrochelatase as a template. The sequences used in modeling wild-type and mutant
murine ferrochelatase were at least 91% similar to the human ferrochelatase template.
The average free energy of the structural models was approximately 16 kcal/mol. The
Ramachandran plots showed a normal distribution of points with at least 99% residues
occupying the allowed regions. C-α chirality, amide torsion (ω) and side chain torsions
(χ1 and χ2) showed no major deviation from the corresponding allowed values.
Superimposition of the monomeric model of wild-type murine ferrochelatase with the Xray crystal structure of human ferrochelatase gave a RMSD of 1.23 Å for the Cα-atoms
of the 357 aligned residues. Structural models of the loop variants (Figure 14) exhibited
slightly more resemblance to human ferrochelatase, as indicated by a small reduction in
RMSD values (~0.8-0.9 Å).
In the wild-type model, the N-terminal loop residues Q248 and S249 were buried
deeply inside the active site cavity and in very close proximity (about 4 Å) to H209 and
E289, which were previously proposed to be essential for catalysis (Kohno et al. 1994;
Gora et al. 1996b; Franco et al. 2001; Sellers et al. 2001). K250 was solvent-exposed
with the side chain projecting to the protein exterior and in close contact with the Q260
residue. V251 oriented its side chain towards the interior of the active site pocket, while
G252 occupied the tip of the loop, and together with P253, V254 and P255, formed a
solvent-exposed patch. The indole ring of W256 was positioned nearly perpendicular to
the H209 and E289 side chains, a d L257 was exposed to the protein surface with the side
chain extended away from the active site pocket. The spatial arrangement of the loop
residues was not significantly altered by the functional substitutions in the selected
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Figure 14. Molecular modeling of wild-type murine ferrochelatase and selected loop
variants.
The structural models (monomeric) were generated by homology modeling on Geno3D
servers (Combet et al. 2002) using the X-ray crystal structure of human ferrochelatase
(PDB code 1hrk) as a template. Substituted residues in the loop motif (red) are marked
(green). The color scheme for the secondary structures is: α-helix in blue, β-strand in
yellow, 310-helix in lime, π-helix in purple, turns and coils in cyan. The N-terminal α2
helix and its extension in the loop variants are indicated by open arrows; the second
domain π-helix and its variations are indicated by filled arrows. When not occluded by
structural elements, the N- and C-termini are indicated. The three-dimensional models
are shown for: (A) wild-type murine ferrochelatase, (B) single mutant V251L, (C) single
mutant P255R, (D) triple mutant S249A/K250Q/V251C, (E) triple mutant
K250M/V251L/W256Y, (F) quadruple mutant Q248P/S249G/K250P/G252W. Images
were generated using VMD 1.7 (Humphrey et al. 1996).
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variants (Figure 14).
For all loop variants, changes in the secondary structure were observed in the Nterminal domain forming one side of the active site cavity, and in the second domain πhelix region located adjacent to the active site cleft (Figure 14). At the N-terminus,
immediately following the second α-helix (α2), the variants showed an increase of
helical content in place of the relatively unstructured turns. While in the structural model
of wild-type protein the α2 helix consists of 10 residues Q52-K61 (Figure 14A), in the
loop variants, the α2 helix was extended by a short α-helix or 310-helix to include 5-7
additional residues (Figure 14B-F). These additional residues along with the meandering
loop that follows appear to contact residues in the second domain of the enzyme close to
the active site cavity.
The structural model of wild-type murine ferrochelatase revealed a short π-helix,
consisting of five residues

290

TLYEL294 in the second domain near the bottom of the

active site pocket (Figure 14A), in an analogous fashion to the π-helix observed in the
crystal structures of human (349ELDIE353) and yeast (318EIDLG322) ferrochelatases (Fodje
and Al-Karadaghi 2002).
S249A/K250Q/V251C

This π-helix was replaced by an α-helix in the triple mutant
(Figure

14D).

In

contrast,

the

Q248P/S249G/K250P/G252W had a long π-helix comprising the

quadruple
289

mutant

ETLYELDIEY298

sequence, which is enriched with acidic residues (Figure 14F). In the single mutants
V251L and P255R and the triple mutant K250M/V251L/W256Y, the π-helix shifted
positions slightly to include two glutamate residues (Figure 14B, 14C, 14E). In these
structures, the π-helix was formed by groups of five residues including
V251L and P255R and 289ETLYE293 in K250M/V251L/W256Y.
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Interaction of ferrochelatase with mitochondrial membrane lipids

Polarity distribution among the functional substitutions in the loop variants
indicated that mutations in the three N-terminal loop residues, Q248, S249 and K250,
reduced the hydrophilic environment of the N-terminal looplet (Figure 15A).
Conversely, the seven non-polar C-terminal residues V251-L257 were replaced by
mostly polar, acidic or basic amino acids (Figure 15A). Furthermore, basic amino acid
substitutions were enriched in the C-terminal loop region of the active variants. In order
to examine potential interaction of the variants with the negatively-charged membrane
lipids, liposomes were formulated to mimic lipid composition of the mouse liver inner
mitochondrial membrane, with which ferrochelatase is associated in vivo. The average
diameter of liposomes was determined to be approximately 170 nm by dynamic light
scattering. Liposomal binding assay results indicated that affinities for the membrane
lipids can be modified by loop mutations (Figure 15B). In general, the variants carrying
basic residues in the C-terminal looplet exhibited stronger interaction with liposomes
than wild-type protein, implying that the localized positive charges favor lipid interaction
(Figure 15C).
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Figure 15. Interaction between ferrochelatase and the mitochondrial membrane
lipids.
(A) Polarity distribution at each loop position in the functional variants. Basic amino
acid substitutions accumulated in the C-terminal looplet positions G252, P253, V254,
P255 and L257. Hydrophobic residues include A, F, G, I, L, M, P, V and W; polar
residues include C, N, Q, S, T and Y; acidic residues include D and E; basic residues
include H, K and R. (B) Protein-lipid interactions among wild-type ferrochelatase and
active loop variants. Proteins were purified in a 96-well format, spotted onto
nitrocellulose membrane in a dilution series, and probed with biotinylated liposomes.
Bound liposomes were detected using peroxidase-conjugated extravidin and visualized
using the enhanced chemiluminescence (ECL) system. Examples are shown for
enhanced lipid-binding to variant P253Q/V254K/P255T (row 1) and decreased binding to
variant Q248P/S249G/K250P/G252W (row 2) relative to the wild-type protein (row 3).
The variant G252D/V254I (row 4) was included as an internal control. (C) Analysis of
liposomal binding affinities of the active variants. The right panel illustrates the
liposome-binding affinity of each variant normalized against that of the wild-type
ferrochelatase. The left panel indicates the polarity of individual loop residues in each
variant using a color code corresponding to: blue for hydrophobic residues, yellow for
polar residues, black for acidic residues, and red for basic residues. Mutated positions in
each variant are marked by an X.
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Resonance Raman spectroscopic analysis of porphyrin binding in the loop variants

An important step in the enzymatic reaction catalyzed by ferrochelatase involves
distortion of the porphyrin macrocycle to expose the lone-pair orbitals of pyrrole
nitrogens to incoming metal ion, thereby facilitating metal chelation. In order to assess
the role of the loop residues in porphyrin deformation, the vibrational modes of
porphyrins bound to wild-type enzyme and loop variants were examined by resonance
Raman spectroscopy.

Binding of substrate protoporphyrin to the variants

Substrate (i.e., free-base protoporphyrin) binding in the active site of
ferrochelatase loop variants was examined at a 0.1 porphyrin / protein molar ratio using
RR spectroscopy in a similar fashion to that previously devised for wild-type murine
ferrochelatase (Lu et al. 2002). The RR spectra of the variant-bound porphyrin exhibited
clear differences from those of unbound porphyrin in the detergent miscelle environment
and porphyrin bound to wild-type enzyme (Figure 16). In the low-frequency region, as
was found previously for wild-type ferrochelatase [(Lu et al. 2002) and Figure 16A,
spectrum b], the ν7 line upshifted from 666 cm-1 for unbound porphyrin in the
equilibration buffer to 673-675 cm-1 in four variants (Figure 16A, spectra d-g); the largest
shift (to 677 cm-1) was detected in porphyrin bound to the triple mutant
K250M/V251L/W256Y (Figure 16A, spectrum c). The ν16 line was at 738 cm-1 for
unbound porphyrin (Figure 16A, spectrum a) and its intensity and frequency were
reduced upon binding to wild-type protein and four variants (Figure 16A, spectra b, d-g)

105

A

B

Figure 16. The resonance Raman spectra of protoporphyrin incubated with
ferrochelatase at a porphyrin-to-protein molar ratio of 0.1.
The spectra are aligned in the (A) low-frequency (300-800 cm-1) and (B) high-frequency
(1300-1700 cm-1) regions. The spectra are shown for (a) unbound porphyrin in
equilibration buffer; (b) porphyrin bound to wild-type ferrochelatase; (c)-(g) porphyrin
bound to loop variants including (c) triple mutant K250M/V251L/W256Y, (d) single
mutant P255R, (e) single mutant P255G, (f) triple mutant S249A/K250Q/V251C, (g)
quadruple mutant Q248P/S249G/K250P/G252W.
Asterisks denote buffer lines.
Vibrational bands of the major structure-sensitive modes are labeled.
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in the triple mutant K250M/V251L/W256Y, the ν16 band was shifted to higher frequency
albeit with diminished intensity (Figure 16A, spectrum c). More importantly, the γ15
mode was activated upon protein binding (Figure 16A). The γ15 mode, a B2u symmetry
saddling-like mode, was previously observed and attributed to saddling deformation of
the porphyrin upon binding to wild-type enzyme (Hu et al. 1996; Lu et al. 2002). The
intensity of γ15 mode for porphyrin bound to the variants exhibited differences from that
for wild-type protein.
In the high-frequency region, the ν2 line was considerably diminished in intensity
for porphyrin bound to both wild-type enzyme and the variants (Figure 16, spectra b-g)
when compared to unbound porphyrin (Figure 16B, spectrum a). In particular, the ν2 line
upshifted by an additional 5 cm-1 in porphyrin bound to the triple mutant
K250M/V251L/W256Y relative to wild-type protein (Figure 16B, spectra b, c), and this
shift was the highest observed when all variants were considered and indicated important
changes in the vinyl interaction with the protein (Figure 16B, spectra b-g). Moreover,
protein binding led to sharpening of the vinyl stretching mode νCa=Cb of free-base
porphyrin (Figure 16B). While the frequency of the νCa=Cb mode remained unchanged for
porphyrin bound to wild-type protein and four variants (Figure 16B, spectra b, d-g), the
νCa=Cb band was broadened and downshifted upon binding to the variant
K250M/V251L/W256Y (Figure 16B, spectrum c), again implicating disruption of
interaction between the porphyrin vinyl groups and the active site matrix.
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Binding of hemin to the variants

Interaction of the loop variants with hemin, an inhibitor of ferrochelatase (Dailey
and Fleming 1983), was examined by comparing the RR spectra of protein-bound hemin
with free hemin in the equilibration buffer (Figure 17). Hemin binding to both P255
variants resulted in a 5 cm-1 downshift of the ν2 band for P255R (Figure17B, spectrum d)
and 4.2 cm-1 for P255G (Figure 17B, spectrum e), whereas all other variants produced
smaller (typically 1.5 cm-1) shifts to higher frequencies (Figure 17B, spectra c, f, g). The
ν38 line, associated with the Cβ-Cβ and Cβ-C1 stretches, increased intensity in the variants
P255R and P255G as compared to wild-type protein, although it did not appreciably shift
(Figure 17B, spectra b, d, e). Both the ν2 and ν38 lines derived from vinyl-associated
modes, so the fact that they altered in tandem indicates significant structural changes in
the vinyl groups of the variant-bound hemin. In the low-frequency region, the ν7 line was
upshifted by 1.8 cm-1 in the variant K250M/V251L/W256Y (Figure 17A, spectrum c) and
1.5 cm-1 in the variant S249A/K250Q/V251C (Figure 17A, spectrum f) when compared
to binding to wild-type ferrochelatase (Figure 17A, spectrum b).

Binding of nickel-protoporphyrin to the variants

NiPP is a strongly distortion-sensitive metalloporphyrin and has been shown to
undergo deformation upon binding to wild-type ferrochelatase in previous RR studies (Lu
et al. 2002). Compared to unbound NiPP in the equilibration buffer, incubation with
wild-type protein and the variants resulted in sharpening the RR lines of NiPP in the
high-frequency region of the spectra (Figure 18B). Protein binding also led to downshift
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A

B

Figure 17. The resonance Raman spectra of hemin incubated with ferrochelatase at
a hemin-to-protein molar ratio of 0.1.
The spectra are aligned in the (A) low-frequency (300-800 cm-1) and (B) high-frequeny
(1300-1700 cm-1) regions. The spectra are shown for (a) unbound hemin in equilibration
buffer; (b) hemin bound to wild-type ferrochelatase; (c)-(g) hemin bound to the loop
variants including (c) triple mutant K250M/V251L/W256Y, (d) single mutant P255R, (e)
single mutant P255G, (f) triple mutant S249A/K250Q/V251C, (g) quadruple mutant
Q248P/S249G/K250P/G252W. Asterisks denote buffer lines. Vibrational bands of the
major structure-sensitive modes are labeled.
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of the ν2 and ν10 bands of NiPP, while the vinyl stretching band νCa=Cb, was sharpened
and enhanced in intensity (Figure 18B). Compared with NiPP bound to wild-type protein
(Figure 18A, spectrum b), the low-frequency regions of the RR spectra for the variants
K250M/V251L/W256Y (Figure 18A, spectrum c) and S249A/K250Q/V251C (Figure
18A, spectrum f) exhibited broader ν7 lines and propionate lines with less pronounced
frequency shifts. These alterations make the spectra for the variant-bound NiPP resemble
more closely the spectrum of unbound NiPP (Figure 18A, spectrum a) rather than that of
NiPP bound to wild-type enzyme (Figure 18A, spectrum b). This suggests that, relative
to wild-type ferrochelatase, both triple mutants had lower affinity towards NiPP, or the
bound NiPP was less conformationally constrained in the triple mutants.
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Figure 18. The resonance Raman spectra of nickel-protoporphyrin incubated with
ferrochelatase at a porphyrin-to-protein molar ratio of 0.1.
The spectra are aligned in the (A) low-frequency (300-800 cm-1) and (B) high-frequency
(1300-1700 cm-1) regions. The spectra are shown for (a) unbound NiPP in equilibration
buffer; (b) NiPP bound to wild-type ferrochelatase; (c)-(g) NiPP bound to the loop
variants including (c) triple mutant K250M/V251L/W256Y, (d) single mutant P255R, (e)
single mutant P255G, (f) triple mutant S249A/K250Q/V251C, (g) quadruple mutant
Q248P/S249G/K250P/G252W. Asterisks denote buffer lines. Vibrational bands of the
major structure-sensitive modes are labeled.
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Inhibition of ferrochelatase by N-methyl protoporphyrin

N-alkylated porphyrins have been known to competitively inhibit substrate
porphyrin binding to mammalian ferrochelatase (Figure 19). N-methyl protoporphyrin
exhibits a very high binding affinity for ferrochelatase (Dailey and Fleming 1983; Cole
and Marks 1984; Nunn et al. 1988) The X-ray crystal structural analysis of B. subtilis
enzyme with bound N-methyl mesoporphyrin indicated that the loop residues are in close
contact with the porphyrin macrocycle (Lecerof et al. 2000). This raises the possibility
that mutations in the loop may modulate binding of N-alkylated porphyrins. In order to
test this hypothesis, loop variants were examined with respect to interaction with Nmethyl protoporphyrin.
To find out whether loop mutations could possibly alter inhibitor binding, a subset
of the functional loop variants including K250N, V251L, P255R, P255G,
K250M/V251L/W256Y and Q248P/S249G/K250P/G252W were transformed into Δvis
cells, and the cells were grown on agar plates with increasing concentrations of NMPP.

Δvis cells transformed with variants P255R and P255G could not grow on plates in the
presence of 20 μM NMPP, whereas Δvis cells transformed with wild-type protein and
other variants could. Based on this observation, P255 variants were selected for further
characterization.

It is recognized that the current assay was not intended to be a

comprehensive screen to cover the full spectrum of mutations that can affect interaction
with the inhibitor. However, it revealed the variants which behaved differently from
wild-type enzyme and therefore provided support to the original hypothesis that mutation
in the loop could modulate inhibitor binding. This may serve as an initial step towards
understanding the structural basis of ferrochelatase inhibition by N-alkylated porphyrins.

112

A

B
N

N
CH3

N

D

HN

C

COOH HOOC

Figure 19. The structural diagram of N-methyl protoporphyrin.
An isomeric form containing methylated A ring pyrrole nitrogen atom is shown in the
diagram.
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Equilibrium binding of inhibitor to ferrochelatase

Binding affinity of NMPP to the enzyme was determined from fluorescence
quenching measurements. Intrinsic fluorescence derives from tryptophan residues in the
protein and is sensitive to protein conformation (Eftink and Ghiron 1976). In wild-type
ferrochelatase, five tryptophan residues give rise to the intrinsic fluorescence which
exhibits an excitation maximum near 280 nm and an emission maximum near 330 nm
(Figure 20A). The fluorescence is linearly dependent on protein concentration (Figure
20B).

Interestingly, in a number of variants, the intensity of protein fluorescence

appeared to be lower than that of wild-type ferrochelatase (Figure 20B). The decrease in
intrinsic fluorescence suggests that loop mutations lead to modification of protein
conformation consistent with observations obtained from structural models (Shi and
Ferreira 2004). Because incubation of ferrochelatase with NMPP resulted in reduction of
the intrinsic fluorescence, the dissociation constant of NMPP for the enzyme could be
measured by quantifying the quenching effect. While the inhibitor exhibited high affinity
to wild-type protein with a Kd of 9 ± 5 nM, binding affinity to the variants was decreased
by one order of magnitude with a Kd of 160 ± 7 nM for P255R and Kd of 300 ± 100 nM
for P255G (Figure 21).

Kinetic pathway of inhibition

The kinetic steps involved in NMPP binding to ferrochelatase were investigated
by monitoring enzymatic reaction with Zn2+ and protoporphyrin as substrates using
stopped-flow absorbance spectroscopy (Figure 22A).

Kinetic traces for zinc-

protoporphyrin formation in the presence of various concentrations of NMPP were fitted
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Figure 20. The intrinsic fluorescence of ferrochelatase.
(A) The excitation and emission spectra of wild-type ferrochelatase. 0.9 μM purified
protein was diluted in 10 mM Tris-acetate pH 8 containing 0.05% (v/v) Tween-80. The
emission spectrum exhibited a maximum at 331 nm (λex = 283 nm), while the excitation
spectrum showed a maximum at 283 nm (λem = 331 nm). (B) The intrinsic fluorescence
is proportional to protein concentration, and fluorescence intensity is diminished in the
loop variants. Protein fluorescence was measured at 331 nm across a range of
concentrations for wild-type ferrochelatase (□), single mutant V251L (●), single mutant
P255R (∆), quadruple mutant Q248P/S249G/K250P/G252W (♦), and triple mutant
K250M/V251L/W256Y (○).
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Figure 21. Binding curves generated from protein fluorescence quenching
measurements following titration with N-methyl protoporphyrin.
Aliquots of NMPP solution were mixed with purified ferrochelatase in quenching buffer
containing 10 mM Tris-acetate pH 8 and 0.05% (v/v) Tween-80. The mixture was
incubated on ice for 1 hr. Fluorescence intensity of the solution was measured at 23 oC at
331 nm (λex = 283 nm). Kd for NMPP was determined by fitting data to Equation 2
ΔF ⎡(Et +L +K d ) −
⎢⎣
F = F0 −

(Et + L + K d )2 − 4 Et L ⎤⎥
2 Et

⎦.

Proteins used in each set of assays are: (A)

wild-type ferrochelatase (40 nM); (B) variant P255R (250 nM); (C) variant P255G (120
nM).
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to Equation 3 (Williams and Morrison 1979) to obtain the pseudo first-order rate
constants for inhibitor binding (Figure 22C):
A = A0 + vst +

v0 − vs
1 − e − kt
k

(

)

(Eq.3)

For wild-type enzyme and variant P255R, the rate constants exhibited a
hyperbolic dependence on NMPP concentration (Figure 23A, 23B) suggesting that
inhibitor binding occurred in two kinetic steps, i.e.
FC + NMPP

k1
k-1

[FC · NMPP]1

k2
k-2

[FC · NMPP]2

The first step was rapid and involved the initial binding of the inhibitor to ferrochelatase.
The second step was slow, and possibly it was associated with a conformational change
of the inhibitor-protein complex. The hyperbola can be described by the equation:
k = k− 2 +

k2 I 0
⎛
S ⎞
I 0 + K i ⎜⎜1 + 0 ⎟⎟
⎝ Km ⎠

(Eq.4)

where k is the pseudo first-order rate constant for the approach to the steady-state phase,
⎛
S ⎞
I0 is the inhibitor concentration, S0 is the initial substrate concentration, K i ⎜⎜1 + 0 ⎟⎟ is
⎝ Km ⎠

the apparent inhibition constant Kiapp, k2 and k-2 are the second step forward and reverse
rate constants. For wild-type protein, k2 was 6.4 ± 0.4 s-1, k-2 was 24.5 ± 0.3 s-1, and Kiapp
was 2.8 ± 0.6 nM. For variant P255R, k2 was 8.3 ± 1.1 s-1, k-2 was 19.3 ± 0.7 s-1, and Kiapp
was 1.0 ± 0.5 μM. In contrast, for variant P255G, the pseudo-first order rate constant k
was linearly dependent upon inhibitor concentration (Figure 23C), consistent with a
single kinetic step for NMPP binding, i.e.
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Figure 22. Transient kinetic analysis of the ferrochelatase-catalyzed reaction.
Purified variant P255R (2 μM) was pre-incubated with protoporphyrin (10 μM) in 100
mM Tris-acetate pH 8 containing 0.5% (v/v) Tween-80. The solution was mixed with
zinc-acetate (15 μM) to initiate enzymatic reaction. (A) Wavelength scans of the reaction
mixture at different reaction times. Spectra were collected at 96 ms, 144 ms, 192 ms, 240
ms and 288 ms since the inception of reaction. Isosbestic point at 412 nm indicated
conversion of molecular species in the course of enzymatic reaction. (B) The absorbance
spectrum of zinc-protoporphyrin. The spectrum was shown for ZnPP (5 μM) in assay
buffer with an absorbance maximum at 420 nm. (C) The time course for ZnPP formation
catalyzed by ferrochelatase. The increase of absorbance at 420 nm was continuously
monitored over the course of reaction. Progress curve was fitted to Equation 3
v −v
A = A0 + vs t + 0 s 1 − e − kt to obtain the rate constant k for NMPP binding.
k

(

)
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FC + NMPP

k1
k-1

[FC · NMPP]

By fitting the line to the equation
k = k −1 +

k1 I 0
S
1+ 0
Km

the forward rate constant

(Eq.5)

k1
was determined to be 8.2 ± 0.7 s-1μM-1, the reverse rate
S0
1+
Km

constant k-1 was 18.7 ± 2.3 s-1. Kiapp was calculated from

S ⎞
k −1⎛
⎜⎜1 + 0 ⎟⎟ and was found to
k1 ⎝ K m ⎠

be 2.3 μM.

Size measurement of the active site pocket

In order to compare the size of the active site in the variants with that of wild-type
protein, the volume and Connolly’s surface area of the porphyrin-binding pocket in the
structural models were estimated using the program CAST (Liang et al. 1998). The
active site of wild-type ferrochelatase was found to occupy a surface area of 2138 Å2 and
a volume of 3015 Å3, while variant P255R had a smaller surface area of 1340 Å2 and a
reduced volume of 1932 Å3, and variant P255G had the smallest surface area of only
1048 Å2 and a volume of 1604 Å3. Overall, the binding pocket size was significantly
reduced as a result of P255 mutations. Variant P255R retained ~70% of the volume and
surface area relative to wild-type protein, whereas P255G only kept ~50% the size of
wild-type porphyrin-binding pocket.
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Figure 23. Dependence of the rate constants for ferrochelatase binding on N-methyl
protoporphyrin concentration.
Ferrochelatase (0.5 μM) was reacted with protoporphyrin (5 μM) and zinc-acetate (15
μM) in the presence of various concentrations of NMPP. The pseudo first-order rate
constant k for inhibitor binding was obtained from by analyzing progress curve as
described previously. The values of k were plotted against inhibitor concentrations. The
proteins used in each set are: (A) wild-type ferrochelatase; (B) variant P255R; (C)
variant P255G.
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FeS cluster and oligomeric assembly in ferrochelatase variants

During profiling of the UV-vis absorbance spectra of the functional loop variants,
a number of variants exhibited absorbance features with some differences from wild-type
protein. This raises the question of whether the variants have alterations in the FeS
cluster. Because the FeS cluster has been thought to be located near the dimer interface
in wild-type ferrochelatase, it was suspected that dimeric interaction may be disrupted in
the variants. To address this issue, the variants were further examined with regard to
their oligomerization state and the properties of FeS cluster.

UV-visible absorbance spectra of the variants

The UV-vis absorbance spectra of selected variants including triple mutants
S249A/K250Q/V251C and S249A/K250R/G252W exhibited features somewhat different
from wild-type protein (Figure 24).

In wild-type ferrochelatase, the absorbance

maximum at 330 nm and the shoulder regions around 450 nm and 510 nm are consistent
with the presence of a [2Fe-2S] cluster. In the variants, the region around 450 nm
appears blue-shifted to around 410 nm, while the absorbance maxima at 330 nm and 510
nm remain.

These absorbance features bear some resemblance to those for biotin

synthase, which contains mixtures of [2Fe-2S] and [4Fe-4S] clusters (Ugulava et al.
2000; Ugulava et al. 2001).
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B

C

Figure 24. The UV-visible absorbance spectra of purified wild-type ferrochelatase
and variants.
The absorbance spectra are shown for (A) wild-type ferrochelatase (9 μM), (B) triple
mutant S249A/K250Q/V251C (27 μM), and (C) triple mutant S249A/K250R/G252W
(31 μM). In wild-type protein, the absorbance maximum at 330 nm and the shoulder
regions around 450 nm and 510 nm are indicative of a [2Fe-2S] cluster. In the variants,
the absorbance shoulder region around 450 nm appears to blue-shift to around 400 nm,
while the absorbance maximum at 330 nm and shoulder around 510 nm remain.
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Metal content analysis

Determination of metal content of purified wild-type ferrochelatase and variant
S249A/K250Q/V251C by plasma emission spectroscopy showed that the stoichiometry
ratio of Fe/protein was 1.3 for each monomer of wild-type protein and 2 for variant
S249A/K250Q/V251C (Shi and Ferreira 2004). The ratio for wild-type protein is in
agreement with a previous report indicating a stoichiometry of one [2Fe-2S] cluster per
monomer (Lloyd et al. 1996). The molar ratio of Fe/protein was approximately 50%
higher in variant S249A/K250Q/V251C relative to wild-type enzyme.

Dependence of enzymatic activity on FeS cluster synthesis

The requirement of FeS cluster for enzymatic activity was assessed using the
bacteria strain iscS- (PK4331), which is deficient in cluster assembly as a result of
deletion of cysteine desulfurase, the sulfur donor for FeS cluster synthesis (Schwartz et
al. 2000).

Growth in PK4331 cells rendered wild-type ferrochelatase catalytically

inactive, whereas the enzyme was active in RZ4500 cells (Figure 25). These results are
consistent with the suggestion that FeS cluster is important to maintaining wild-type
ferrochelatase activity (Sellers et al. 1998b; Schneider-Yin et al. 2000b). Single mutant
C341A was not functional in either RZ4500 or PK4331 cells and was used as a negative
control (Figure 25).

Interestingly, both variants S249A/K250Q/V251C and

S249A/K250R/G252W retained 50-75 % residual activities in PK4331 cells suggesting
that catalysis could take place in the absence of FeS cluster assembly (Figure 25).
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Figure 25. Dependence of ferrochelatase activity on FeS cluster synthesis.
RZ4500 (iscS+) and PK4331 (iscS-) cells were transformed with expression plasmids
encoding wild-type ferrochelatase, single mutant C341A, and triple mutants
S249A/K250Q/V251C and S249A/K250R/G252W.
Enzymatic activities were
determined by monitoring zinc-protoporphyrin formation using cell lysates prepared from
each transformant.
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Subunit assembly of purified ferrochelatase

Consistent with previous observations that mammalian ferrochelatase is a
homodimer (Straka et al. 1991; Wu et al. 2001), gel filtration chromatography of purified
recombinant wild-type murine ferrochelatase yielded a single dimeric species with an
approximate apparent molecular weight of 88 kDa (Figure 26). Dynamic light scattering
analysis showed that wild-type murine ferrochelatase in solution had an estimated
hydrodynamic radius of 4.6 nm (Figure 27). This is in agreement with the results
obtained for purified human ferrochelatase, which showed a hydrodynamic radius of 4.4
nm corresponding to an estimated molecular mass of 100 kDa for globular protein
(Burden et al. 1999). In contrast, gel filtration analysis of variants S249A/K250Q/V251C
and S249A/K250R/G252W indicated the presence of higher order oligomers (Figure
26B, 26C). Interestingly, all of the molecular species eluted from the gel filtration
column were enzymatically active and exhibited comparable specific activity.

Size

distribution of the ferrochelatase oligomers was further analyzed using dynamic light
scattering, and the results were comparable to those obtained from gel filtration
chromatography. Variant S249A/K250Q/V251C exhibited an estimated hydrodynamic
radius of 20 nm suggesting that it is present as a homogeneous high molecular weight
species in solution (Figure 27A). Variant S249A/K250R/G252W also yielded oligomeric
assembly larger than wild-type protein with a hydrodynamic diameter of 12.8 nm (Figure
27B).
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Figure 26. Molecular weight assessment of purified wild-type ferrochelatase and
variants by gel filtration chromatography.
All the proteins were loaded onto a Superdex-200 HPLC column equilibrated with a
buffer containing 20 mM TrisCl pH 8.0, 150 mM NaCl and 5% glycerol. Purified wildtype ferrochelatase (240 μM) and variants S249A/K250Q/V251C (600 μM) and
S249A/K250R/G252W (800 μM) were injected separately. Elution was monitored by
absorption at 280 nm. (A) Calibration of the column with protein markers of known
molecular masses including amylase (200 kDa), alcohol dehydrogenase (150 kDa),
albumin (66 kDa), carbonic anhydrase (29 kDa) and cytochrome c (12.4 kDa). The void
volume (V0) was determined to be 38 mL based on the elution of blue dextran. (B)
Elution profiles of wild-type ferrochelatase (○) and variant S249A/K250Q/V251C (♦).
(C) Elution profiles of wild-type ferrochelatase (○) and variant S249A/K250R/G252W
(▲).
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Figure 27. Molecular size determination of purified wild-type ferrochelatase and
variants by dynamic light scattering (DLS).
Solutions of purified ferrochelatase (6 μM) in solubilization buffer containing 20 mM
TrisCl pH 8.0, 150 mM NaCl, 0.5% NaCholate and 10% glycerol were examined on a
particle size analyzer. (A) DLS results for wild-type protein (○) and variant
S249A/K250Q/V251C (♦). (B) DLS results for wild-type protein (○) and variant
S249A/K250R/G252W (▲).
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Electron paramagnetic resonance spectra of ferrochelatase

At high power level (25 mW) and high temperature (70 K), the EPR spectra of
wild-type ferrochelatase exhibited features of a [2Fe-2S] cluster-containing protein
(Figure 28A), consistent with the previous observations (Ferreira et al. 1994). Both
variants

S249A/K250Q/V251C

and

S249A/K250R/G252W

showed

similar

characteristics indicating they also contained [2Fe-2S] clusters (Figure 28B). In order to
examine whether [4Fe-4S] cluster was also present in the variants, temperature sweep of
EPR signals was carried out. Only variant S249A/K250Q/V251C was analyzed so far.
Temperature-dependence of the signal intensity at g value of 1.93 exhibited a maximum
at low power levels (0.002-25 mW) and became linear at higher power levels (25-200
mW) (Figure 29).
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Figure 28. EPR spectra of purified wild-type ferrochelatase and variants.
Typically purified proteins were reduced by dithionite prior to collecting EPR spectra.
X-band EPR spectra were recorded at 70 K and 25 mW. (A) The spectra are shown for
dithionite-reduced wild-type ferrochelatase with 5X His-tag at 400 μM (▬), with 5X
His-tag at 190 μM (▬), and without His-tag at 200 μM (▬). The spectra of as purified
wild-type ferrochelatase with 5X His-tag at 400 μM is also shown (▬). (B) EPR spectra
are shown for dithionite-reduced variants S249A/K250Q/V251C at 426 μM (▬) and
S249A/K250R/G252W at 95 μM (▬).
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Figure 29. Temperature-dependence of the EPR signal intensity for a purified
ferrochelatase variant.
Purified variant S249A/K250Q/V251C (426 μM) was reduced with dithionite, and Xband EPR spectra were collected. Signal intensity at g value of 1.93 was plotted as a
function of temperature at different microwave power levels.
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Chapter Four

Discussion

Continuous assay for ferrochelatase activity

Over the past four decades, a number of assays have been developed to determine
ferrochelatase activity (Dailey and Dailey 2003). One of the most commonly used
methods is a discontinuous assay using ferrous iron and porphyrin as substrates. In this
method, synthesized heme is spectrophotometrically quantified following quantitative
conversion to the pyridine-hemochromogen (Porra and Jones 1963a; 1963b; Porra et al.
1967). This assay facilitates quantification of enzymatic activities as low as 1 nmol
protoheme min-1 (Taketani and Tokunaga 1981). To maintain the iron substrate in the
ferrous state, thiol compounds have been routinely included in the reaction mixture
(Porra et al. 1967). However, hemes degrade in the presence of thiol compounds (Porra
et al. 1967); additionally, dithiothreitol competes with ferrochelatase for binding to free
ferrous iron (Franco et al. 1995).

A second, dual-wavelength assay measures

ferrochelatase activity by following the disappearance of the porphyrin substrate (Labbe
et al. 1963; Porra et al. 1967; Jones 1969; Camadro and Labbe 1982). Under these assay
conditions, the absorption spectra of porphyrin and heme exhibit clear isosbestic points
indicating conversion of substrate into product, and the progress of the reaction can be
followed using electronic absorption spectroscopy (Porra et al. 1967). While this assay
offers the prospect for development of a continuous assay, its inherently reduced
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sensitivity (Porra et al. 1967), compared to that of the pyridine-hemochromogen method,
has restricted its application. In addition, reducing reagents, such as glutathione, which
appear to interfere with heme stability, were included in this procedure (Porra et al.
1967). A radiochemical assay for ferrochelatase activity quantifies the incorporation of
59

Fe into porphyrin (Goldberg et al. 1956). However, this method has had limited use

because of requirements for safety precautions, expense and labor (Goldberg et al. 1956;
Jones and Jones 1968; Dailey 1977).
To overcome the technical constraints of maintaining the iron substrate in the
reduced state and the requirement of strict anaerobicity, alternative assays take advantage
of the fact that ferrochelatase can catalyze the incorporation of other divalent metal ions
(Johnson and Jones 1964; Neuberger and Tait 1964; Porra and Ross 1965; Jones 1969;
Camadro and Labbe 1982; Taketani and Tokunaga 1982). Indeed, a convenient method
is to determine zinc-chelatase activity (Neuberger and Tait 1964), since the fluorescence
of the zinc-protoporphyrin product can be followed continuously (Camadro and Labbe
1982; Abbas and Labbe-Bois 1993). Chelation of Co2+ has also been used to determine
the enzymatic activity of ferrochelatase (Johnson and Jones 1964; Porra and Ross 1965;
Jones 1969). Cobalt-chelatase activity can be measured by the pyridine-hemochromogen
assay or by monitoring the absorbance decrease of the porphyrin substrate (Jones 1969;
1970; Canepa and Llambias 1988).

Despite the convenience of these assays using

alternative metal substrates, kinetic and X-ray absorption studies (Camadro and Labbe
1982; Ferreira et al. 2002) have provided evidence that chelation of non-physiological,
metal substrates by ferrochelatase might not be mechanistically identical to that of the
Fe2+ substrate. While Fe2+ was a strong competitive inhibitor of zinc-chelatase activity,
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Zn2+ competitively inhibited iron chelation with a Ki of only 1.5 μM (Camadro and Labbe
1982). Moreover, the recent X-ray absorption spectroscopy studies of metal binding sites
in murine and yeast ferrochelatases indicated that coordination of Zn2+ was different from
that of Fe2+ or Co2+ (Ferreira et al. 2002).
Thus, while there are convenient methods available to determine the enzymatic
activity of ferrochelatase, each has limitations that reduce its usefulness, particularly in
enzyme kinetic studies. In this study, a continuous, fluorimetric assay for ferrochelatase
activity has been developed using the physiological substrates, ferrous iron and
protoporphyrin, by measuring the rate of porphyrin consumption. Using this method, the
kinetic constants determined for the wild-type murine ferrochelatase were shown to be
comparable to values reported for the wild-type human ferrochelatase (Table 2).
Overall, the continuous assay offers significant advantages over the existing
procedures. Because the time course of reaction can be monitored by following the
decrease of porphyrin fluorescence, this assay allows the initial rate to be determined
from the slope of progress curves at the inception of enzymatic reaction, and thereby
eliminates the problem of non-linearity in velocity calculations in end-point assays which
results from prolonged incubation. By imposing strictly anaerobic conditions, the assay
permits the determination of ferrochelatase activity for the physiological substrate,
ferrous iron, instead of metal ion substitutes, such as Zn2+ and Co2+.

Additionally,

reducing agents are eliminated in the reaction, including the thiol-containing compounds,
which are known to promote heme degradation (Porra et al. 1967). The reaction medium
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Table 2. Comparison of the steady-state kinetic parameters of ferrochelatase
determined by various assay methods.

Ferrochelatase
source

Vmax
KmPorp KmFe2+ Porphyrin
(nmol mg-1
(μM) (μM) substrate
min-1)

Reducing
agent

Assay Method

Ref.

Continuous
fluorimetric
Assay

(Shi and Ferreira
2003)

Murine
(recombinant)

97.4

1.4

1.9

Protoporphyrin

None

Murine
(recombinant)

136

95

112.5

Deuteroporphyrin

DTT

Human
(recombinant)

165 a

9.3 a

9.0 a

Proto- Not specified
porphyrin in the text

Human
(recombinant)

---

8.19 a

9.35 a

Protoβ-mercapto- Hemochromogen
porphyrin
assay
ethanol

Yeast
(mitochondrial
membrane
extracts)

---

5.9 a

1.63 a

ProtoNone;
porphyrin anaerobiosis b

Bovine (liver)

105 a

80 a

11 a

Protoporphyrin

DTT

Hemochromogen (Dailey and
assay
Fleming 1983)

Bovine (liver)

88 a

54 a

46 a

Protoporphyrin

DTT

Hemochromogen (Taketani and
assay
Tokunaga 1982)

Rat (liver)

120 a

28.5 a

33.1 a

Protoporphyrin

DTT

Hemochromogen (Taketani and
assay
Tokunaga 1981)

a

Apparent steady-state kinetic parameter values.
enzymatic oxygen uptake (Camadro and Labbe 1982).
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b

Hemochromogen
(Ferreira 1994)
assay
Porphyrin
absorbance
decrease

Porphyrin
absorbance
decrease

(Sellers et al.
2001)
(Sellers and
Dailey 1997)
(Camadro and
Labbe 1982)

Anaerobiosis was achieved by

is prepared at the optimal pH of 8.0 (Taketani and Tokunaga 1981; 1982; Franco et al.
1995), and the detergent, Tween-80 [0.5% (v/v)], is included to allow maximal
solubilization of protoporphyrin (Porra and Jones 1963a; Porra et al. 1967; Jones 1969;
Camadro and Labbe 1982). As ferrochelatase in the range of 10-100 nM has been found
sufficient for the assay, the procedure allows the enzyme to be used in concentrations
approximately one to two orders of magnitude lower than those routinely employed in
non-fluorimetric assays. Moreover, the calculated limit of reliable detection is improved
up to two orders of magnitude over that of the pyridine-hemochromogen assay (Taketani
and Tokunaga 1981). Thus, the assay permits economical use of purified enzyme stocks,
and also makes it possible to detect ferrochelatase in biological samples of low specific
activity such as in porphyria patients.
In summary, the continuous assay provides a novel method to measure
ferrochelatase activity using the physiological ferrous iron substrate. The sensitivity of
this assay is enhanced up to two orders of magnitude over other assays currently in use,
making it possible to determine the initial rate of enzymatic reaction at lower substrate
concentrations than those previously reported.

Characterization of the active site loop variants

The overall fold and active site structure of ferrochelatase are highly conserved
throughout evolution. Crystal structures of B. subtilus, yeast and human enzymes reveal
two domains in each monomeric unit and each domain is comprised of a Rossmann-type
fold (Al-Karadaghi et al. 1997; Lecerof et al. 2000; Wu et al. 2001; Karlberg et al. 2002).
The active site is located in a deep cleft between the two domains. This cleft is enriched
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with many conserved residues that have been found to be important in metal binding and
catalysis (Al-Karadaghi et al. 1997; Lecerof et al. 2000; Wu et al. 2001; Karlberg et al.
2002). One side of the cleft is formed by the first two N-terminal α-helices, α1, α2, and
a loop between them, and the other side consists of a short conserved loop sequence,
which connects a β-strand and an α-helix in the second domain (Al-Karadaghi et al.
1997; Lecerof et al. 2000; Wu et al. 2001; Karlberg et al. 2002). Although ferrochelatase
only exhibits an overall sequence identity of no more than 20% in evolution, the loop
motif is highly conserved (Figure 11). Based on molecular dynamics calculations of B.
subtilis ferrochelatase with bound nickel-protoporphyrin (NiPP) (Franco et al. 2000) and
crystal structural analysis of ferrochelatase with bound porphyrin analog N-methyl
mesoporphyrin (Lecerof et al. 2000), it has been proposed that the conserved loop is
directly involved in porphyrin interaction. To test this hypothesis, random mutagenesis
and genetic complementation were applied to identify functional substitutions and to
evaluate the information content of each of the 10 consecutive loop residues (Q248L257) in murine ferrochelatase.
The results indicated that despite conservation of the loop (Figure 11), every
amino acid within this sequence tolerated functionally permissible substitutions (Figure
13). The degree of acceptable substitutions varied, however, from position to position.
K250, V251, P253, V254 and P255 tolerated diverse mutations including single
substitutions and contained low informational content. Interestingly, single amino acid
substitutions identified at the low informational content positions were also co-selected in
the multiply substituted variants (Figure 13), and a few of these amino acid substitutions
are also present in nature (Figure 11). The remaining five loop positions Q248, S249,
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G252, W256 and L257 had high informational content, because they only allowed very
limited substiutions, and mutations were only possible when they were associated with
changes in other loop residues whereas no single substitutions were observed (Figure 13).
While G252 was the most amenable to change, even with drastic substitution such as W
or R (Figure 13), substitutions at Q248, S249 and W256 were scarce, occurring primarily
in triple and occasionally in quadruple mutants, suggesting that complementary changes
in the loop are necessary to counterbalance the loss of wild-type residues at these
positions.
The attachment of ferrochelatase to the mitochondrial membrane has been
proposed to play a role in facilitating uptake of the water-insoluble porphyrin substrates
from a hydrophobic environment and also providing a pathway for heme release (Gora et
al. 1996a; Wu et al. 2001). As shown in the X-ray crystal structures of human and yeast
ferrochelatases, the active site entrance is delimited by two, oppositely located loops,
which are enriched with hydrophobic residues and possibly involved in mediating
membrane association (Gora et al. 1996a; Wu et al. 2001; Karlberg et al. 2002). Further,
a number of positively charged residues in these loops have been implicated in
interaction with the phosphate groups of the membrane phospholipids (Karlberg et al.
2002). One of these loops surrounding the active site entrance corresponds to the murine
ferrochelatase sequence Q248-L257, and consistent with the above hypothesis, positively
charged amino acid substitutions were found to accumulate at the C-terminal
hydrophobic loop residues G252, P253, V254 and P255 (Figure 15A). They conferred an
overall increase in the binding affinities of the variants towards liposomes mimicking the
composition of the inner mitochondrial membranes (Figure 15B, 15C).
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An important step in ferrochelatase catalysis is the binding and distortion of
porphyrin macrocycle to facilitate metal chelation. An overall increase in the KmPPIX
values of the selected loop variants (Table 1) supports the proposal that loop residues
contribute to porphyrin-ferrochelatase interaction. K250M/V251L/W256Y was the only
variant with both a lower kcat and a higher KmPPIX than those of wild-type ferrochelatase
(Table 1). Indeed, this variant exhibited a catalytic efficiency towards porphyrin 10-fold
lower than wild-type enzyme (Table 1). Although three residues were mutated in variant
K250M/V251L/W256Y, the primary effect was thought to derive from the W256Y
mutation. Specifically, the V251L mutation alone did not bring a decrease in the kcat
value or a significant increase in the KmPPIX value (Table 1), and mutation of the K250
residue was not expected to produce dramatic effect on the function of ferrochelatase, as
it occupies a low information content position (Figure 13). In addition, mutation of the
corresponding residue in yeast ferrochelatase (W282) yielded a variant (W282L) showing
a 10-fold decrease in KmPPIX and an unaltered Km for the metal substrate (Gora et al.
1996b). Actually, the homologous residue in B. subtilis ferrochelatase (W230) was
shown to stack against the pyrrole ring, thereby stabilizing the position of the porphyrin
ring in the crystal structure (Lecerof et al. 2000).
The

over

7-fold

increase

in

the

KmPPIX

of

the

quadruple

mutant

Q248P/S249G/K250P/G252W (Table 1) most likely stemmed from the G252W mutation.
Replacement of G252 with bulky aromatic tryptophan possibly blocked active site
opening, thus hindering entry and binding of the porphyrin substrate. This hypothesis
agrees with the observation, based on the crystal structure of B. subtilis ferrochelatase
(Al-Karadaghi et al. 1997), that any side chain other than glycine would introduce steric
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hindrance at this position. The triple mutant S249A/K250Q/V251C also exhibited a
considerable increase (approximately 5-fold) in the KmPPIX. While S249 contains high
informational content (Figure 13) and is buried deeply in the active site cavity, the V251
side chain is directed towards the path of porphyrin entry. Possibly, combinatorial
changes in the three positions led to misalignment or destabilization of porphyrin
binding. Unexpectedly, with the exception of the triple mutant K250M/V251L/W256Y,
kcat, increased in all of the loop variants (Table 1). The increase, ranging from 2- to 4.4fold, conceivably resulted from conformational flexibility of the loop motif. Surface
loops are frequently identified as mobile elements mediating protein conformational
changes (Pompliano et al. 1990; Osborne et al. 2001). They may control access to the
active site by adopting an open conformation to permit substrate entry and product
release, and a closed conformation to protect active site from the solvent and promote
enzyme-substrate interactions required for catalysis (Pompliano et al. 1990). It is likely
that some variants prefer closed conformations which are more conducive to catalysis.
For example, in variant Q248P/S249G/K250P/G252W, the indole ring and the
pyrrolidine rings at the 252 and 248/250 positions, respectively, might restrict
conformational plasticity of the loop region and promote a closed conformation more
favorable to catalysis. Alternatively, a higher kcat might result from stabilization of the
transition state intermediates.
Although the protein ligands for iron substrate remain to be unequivocally
identified, nitrogenous and/or oxygenous side chains appear to coordinate metal substrate
in ferrochelatase (Franco et al. 1995; Gora et al. 1996b; Ferreira et al. 2002). The active
site residues H209 and E289 (murine ferrochelatase numbering) have been recognized as
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metal ligands and/or have an essential role in catalysis (Gora et al. 1996b; Lecerof et al.
2000; Franco et al. 2001). Analysis of the crystal structure of yeast ferrochelatase with
bound metal ions suggested that yeast H235, E314 and S275 (equivalent to murine
residues H209, E314 and S249, respectively) are involved in coordinating Co2+ and Cd2+
(Karlberg et al. 2002).

Thus, the increase in the KmFe2+ of the triple mutant

S249A/K250Q/V251C may result from the loss of stabilization provided by S249 (Table
1). Curiously, the differences in the KmFe2+ values of the loop variants correlate with the
presence of a π-helix in the second domain of ferrochelatase (Figure 14). In a number of
proteins, π-helix residues function to coordinate metal ions required for enzymatic
activity (Weaver 2000; Fodje and Al-Karadaghi 2002; Shin et al. 2003). In the structural
model of murine ferrochelatase, residues arranged along the helical edge of the π-helix
form a channel that connects the interior of the active site to the protein exterior (Figure
30A). The quadruple mutant Q248P/S249G/K250P/G252W, whose KmFe2+ value was the
lowest among the analyzed variants (Table 1), exhibits a long (i.e., ten residues) π-helix
(Figure 30C). Given that the unit rise per residue of a π-helix is the shortest among all
helical structures (Al-Karadaghi et al. 1997; Fodje and Al-Karadaghi 2002), the π-helical
alignment of residues allows the side chains of E289, E293 and E297 to packed more
closely and thereby might promote the efficiency of metal substrate uptake. This is
consistent with the observed decrease in the KmFe2+ value in the quadruple mutant. In
contrast, S249A/K250Q/V251C is the only variant with a regular α-helix in place of the
π-helix (Figure 30B); this should result in a longer distance between the glutamate
residues and thus slower metal transfer, which might account for a higher KmFe2+. The
mode
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metal

substrate
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Figure 30.
Structural features of the murine ferrochelatase models.
The opening of the active site cavity consists of two N-terminal helices (lime) and the
conserved loop (cyan). Substituted residues in the loop are marked (green). Three
glutamate residues (purple) are located in the back of the active site cavity. (A) In wildtype ferrochelatase, two of the glutamate residues are arranged along a π-helix (red).
(B) In triple mutant S249A/K250Q/V251C, the glutamate residues are located on the α(C) In quadruple mutant
helix which is in place of the π-helix.
Q248P/S249G/K250P/G252W, three glutamate residues are aligned along a long πhelix. All images were generated using VMD 1.8.3 (Humphrey et al. 1996).
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is consistent with metal binding studies in yeast ferrochelatase (Karlberg et al. 2002;
Lecerof et al. 2003). According to this model, metal binding would require the conserved
H209 and occur on the same side of active site as that of porphyrin binding, whereas the
distal residues, including glutamates in the π-helical region, play a regulatory role by
promoting metal release from the primary binding site (Lecerof et al. 2003).
Overall, a mutational survey of the conserved loop motif (Q248-L257, murine
ferrochelatase numbering) demonstrated that the loop possessed a considerable degree of
plasticity. While multiple functional substitutions were tolerated, the positions occupied
by Q248, S249, G252, W256 and L257 exhibited the highest stringency. Kinetic analysis
of selected, active variants suggested that loop mutations result in a general disruption of
interaction between the porphyrin substrate and ferrochelatase. Further, the loop motif
was also shown to play an important role in maintaining the active site architecture as
well as modulate ferrochelatase interaction with the metal substrate.

Resonance Raman spectroscopy analysis of ferrochelatase-induced porphyrin
distortion

The most widely accepted reaction mechanism for ferrochelatase suggests that a
critical step involves distortion of the porphyrin macrocycle to expose the lone-pair
orbitals of pyrrole nitrogens to incoming metal ion (Dailey and Dailey 2003). This
notion has received support from both experimental and theoretical studies (Cochran and
Schultz 1990; Blackwood et al. 1997; Blackwood et al. 1998; Lecerof et al. 2000).
Antibodies raised against non-planar alkylated porphyrins were found to catalyze
porphyrin metallation by Zn2+ and Cu2+ (Cochran and Schultz 1990). Resonance Raman
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(RR) spectra of antibody-bound mesoporphyrin revealed a saddling distortion
(Blackwood et al. 1998), and X-ray crystal structure of the Michaelis complex of
catalytic antibody bound to substrate mesoporphyrin in the absence of metal ions
demonstrated out-of-plane macrocycle distortion including saddling, ruffling and some
doming deformations (Yin et al. 2003). These studies indicated that antibody-induced
porphyrin distortion resembles deformation observed in N-alkyl porphyrins (Blackwood
et al. 1998; Yin et al. 2003). Recent studies towards quantification of distortion led to the
proposal that activation of the Raman band assigned to γ15, an out-of-plane vibrational
mode for bound porphyrin, is directly related to the degree of affinity maturation of
catalytic antibodies (Venkateshrao et al. 2004). Theoretical methods including quantum
and molecular mechanics calculations have been used to calculate the energetics
associated with porphyrin distortion, especially within protein matrices (Sigfridsson and
Ryde 2003). These model studies indicated that, other than exposing pyrrole nitrogens to
incoming metal ions, porphyrin deformation favors decreases in pKa of the macrocycle,
thereby promoting deprotonation of the pyrrole rings. Since deprotonation precedes
metal insertion, catalytic reaction is allowed to progress. In addition, porphyrin distortion
may facilitate product release, as metalloporphyrins are harder to distort than free-base
porphyrin and thus have lower affinity for the active site (Sigfridsson and Ryde 2003).
Previous RR spectroscopic analysis of porphyrin binding to wild-type murine
ferrochelatase showed that the enzyme could induce porphyrin distortion even in the
absence of metal substrate (Franco et al. 2000; Lu et al. 2002). A high degree of
specificity for porphyrin interaction with the protein was established by titrating
ferrochelatase with a substoichiometric amount of porphyrin, which allowed observation
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of the vibrational modes of bound porphyrins in the RR spectra, and revealed frequency
shifts in the structure-sensitive lines upon protein binding (Lu et al. 2002). In particular,
γ15, an out-of-plane saddling-like mode of B2u symmetry, was activated in the RR spectra
of free-base protoporphyrin bound to wild-type ferrochelatase (Lu et al. 2002). Saddling
was also shown to be a major component of the nonplanar distortion of N-methylmesoporphyrin when bound to B. subtilis ferrochelatase by X-ray crystal structural
analysis (Lecerof et al. 2000). Significantly, saddling is an out-of-plane deformation that
exposes both the protons and lone-pair orbitals of the nitrogen atoms of the macrocycle,
thus consistent with a porphyrin set-up for metal insertion in a reaction facilitated by
ferrochelatase.
Previous studies have shown that a conserved active site loop motif mediates
interaction of porphyrin with ferrochelatase (Shi and Ferreira 2004). Porphyrin binding
to the loop variants was examined using RR spectroscopy. Analysis of the RR spectra for
substrate protoporphyrin demonstrated that the γ15 mode was activated upon porphyrin
binding to wild-type protein and variants (Figure 16A). Consistent with previous RR
studies (Franco et al. 2000; Lu et al. 2002), this observation confirmed porphyrin
saddling is an important form of non-planarity induced by the enzyme. Further, the
extent of porphyrin saddling could be quantified by normalizing the integrated intensity
of γ15 line to the intensity of ν7 line for the same spectrum (Table 3). Interestingly, as the
variants became deficient in producing saddled porphyrins, their catalytic efficiencies
were diminished accordingly (Table 3). The strongest reduction was observed in variant
K250M/V251L/W256Y in which porphyrin saddling was less than 30% of that in the
wild-type enzyme (Table 3). This diminished out-of-plane distortion was accompanied
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Table 3. Results of simulation for the low-frequency resonance Raman spectra of
ferrochelatase-bound protoporphyrin.
The Raman spectra were exported as even-X ASCII files, and spectral simulation for
the frequency region from 580 to 780 cm-1 was based on least squares fitting with
Lorentzian line shapes and a fixed half-width at half maximum (2.814 cm-1) for the γ15
line using the program PeakFit (SYSTAT).
ν7
(cm-1)

ν7
intensity
(area)

Wild-type
ferrochelatase

673.3

1624.5

678.0

1408.8

P255R

674.3

1059.6

679.0

745.6

S249A/K250Q/
V251C

673.8

2166.5

678.5

1517.9

P255G

675.3

1752.3

682.7

514.4

Q248P/S249G/
K250P/G252W

674.9

6632.7

679.8

2349.2

K250M/V251L
/W256Y

676.8

3124.6

685.5

531.9

Proteins

ν7
total
intensity
(area)

γ15
(cm-1)

γ15
total
intensity
(area)

γ15/ν7
relative
intensity

% Wildtype
γ15/ν7
relative
intensitya

kcat / KmPPIX
(min-1 μM-1)

3033.3

700.4

455.8

0.150

100.0

2.93

1805.2

701.0

244.4

0.135

90.1

2.94

3684.4

700.8

481.8

0.131

87.0

2.63

2266.7

700.6

126.0

0.056

37.0

2.35

8981.9

701.0

1088.9

0.121

80.7

1.36

3656.5

701.3

158.6

0.043

28.8

0.27

a

% wild-type γ15/ν7 relative intensity was determined by normalizing the relative
intensity of the γ15 line versus the ν7 line observed in porphyrins bound to each variant
against that obtained from porphyrins bound to wild-type ferrochelatase.
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by a catalytic efficiency (kcat/KmPPIX) one order of magnitude lower than the wild-type
enzyme (Table 3). Studies using synthetic non-planar porphyrins dissolved in solvents of
different polarity suggested that saddling could affect the potential-energy surfaces to
allow porphyrin to access multiple configurations with small energy barriers from the
ground state (Sazanovich et al. 2001). Conceivably, a similar mechanism might be used
for ferrochelatase to solvate porphyrin substrate and to facilitate its conversion into
catalytically competent forms.
Similar observations have been made for porphyrin distortion by catalytic
antibodies (Venkateshrao et al. 2004). An out-of-plane vibrational mode, γ15, assigned to
the Raman band at 680 cm-1, was activated in mesoporphyrin upon binding to affinitymatured antibody, and its intensity was ~3-fold higher than that resulted from binding to
the germLine precursor antibody (Venkateshrao et al. 2004). Somatic mutations which
allowed reversion to the germLine residues yielded intermediate intensity values for the
γ15 band of bound porphyrins (Venkateshrao et al. 2004). Indeed, an approximate linear
correlation was shown between the logarithm of catalytic efficiency and the intensity of
γ15 line normalized to ν7. These results implied that the extent of γ15 activation was
mainly proportional to activation energy of the reaction, and reiterated the idea that
catalysis involves substrate straining, and binding energy is evolved to lower the
activation energy required for reaction to proceed (Venkateshrao et al. 2004). The
mechanisms of porphyrin metallation seem to proceed through a highly conserved
transition state, regardless of whether the reaction is catalyzed by a catalytic antibody or
ferrochelatase. Out-of-plane porphyrin distortion appears to be a common and crucial
thread that connects all of the transition states.
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It is likely that multiple factors can influence the competency of ferrochelatase to
distort porphyrin from its naturally planar conformation. Maximal porphyrin distortion
may require optimal active site geometry. Previous studies indicated that loop mutations
led to alteration of the active site architecture (Shi and Ferreira 2004), and as a result,
conformational changes of porphyrins bound in the active sites of the loop variants might
not achieve those of the transition state for Fe2+ insertion. This is consistent with the
correlation between the decrease in porphyrin saddling observed in the variants and the
loss of catalytic efficiency (kcat/KmPPIX) (Table 3).

Studies of catalytic antibodies

suggested that specific residues appeared to play a dominant role in inducing porphyrin
distortion (Venkateshrao et al. 2004). Although residues of the loops in both light and
heavy chains contributed to mesoporphyrin deformation, mutational analysis indicated
that heavy chain residues dominated the activation of the γ15 mode.
The dominant effect of certain amino acid residues on porphyrin deformation in
ferrochelatase is best demonstrated by variant K250M/V251L/W256Y. This variant was
the least efficient in porphyrin distortion, as it induced only about 30% of the saddling
seen in the wild-type enzyme. Previous studies showed that while K250 and V251
tolerated multiple replacements and were less likely to play a critical role in porphyrin
interaction, functional substitutions at the W256 position were very limited suggesting
the importance of W256 to enzymatic function (Shi and Ferreira 2004). Thus, while the
possibility

that

K250,

V251

and

W256

act

synergistically

in

variant

K250M/V251L/W256Y to promote deformation of the porphyrin substrate cannot be
dismissed, it seems unlikely that K250 and V251 are themselves the major determinants
in porphyrin distortion. In the structural model of murine ferrochelatase, K250 side chain
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was oriented towards the protein exterior, thus making it very unlikely that K250 would
contact the bound porphyrin directly (Figure 31). Although the side chain of V251
pointed into active site pocket (Figure 31), porphyrin binding to variant V251L yielded
RR spectra similar to that of wild-type protein (data not shown), indicating that the
V251L mutation alone does not alter the degree of porphyrin distortion from that
observed for the wild-type enzyme. In agreement with these observations, variants
S249A/K250Q/V251C and Q248P/S249G/K250P/G252W, which also contained K250
and V251 substitutions, exhibited only a mild decrease in porphyrin saddling at 10-15%
of the wild-type level (Table 3). The invariant W256 oriented its bulky aromatic side
group towards the interior of the active site cleft. X-ray crystal structural analysis of B.
subtilis ferrochelatase indicated that W230, equivalent to the murine W256 residue, was
in close proximity to the bound N-methyl-mesoporphyrin (Lecerof et al. 2000). In
particular, the minimum distance between the C6 of tryptophan indole group and the
nitrogen of pyrrole ring C of porphyrin was only ~3 Å. This made it possible for the
tryptophanyl indole ring to be positioned to tilt down the pyrrole group in a manner
required for generating the observed non-planar structure. Based on this model, it seems
likely that W256Y substitution in murine ferrochelatase would make it difficult for the
side group to reach the proximal pyrrole ring and tilt it down, because tyrosine presents a
shorter phenolic ring than the indole ring in tryptophan (Figure 31). Taken together, the
loop residue W256 appears to play a dominant role in producing porphyrin deformation
in the active site matrix of murine ferrochelatase.
In addition to modulating saddling of the porphyrin core, loop residues are found
to mediate interaction of the porphyrin vinyl substituents with the active site. While the
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A

C

B

Figure 31. Three-dimensional views of the porphyrin-binding cleft in ferrochelatase.
(A) The active site of B. subtilis ferrochelatase with bound N-MeMP as shown in the Xray crystal structure (PDB code 1C1H). The side chain of the conserved W230 (green) in
the loop motif (cyan) lies in close proximity to pyrrole ring C of bound porphyrin (red).
(B) The active site (arrow) in the structural model of wild-type murine ferrochelatase. The
side group of the conserved W256 (green) in the loop motif (cyan) is oriented towards the
interior of porphyrin-binding pocket. (C) The active site (arrow) in the structural model of
variant K250M/V251L/W256Y. Among the mutated residues in the loop (cyan), the side
chains of L251 (blue) and Y256 (green) are directed towards the interior of the porphyrinbinding cleft, while the side group of M250 (orange) points to the protein exterior.

149

vinyl groups adopted defined conformations upon porphyrin binding to wild-type protein,
the interaction was generally weakened in loop variants, possibly due to global changes
in the active site structure (Shi and Ferreira 2004). The RR spectra of protoporphyrin and
NiPP revealed sharpening of the vinyl stretching band νCa=Cb upon protein binding
(Figures 16B, 18B), suggesting that vinyl groups had a reduced freedom of movement
and adopted a more restricted orientation within the protein matrix. However, in variant
K250M/V251L/W256Y, the vinyl groups of protoporphyrin appeared less defined than in
wild-type protein and other variants (Figure 16B).

Notably, the νCa=Cb band was

downshifted suggesting rotation of the vinyl side chains into the plane of the porphyrin
core, whereas broadening of the νCa=Cb line indicated that vinyl groups might take
alternative conformations (Kalsbeck 1995; Marzocchi and Smulevich 2003).
The loop residues may also function to restrict the configuration of porphyrin ring
imposed by the active site. Using ν2 as a core-size marker (Parthasarathi 1987), hemin
exhibited expansion of the macrocycle upon binding to wild-type ferrochelatase (Figure
17B). The ring was further enlarged in the variants P255R and P255G, as indicated by
the downshift of the ν2 line for bound hemin (Figure 17B). However, in the active sites
of

the

variants

K250M/V251L/W256Y,

S249A/K250Q/V251C

and

Q248P/S249G/K250P/G252W, the macrocycle was more contracted as suggested by the
upshift of ν2, making it resemble unbound hemin. For NiPP binding, the ν2 and ν10 lines
were downshifted in wild-type protein and the variants (Figure 18B), indicating that the
ring was similarly expanded in the protein matrix. While unbound NiPP adopted both
planar and non-planar conformations in solution, as indicated by the deconvolution of the
ν10 band into a planar and non-planar component, only the non-planar form was retained
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in the protein environment (Figure 18B), reminiscent of the conformation previously
observed for NiPP bound to wild-type enzyme (Franco et al. 2000).
In conclusion, the conserved active site loop motif in ferrochelatase plays an
important role in porphyrin binding and distortion.

Most significantly, the induced

porphyrin saddling is shown to modulate catalytic efficiency of ferrochelatase towards its
substrate, and the invariant tryptophan is a major protein determinant of the saddled
conformation of the macrocycle. Additionally, the loop residues function in specifically
orienting the porphyrin vinyl substituents and likely the entire porphyrin ring.

Inhibition of ferrochelatase by N-methyl protoporphyrin

N-methyl protoporphyrin has long been known as a potent inhibitor of
mammalian ferrochelatase (Dailey and Fleming 1983; Cole and Marks 1984; Nunn et al.
1988). Since alkylation of a pyrrole nitrogen atom introduces non-planarity into the
porphyrin macrocycle (Caughey and Iber 1963), NMPP is thought to bear structural
resemblance to the distorted porphyrin intermediate in the enzymatic reaction, and
therefore is strongly inhibitory to ferrochelatase catalysis. N-alkylated porphyrins are
generated in vivo from modification of the cytochrome P450 heme moiety upon drug
exposure (Marks et al. 1988; Lavigne et al. 2002). Xenobiotics taken up by hepatic cells
have been shown to bind to the active site of P450 and inactivate the enzyme by Nalkylation of a heme pyrrole ring (Marks et al. 1988).

Recently, N-alkylporphyrin

formation has been associated with specific isoforms of P450 undergoing mechanismbased inactivation in human liver microsomes (Gamble et al. 2003).
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While wild-type ferrochelatase showed high affinity towards NMPP consistent
with previous studies (Dailey and Fleming 1983), the stability of this complex was
reduced due to mutations in loop residue P255. Studies of enzymes including thrombin
(Lewis et al. 1998) and pyruvate dehydrogenase (Nemeria et al. 2001) suggested that a
slow conformational change of the protein-inhibitor complex could play an important
role in providing high affinity binding of a substrate analog to the protein, because it
would ensure optimal alignment of the ligand in the active site environment. In order to
find out whether this mechanism is applicable to ferrochelatase, the rate constants for
NMPP binding to ferrochelatase were determined using stopped-flow analysis. For wildtype enzyme, the inhibitor binding process was found to consist of two kinetic steps.
There was a fast step for initial binding of NMPP to the enzyme (Figure 23A). It was
followed by a slow step, which might be related to conformational rearrangement of the
protein-inhibitor

complex

(Figure

23A).

Consistent

with

this

mechanism,

crystallographic studies revealed that binding of porphyrin analog N-methyl
mesoporphyrin to B. subtilis ferrochelatase triggered a significant conformational change
of the active site pocket involving the loop residues (Lecerof et al. 2000).
Similar to wild-type enzyme, binding of NMPP to variant P255R also proceeded
in two steps (Figure 23B). For the slow step, i.e. the second step, the forward and reverse
rate constants k2 and k-2, were comparable to those of wild-type protein. Therefore
diminished inhibition of variant P255R did not stem from changes in the rate of NMPP
binding. In variant P255G, NMPP binding occurred in one step and did not involve
conformational change of the protein-inhibitor complex (Figure 23C). Nevertheless, the
rate constants k1 and k-1 for variant P255G were similar to those determined for the rate-
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limiting step, i.e. k2 and k-2, in wild-type protein and variant P255R, suggesting that the
rate of NMPP binding was unlikely to contribute to its lessened inhibitory effect on
P255G.
It is possible that binding affinity for NMPP can be modulated by the steric
features of the active site of ferrochelatase. Structural modeling suggested that loop
mutations result in alterations in the active site architecture (Shi and Ferreira 2004).
Examination of the dimension of the active site cavity using the CAST program indicates
that the size of porphyrin-binding pocket is reduced by 30% in variant P255R and 50% in
variant P255G relative to wild-type protein. Based on these observations, it seems
plausible that the P255 residue plays a role in supporting an open conformation of the
active site in wild-type ferrochelatase, whereas P255 variants are deficient in opening the
active site cleft, which can lead to restricted NMPP entry and decreased binding affinity.
This possibility is consistent with the function of proline as a conformational switch,
which has been demonstrated in a variety of proteins such as interleukin-2 tyrosine kinase
and serine proteases (Mallis et al. 2002; Bobofchak et al. 2005).
In spite of marked differences with respect to NMPP binding, the variants
exhibited kinetic properties similar to wild-type enzyme. While wild-type ferrochelatase
had a kcat of 4.1± 0.3 min-1, the catalytic activity was slightly increased in the variants,
with a kcat of 7.8 ± 0.8 min-1 for P255R and 5.9 ± 1.4 min-1 for P255G (Table 1 and
unpublished results). The KmPPIX for wild-type enzyme was 1.4 ± 0.2 μM, and it was
slightly higher in the variants with 2.65 ± 0.44 μM for P255R and 2.51 ± 0.80 μM for
P255G (Table 1 and unpublished results).

Thus, the specificity constant for

protoporphyrin, i.e. kcat/KmPPIX, was 2.92 for wild-type ferrochelatase, 2.94 for P255R and
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2.35 for P255G. These results imply that specificity towards the endogenous substrate
porphyrin is distinct from selectivity towards NMPP, and the mechanism involving
substrate porphyrin interaction in the catalytic pathway might be different from that for
inhibitor binding. Overall, while selectivity towards NMPP is prone to perturbation as a
result of active site mutations, it is much more difficult to alter specificity towards
substrate porphyrin. It is conceivable that the active site of ferrochelatase is optimized
for interaction with substrate protoporphyrin and retains a certain degree of plasticity
towards this end. Possibly, this facilitates induction of porphyrin deformation in the
protein matrix, and in so doing, ensures catalytic reaction to proceed. In contrast, active
site does not appear to be flexible towards interaction with porphyrin analog such as
NMPP.
One potential application of the ferrochelatase variants with improved tolerance
towards NMPP is to use them in the cell assay system for studying physiological
responses resulted from heme deficiency. Recent reports have suggested that heme
deficiency is associated with various disorders such as Alzheimer’s disease, frataxindeficiency mediated diseases and oxidative damages resulted from hyperoxia (Atamna
and Frey 2004; Campian et al. 2004; Schoenfeld et al. 2005). In these studies, NMPP
treatment of cultured cells has been used as a convenient model system to induce heme
deficiency (Atamna et al. 2001; Campian et al. 2004). Interestingly, NMPP-treated cells
typically exhibited impaired enzymatic activity and assembly of mitochondrial electron
transport complex IV, i.e. cytochrome c oxidase (COX) (Tangeras 1986; Atamna et al.
2001; Campian et al. 2004). COX has been proposed to have a cytoprotective role by
removing reactive oxygen species, and COX deficiency renders cells more susceptible to
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oxidative stress (Atamna et al. 2001; Campian et al. 2004). It should be interesting to
find whether the observed NMPP-induced cytotoxicity can be alleviated by expressing
constitutively active ferrochelatase, for instance, the P255 variants which would confer
resistance to NMPP inhibition and thereby keep heme synthesis uninterrupted.
In summary, ferrochelatase variants P255R and P255G have been found to be
much less inhibited by the porphyrin analog NMPP when compared to wild-type protein.
This is likely to derive from structural features of the mutant active sites and not due to
changes in the rate constants of inhibitor binding. This raises the possibility of lowering
selectivity towards active site-directed inhibitor without compromising substrate
specificity and catalysis, for instance, through modification of protein conformation. The
variants can also be applied to disease studies relevant to heme deficiency, for example,
to protect cells from cytotoxicity resulted from heme deficiency.

FeS cluster assembly and oligomeric organization in ferrochelatase

Wild-type mammalian ferrochelatase has been shown to exist as a homodimer
(Straka et al. 1991; Wu et al. 2001), and there is one [2Fe-2S] cluster associated with
each monomeric subunit (Wu et al. 2001). FeS cluster is coordinated by four cysteine
ligands C403, C406 and C411 in a conserved C-terminal motif and a distant C196 in the
N-terminal portion [(Crouse et al. 1996; Wu et al. 2001) and Figure 32]. Mutations in the
C-terminus including cysteine ligand substitutions resulted in deficiency in catalytic
activity and cluster assembly, suggesting that the FeS cluster plays an important role in
wild-type protein function (Brenner et al. 1992; Dailey et al. 1994a; Crouse et al. 1996).
The current study indicates while FeS cluster assembly is important to enzymatic activity
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Figure 32. Position of the FeS cluster relative to the active site in ferrochelatase.
Locations of the [2Fe-2S] cluster (sulfur atoms in pink and iron atoms in green) and the
four coordinating cysteine ligands (red) are shown in the X-ray crystal structure of
human ferrochelatase homodimer (PDB code 1hrk). The active site cavity in a
monomeric subunit is indicated by an arrow. The loop motif is marked in cyan. The
homology model of murine ferrochelatase (lime) is superimposed onto the monomeric
structure of human ferrochelatase (yellow). Image was generated using VMD 1.8.3
(Humphrey et al. 1996).
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of wild-type murine ferrochelatase, it is dispensible in variants S249A/K250Q/V251C
and S249A/K250R/G252W (Figure 25). This implies that the catalytic mechanism of
ferrochelatase may be independent of FeS cluster, which is in agreement with previous
observations (Medlock and Dailey 2000). Using chimeric constructs of human and yeast
ferrochelatase, it has been shown that a fusion protein containing the C-terminal tail from
yeast enzyme and the remaining of human enzyme was active without having the FeS
cluster from human ferrochelatase (Medlock and Dailey 2000). Also, truncated human
ferrochelatase lacking the C-terminal cluster-coordinating region was catalytically active
(Ohgari et al. 2005). Because the catalytic core of ferrochelatase is highly conserved
(Dailey and Dailey 2003), it is likely that the reaction pathway for mammalian enzyme
is analogous to that for the clusterless enzyme from B. subtilis and S. cerevisiae and does
not directly involve FeS cluster (Al-Karadaghi et al. 1997; Karlberg et al. 2002).
Consistent with the notion that mammalian ferrochelatase exists as a homodimer
(Straka et al. 1991; Wu et al. 2001), size determination by gel filtration analysis (Figure
26) and dynamic light scattering (Figure 27) indicated that purified wild-type murine
ferrochelatase is a homodimer in solution. Nevertheless, higher order oligomers were
found in variants S249A/K250Q/V251C and S249A/K250R/G252W and they remained
enzymatically active (Figure 26 and 27). These observations suggest that ferrochelatase
can adopt alternative quaternary structures other than homodimer, and oligomerization
state is not directly related to enzymatic activity. In line with this proposal, recent studies
of human ferrochelatase showed that a wild-type monomer was capable of forming a
heterodimer with a mutant monomer encoded by alleles derived from EPP patients and
the heterodimers were catalytically active (Najahi-Missaoui and Dailey 2005; Ohgari et
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al. 2005). Interestingly, the presence of high molecular weight species in loop variants
S249A/K250Q/V251C and S249A/K250R/G252W suggest that the quaternary structure
of ferrochelatase can be modified as a result of protein structural changes, and therefore
is not completely controlled by interaction of residues on the dimer interface as suggested
in the crystal structural analysis of human ferrochelatase (Wu et al. 2001). This result is
reminiscent of a conformational study of porphobilinogen synthase, which exhibits
dynamic equilibrium of quaternary structures (Jaffe 2005).

Determining subunit

arrangement in the variants, for instance, by X-ray crystallography, may help to further
understand the structural basis of ferrochelatase oligomerization.
EPR spectroscopic analysis indicated that similar to wild-type protein, [2Fe-2S] is
a predominant, if not the only, form of cluster in the variants (Figure 28). Although
attempts were made to examine the temperature-dependence of EPR spectra in order to
differentiate the possibilities that there are mixed-type clusters such as the [4Fe-4S] and
[2Fe-2S] forms, further analyses will be required to decipher the spectral features (Figure
29). Because variant S249A/K250Q/V251C and S249A/K250R/G252W can exist in
large oligomeric assemblies, the FeS cluster does not appear to directly promote subunit
interaction. This proposal is consistent with recent studies of human ferrochelatase
showing that homodimers and heterodimers could form among the wild-type and mutant
protein subunits in the absence of cluster (Najahi-Missaoui and Dailey 2005; Ohgari et
al. 2005). Therefore, although [2Fe-2S] cluster has been found near the dimer interface
in human ferrochelatase crystal structure (Wu et al. 2001), the notion that the cluster acts
to facilitate dimerization may be questionable.
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Taken together, the current characterization of ferrochelatase variants suggests an
interesting aspect of the catalytic mechanism. It seems plausible that catalytic reaction
may take place on a scaffold provided by higher order oligomeric forms as revealed in
the variants, and the reaction may proceed even without FeS cluster. This helps to
explain the observation that variants S249A/K250Q/V251C and S249A/K250R/G252W
retained significant amount of enzymatic activity in the absence of cluster assembly, i.e.
in PK4331 cells, when compared to the control levels, i.e. in RZ4500 cells, whereas
wild-type protein was inactivated by the loss of cluster assembly (Figure 25).

An

alternative hypothesis is that the FeS cluster plays a role in stabilizing the active site
conformation (Dailey 1997). Because the loop motif has been proposed to play a role in
maintaining the active site structure (Shi and Ferreira 2004), it is likely that the variants
can adopt alternative active site conformations which support enzymatic reaction without
the FeS cluster (Figure 32).
Overall, the current results suggest that the FeS cluster is not directly involved in
catalysis, but rather, it is more likely to regulate enzymatic activity. One possibility is
that the FeS cluster can sense the iron state in vivo and modulate enzymatic activity
accordingly (Taketani et al. 2003; Lange et al. 2004).

This would imply that

ferrochelatase is active if an adequate amount of cluster is assembled, whereas under
conditions such as iron deprivation, FeS cluster assembly is diminished leading to
inactivation of the enzyme and inhibition of the completion of heme synthesis. This
possibility is particularly interesting considering that FeS cluster assembly has very
recently been shown to modulate erythroid heme synthesis by translational regulation of
the first enzyme ALAS2 production (Wingert et al. 2005). Thus, by extending the
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regulatory role of the cluster to the terminal enzyme, ferrochelatase, FeS cluster assembly
machinery becomes tightly coupled to heme biosynthesis pathway, thereby providing a
rapid response to iron status under physiological conditions.
Investigation of the mechanism of ferrochelatase oligomerization and FeS cluster
assembly are relevant to the understanding of EPP pathogenesis. Since EPP mutations
found near the cluster and dimer interface are highly deleterious to ferrochelatase activity
(Schneider-Yin et al. 2000b; Najahi-Missaoui and Dailey 2005; Ohgari et al. 2005),
regulation of enzymatic activity and protein structure and stability is likely to play an
important part in disease development.

One potential application of the variants

described here is to study the regulation of ferrochelatase activity in mammalian cells.
For instance, if ferrochelatase is regulated by FeS cluster assembly, expression of the
variants may override this control and uncouple protoporphyrin IX accumulation from
inadequate cluster assembly. It is hoped that further studies of cluster assembly and
oligomerization shall provide insights into the regulatory mechanism for ferrochelatase
activity.

160

References

Abbas, A., and Labbe-Bois, R. 1993. Structure-function studies of yeast ferrochelatase.
Identification and functional analysis of amino acid substitutions that increase
Vmax and the Km for both substrates. J. Biol. Chem. 268: 8541-8546.
Abitbol, M., Bernex, F., Puy, H., Jouault, H., Deybach, J.-C., Guenet, J.-L., and
Montagutelli, X. 2005. A mouse model provides evidence that genetic
background modulates anemia and liver injury in erythropoietic protoporphyria.
Am. J. Physiol. Gastrointest. Liver Physiol. 288: G1208-1216.
Ades, I.Z. 1983. Biogenesis of mitochondrial proteins regulation of maturation of deltaaminolevulinate synthase by hemin. Biochem. Biophys. Res. Commun. 110: 4247.
Ades, I.Z., and Friedland, D.M. 1988. Properties of chicken erythrocyte deltaaminolevulinate synthase. Int. J. Biochem. 20: 965-969.
Ades, I.Z., and Harpe, K.G. 1981. Biogenesis of mitochondrial proteins. Identification of
the mature and precursor forms of the subunit of delta-aminolevulinate synthase
from embryonic chick liver. J. Biol. Chem. 256: 9329-9333.
Ades, I.Z., and Stevens, T.M. 1988. Maturation of embryonic chick liver deltaaminolevulinate synthase: precursor pools and regulation by intra-cellularly
produced heme. Int. J. Biochem. 20: 959-964.
Aizencang, G., Solis, C., Bishop, D.F., Warner, C., and Desnick, R.J. 2000a. Human
uroporphyrinogen-III synthase: genomic organization, alternative promoters, and
erythroid-specific expression. Genomics 70: 223-231.
Aizencang, G.I., Bishop, D.F., Forrest, D., Astrin, K.H., and Desnick, R.J. 2000b.
Uroporphyrinogen III synthase. An alternative promoter controls erythroidspecific expression in the murine gene. J. Biol. Chem. 275: 2295-2304.
Akhtar, M. 1994. The modification of acetate and propionate side chains during the
biosynthesis of haem and chlorophylls: mechanistic and stereochemical studies.
Ciba Found. Symp. 180: 131-151.

161

Al-Karadaghi, S., Hansson, M., Nikonov, S., Jonsson, B., and Hederstedt, L. 1997.
Crystal structure of ferrochelatase: the terminal enzyme in heme biosynthesis.
Structure 5: 1501-1510.
Alcindor, T., and Bridges, K.R. 2002. Sideroblastic anaemias. Br. J. Haematol. 116: 733743.
Alexander, F.W., Sandmeier, E., Mehta, P.K., and Christen, P. 1994. Evolutionary
relationships among pyridoxal-5'-phosphate-dependent enzymes. Regio-specific
α, β and γ families. Euro. J. Biochem. 219: 953-960.
Alexeev, D., Alexeeva, M., Baxter, R.L., Campopiano, D.J., Webster, S.P., and Sawyer,
L. 1998. The crystal structure of 8-amino-7-oxononanoate synthase: a bacterial
PLP-dependent, acyl-CoA-condensing enzyme. J. Mol. Bio. 284: 401-419.
Alwan, A.F., Mgbeje, B.I., and Jordan, P.M. 1989. Purification and properties of
uroporphyrinogen III synthase (co-synthase) from an overproducing recombinant
strain of Escherichia coli K-12. Biochem. J. 264: 397-402.
Anderson, K.E., Bloomer, J.R., Bonkovsky, H.L., Kushner, J.P., Pierach, C.A., Pimstone,
N.R., and Desnick, R.J. 2005. Recommendations for the diagnosis and treatment
of the acute porphyrias. Ann. Intern. Med. 142: 439-450.
Anderson, K.S., Sikorski, J.A., and Johnson, K.A. 1988. Evaluation of 5enolpyruvoylshikimate-3-phosphate synthase substrate and inhibitor binding by
stopped-flow and equilibrium fluorescence measurements. Biochemistry 27:
1604-1610.
Anderson, P.M., and Desnick, R.J. 1979. Purification and properties of deltaaminolevulinate dehydratase from human erythrocytes. J. Biol. Chem. 254: 69246930.
Anderson, P.M., and Desnick, R.J. 1980. Purification and properties of uroporphyrinogen
I synthase from human erythrocytes. Identification of stable enzyme-substrate
intermediates. J. Biol. Chem. 255: 1993-1999.
Ardail, D., Privat, J.P., Egret-Charlier, M., Levrat, C., Lerme, F., and Louisot, P. 1990.
Mitochondrial contact sites. Lipid composition and dynamics. J. Biol. Chem. 265:
18797-18802.
Arnould, S., and Camadro, J.-M. 1998. The domain structure of protoporphyrinogen
oxidase, the molecular target of diphenyl ether-type herbicides. Proc. Natl. Acad.
Sci. 95: 10553-10558.

162

Arnould, S., Takahashi, M., and Camadro, J.-M. 1999. Acylation stabilizes a proteaseresistant conformation of protoporphyrinogen oxidase, the molecular target of
diphenyl ether-type herbicides. Proc. Natl. Acad. Sci. 96: 14825-14830.
Astner, I., Schulze J. O., van den Heuvel, J., Jahn, D., Schubert, W.D., and Heinz, D.W.
2005. Crystal structure of 5-aminolevulinate synthase, the first enzyme of heme
biosynthesis, and its link to XLSA in humans. EMBO J. 24: 3166-3177.
Atamna, H., and Frey, W.H. 2004. A role for heme in Alzheimer's disease: Heme binds
amyloid-β and has altered metabolism. Proc. Natl. Acad. Sci. 101: 11153-11158.
Atamna, H., Liu, J.K., and Ames, B.N. 2001. Heme deficiency selectively interrupts
assembly of mitochondrial complex IV in human fibroblasts. Relevance to aging.
J. Biol. Chem. 276: 48410-48416.
Avissar, Y.J., Ormerod, J.G., and Beale, S.I. 1989. Distribution of delta-aminolevulinic
acid biosynthetic pathways among phototrophic bacterial groups. Arch.
Microbiol. 151: 513-519.
Bales, L., Day, R.S., and Blekkenhorst, G.H. 1980. The clinical and biochemical features
of variegate porphyria: An analysis of 300 cases studied at Groote Schuur
Hospital, Cape Town. Int. J. Biochem. 12: 837-853.
Barnard, G.F., and Akhtar, M. 1979. Stereochemical and mechanistic studies on the
decarboxylation of uroporphyrinogen III in haem biosynthesis. J. Chem. Soc.
Perkin Trans. I 10: 2354-2360.
Battersby, A.R. 1978. The discovery of nature's biosynthetic pathways. Experientia 34:
1-13.
Battersby, A.R., and Leeper, F.J. 1990. Biosynthesis of the pigments of life: mechanistic
studies on the conversion of porphobilinogen to uroporphyrinogen III. Chem. Rev.
90: 1261-1274.
Bawden, M.J., Borthwick, I.A., Healy, H.M., Morris, C.P., May, B.K., and Elliott, W.H.
1987. Sequence of human 5-aminolevulinate synthase cDNA. Nucleic Acids Res.
15: 8563.
Beale, S.I., Gough, S.P., and Granick, S. 1975. Biosynthesis of delta-aminolevulinic acid
from the intact carbon skeleton of glutamic acid in greening barley. Proc. Natl.
Acad. Sci. 72: 2719-2723.
Berlin, S.O., and Brante, G. 1962. Iron metabolism in porphyria and hemochromatosis.
The Lancet 280: 729-729.

163

Binda, C., Hubálek, F., Li, M., Edmondson, D.E., and Mattevi, A. 2004. Crystal structure
of human monoamine oxidase B, a drug target enzyme monotopically inserted
into the mitochondrial outer membrane. FEBS Lett. 564: 225-228.
Bishop, D., Johansson, A., and Desnick, R.J. 2005. Congenital erythropoietic porphyria:
generation and characterization of knock-in mouse models. J. Inher. Metab.
Disease 28: 258.
Bishop, D.F. 1990. Two different genes encode δ-aminolevulinate synthase in humans:
nucleotide sequences of cDNAs for the housekeeping and erythroid genes.
Nucleic Acids Res. 18: 7187.
Bishop, D.F., Kitchen, H., and Wood, W.A. 1981. Evidence for erythroid and
nonerythroid forms of delta-aminolevulinate synthetase. Arch. Biochem. Biophys.
206: 380-391.
Blackwood, M.E., Rush, T.S., Medlock, A., Dailey, H.A., and Spiro, T.G. 1997.
Resonance Raman spectra of ferrochelatase reveal porphyrin distortion upon
metal binding. J. Am. Chem. Soc. 119: 12170-12174.
Blackwood, M.E., Rush, T.S., Rosenberg, F., Schultz, P.G., and Spiro, T.G. 1998.
Alternative modes of substrate distortion in enzyme and antibody catalyzed
ferrochelation reactions. Biochemistry 37: 779-782.
Bloomer, J., Wang Y, Singhal A, and H., R. 2005. Molecular studies of liver disease in
erythropoietic protoporphyria. J. Clin. Gastroenterol. 39: S167-175.
Bloomer, J.R. 1988. The liver in protoporphyria. Hepatology 8: 402-407.
Bloomer, J.R., Rank, J.M., Payne, W.D., Snover, D.C., Sharp, H.L., Zwiener, R.J., and
Carithers, R.L. 1996. Follow-up after liver transplantation for protoporphyric liver
disease. Liver Transpl. Surg. 2: 269-275.
Bobofchak, K.M., Pineda, A.O., Mathews, F.S., and Di Cera, E. 2005. Energetic and
structural consequences of perturbing Gly-193 in the oxyanion hole of serine
proteases. J. Biol. Chem. 280: 25644-25650.
Boehning, D., and Snyder, S.H. 2003. Novel neural modulators. Ann. Rev. Neurosci. 26:
105-131.
Boese, Q.F., Spano, A.J., Li, J.M., and Timko, M.P. 1991. Aminolevulinic acid
dehydratase in pea (Pisum sativum L.). Identification of an unusual metal-binding
domain in the plant enzyme. J. Biol. Chem. 266: 17060-17066.

164

Bogard, M., Camadro, J.M., Nordmann, Y., and Labbe, P. 1989. Purification and
properties of mouse liver coproporphyrinogen oxidase. Eur. J. Biochem. 181:
417-421.
Bogorad, L. 1958a. The enzymatic synthesis of porphyrins from porphobilinogen. I.
Uroporphyrin I. J Biol Chem 233: 501-509.
Bogorad, L. 1958b. The enzymatic synthesis of porphyrins from porphobilinogen. II.
Uroporphyrin III. J Biol Chem 233: 510-515.
Bogorad, L. 1958c. The enzymatic synthesis of porphyrins from porphobilinogen. III.
Uroporphyrinogens as intermediates. J Biol Chem 233: 516-519.
Bollivar, D., Clauson, C., Lighthall, R., Forbes, S., Kokona, B., Fairman, R., Kundrat, L.,
and Jaffe, E. 2004. Rhodobacter capsulatus porphobilinogen synthase, a high
activity metal ion independent hexamer. BMC Biochemistry 5: 17.
Bonkowsky, H.L., Bloomer, J.R., Ebert, P.S., and Mahoney, M.J. 1975. Heme synthetase
deficiency in human protoporphyria. Demonstration of the defect in liver and
cultured skin fibroblasts. J. Clin. Invest. 56: 1139-1148.
Bottomley, S.S., May, B.K., Cox, T.C., Cotter, P.D., and Bishop, D.F. 1995. Molecular
defects of erythroid 5-aminolevulinate synthase in X-linked sideroblastic anemia.
J. Bioenerg. Biomembr. 27: 161-168.
Boulechfar, S., Da Silva, V., Deybach, J.C., Nordmann, Y., Grandchamp, B., and de
Verneuil, H. 1992. Heterogeneity of mutations in the uroporphyrinogen III
synthase gene in congenital erythropoietic porphyria. Hum. Genet. 88: 320-324.
Breckau, D., Mahlitz, E., Sauerwald, A., Layer, G., and Jahn, D. 2003. Oxygendependent coproporphyrinogen III oxidase (HemF) from Escherichia coli Is
stimulated by manganese. J. Biol. Chem. 278: 46625-46631.
Breinig, S., Kervinen, J., Stith, L., Wasson, A.S., Fairman, R., Wlodawer, A., Zdanov,
A., and Jaffe, E.K. 2003. Control of tetrapyrrole biosynthesis by alternate
quaternary forms of porphobilinogen synthase. Nat. Struct. Mol. Biol. 10: 757763.
Brennan, M.J., Cantrill, R.C., and Kramer, S. 1980. Effect of delta-aminolaevulinic acid
on GABA receptor binding in synaptic plasma membranes. Int. J. Biochem. 12:
833-835.
Brenner, D.A., and Bloomer, J.R. 1980. The enzymic defect in variegate porphyria.
Studies with human cultured skin fibroblasts. New Eng. J. Med. 302: 765-769.

165

Brenner, D.A., Didier, J.M., Fraiser, F., Christensen, S.R., Evans, G.A., and Dailey, H.A.
1992. A molecular defect in human protoporphyria. Am. J. Hum. Genet. 50: 12031210.
Brenner, D.A., and Frasier, F. 1991. Cloning of murine ferrochelatase. Proc. Natl. Acad.
Sci. 88: 849-853.
Brownlie, P.D., Lambert, R., Louie, G.V., Jordan, P.M., Blundell, T.L., Warren, M.J.,
Cooper, J.B., and Wood, S.P. 1994. The three-dimensional structures of mutants
of porphobilinogen deaminase: Toward an understanding of the structural basis of
acute intermittent porphyria. Protein Sci. 3: 1644-1650.
Bulaj, Z.J., Phillips, J.D., Ajioka, R.S., Franklin, M.R., Griffen, L.M., Guinee, D.J.,
Edwards, C.Q., and Kushner, J.P. 2000. Hemochromatosis genes and other factors
contributing to the pathogenesis of porphyria cutanea tarda. Blood 95: 1565-1571.
Burden, A.E., Wu, C., Dailey, T.A., Busch, J.L., Dhawan, I.K., Rose, J.P., Wang, B., and
Dailey, H.A. 1999. Human ferrochelatase: crystallization, characterization of the
[2Fe-2S] cluster and determination that the enzyme is a homodimer. Biochim.
Biophys. Acta 1435: 191-197.
Bygum, A., Christiansen, L., Petersen, N.E., Horder, M., Thomsen, K., and Brandrup, F.
2003. Familial and sporadic porphyria cutanea tarda: clinical, biochemical and
genetic features with emphasis on iron status. Acta Derm. Venereol. 83: 115-120.
Camadro, J.-M., and Labbe, P. 1996. Cloning and characterization of the yeast Hem14
gene coding for protoporphyrinogen oxidase, the molecular target of diphenyl
ether-type herbicides. J. Biol. Chem. 271: 9120-9128.
Camadro, J.M., Chambon, H., Jolles, J., and Labbe, P. 1986a. Purification and properties
of coproporphyrinogen oxidase from the yeast Saccharomyces cerevisiae. Eur. J.
Biochem. 156: 579-587.
Camadro, J.M., Chambon, M., Jolles, J., and Labbe, P. 1986b. Purification and properties
of coproporphyrinogen oxidase from the yeast Saccharomyces cerevisiae. Eur. J.
Biochem. 156: 579-587.
Camadro, J.M., and Labbe, P. 1982. Kinetic studies of ferrochelatase in yeast. Biochim.
Biophys. Acta. 707: 280-288.
Camadro, J.M., and Labbe, P. 1988. Purification and properties of ferrochelatase from the
yeast Saccharomyces cerevisiae. Evidence for a precursor form of the protein. J.
Biol. Chem. 263: 11675-11682.
Campian, J.L., Qian, M., Gao, X., and Eaton, J.W. 2004. Oxygen tolerance and coupling
of mitochondrial electron transport. J. Biol. Chem. 279: 46580-46587.
166

Canepa, E.T., and Llambias, E.B. 1988. Purification and characterization of ferro- and
cobalto-chelatases. Biochem. Cell Biol. 66: 32-39.
Cappellini, M.D., di Montemuros, F.M., Di Pierro, E., and Fiorelli, G. 2002.
Hematologically important mutations: Acute intermittent porphyria. Blood Cells,
Molecules and Diseases 28: 5-12.
Cassidy, M.A., Crockett, N., Leeper, F.J., and Battersby, A.R. 1991. Synthetic studies on
the proposed spiro intermediate for biosynthesis of the natural porphyrins: the
stereochemical probe. J. Chem. Soc., Chem. Comm. 6: 384-386.
Caughey, W.S., and Iber, P.K. 1963. Ring nonplanarity and aromaticity in porphyrins.
nuclear magnetic resonance spectra of etioporphyrin II and its N-alkyl
compounds. J. Org. Chem. 28: 269-270.
Chaufan, G., Corvi, M.M., San Martin de Viale, L.C., Cardenas, M.L., and Carmen Rios
de Molina, M. 2005. Abnormal kinetic behavior of uroporphyrinogen
decarboxylase obtained from rats with hexachlorobenzene-induced porphyria. J.
Biochem. Mol. Toxicol. 19: 19-24.
Chelstowska, A., Zoladek, T., Garey, J., Kushner, J., Rytka, J., and Labbe-Bois, R. 1992.
Identification of amino acid changes affecting yeast uroporphyrinogen
decarboxylase activity by sequence analysis of hem12 mutant alleles. Biochem. J.
288: 753-757.
Chen, F.P., Risheg, H., Liu, Y., and Bloomer, J. 2002. Ferrochelatase gene mutations in
erythropoietic protoporphyria: focus on liver disease. Cell Mol. Biol. (Noisy-legrand) 48: 83-89.
Clement, R.P., Kohashi, M., and Piper, W.N. 1982. Rat hepatic uroporphyrinogen III
cosynthase: purification, properties, and inhibition by metal ions. Arch. Biochem.
Biophys. 214: 657-667.
Coates, L., Beaven, G., Erskine, P.T., Beale, S.I., Avissar, Y.J., Gill, R., Mohammed, F.,
Wood, S.P., Shoolingin-Jordan, P., and Cooper, J.B. 2004. The X-ray structure of
the plant like 5-aminolaevulinic acid dehydratase from Chlorobium vibrioforme
complexed with the inhibitor laevulinic acid at 2.6 A resolution. J. Mol. Biol. 342:
563-570.
Cochran, A.G., and Schultz, P.G. 1990. Antibody-catalyzed porphyrin metallation.
Science 249: 781-783.
Colas, C., and Ortiz de Montellano, P.R. 2003. Autocatalytic radical reactions in
physiological prosthetic heme modification. Chem. Rev. 103: 2305-2332.

167

Cole, S.P., and Marks, G.S. 1984. Ferrochelatase and N-alkylated porphyrins. Mol. Cell
Biochem. 64: 127-137.
Colloc'h, N., Mornon, J.-P., and Camadro, J.-M. 2002. Towards a new T-fold protein?:
The coproporphyrinogen III oxidase sequence matches many structural features
from urate oxidase. FEBS Letters 526: 5-10.
Combet, C., Jambon, M., Deleage, G., and Geourjon, C. 2002. Geno3D: automatic
comparative molecular modelling of protein. Bioinformatics 18: 213-214.
Coomber, S.A., Jones, R.M., Jordan, P.M., and Hunter, C.N. 1992. A putative anaerobic
coproporphyrinogen III oxidase in Rhodobacter sphaeroides. I. Molecular
cloning, transposon mutagenesis and sequence analysis of the gene. Mol.
Microbiol. 6: 3159-3169.
Cooperman, S.S., Meyron-Holtz, E.G., Olivierre-Wilson, H., Ghosh, M.C., McConnell,
J.P., and Rouault, T.A. 2005. Microcytic anemia, erythropoietic protoporphyria,
and neurodegeneration in mice with targeted deletion of iron-regulatory protein 2.
Blood 106: 1084-1091.
Cornejo, J., Willows, R.D., and Beale, S.I. 1998. Phytobilin biosynthesis: cloning and
expression of a gene encoding soluble ferredoxin-dependent heme oxygenase
from Synechocystis sp. PCC 6803. Plant J. 15: 99-107.
Cotter, P.D., Baumann, M., and Bishop, D.F. 1992. Enzymatic defect in X-linked
sideroblastic anemia: Molecular evidence for erythroid delta-aminolevulinate
synthase deficiency. Proc. Natl. Acad. Sci. 89: 4028-4032.
Cotter, P.D., May, A., Li, L., Al-Sabah, A.I., Fitzsimons, E.J., Cazzola, M., and Bishop,
D.F. 1999. Four new mutations in the erythroid-specific 5-aminolevulinate
synthase (ALAS2) gene causing X-linked sideroblastic anemia: Increased
pyridoxine responsiveness after removal of iron overload by phlebotomy and
coinheritance of hereditary hemochromatosis. Blood 93: 1757-1769.
Cox, T.C., Bawden, M.J., Martin, A., and May, B.K. 1991. Human erythroid 5aminolevulinate synthase: promoter analysis and identification of an ironresponsive element in the mRNA. EMBO J. 10: 1891-1902.
Crouse, B.R., Sellers, V.M., Finnegan, M.G., Dailey, H.A., and Johnson, M.K. 1996.
Site-directed mutagenesis and spectroscopic characterization of human
ferrochelatase: identification of residues coordinating the [2Fe-2S] cluster.
Biochemistry 35: 16222-16229.
Da Silva, V., Simonin, S., Deybach, J.C., Puy, H., and Nordmann, Y. 1995. Variegate
porphyria: diagnostic value of fluorometric scanning of plasma porphyrins.
Clinica Chimica Acta 238: 163-168.
168

Dailey, H.A. 1977. Purification and characterization of the membrane-bound
ferrochelatase from Spirillum itersonii. J. Bacteriol. 132: 302-307.
Dailey, H.A. 1997. Enzymes of heme biosynthesis. J. Biol. Inorg. Chem. 2: 411-417.
Dailey, H.A. 2002. Terminal steps of haem biosynthesis. Biochem. Soc. Trans. 30: 590595.
Dailey, H.A., and Dailey, T.A. 1996a. Protoporphyrinogen oxidase of Myxococcus
xanthus. J. Biol. Chem. 271: 8714-8718.
Dailey, H.A., and Dailey, T.A. 2003. Ferrochelatase. In The Porphyrin Handbook. (eds.
K.M. Kadish, K.M. Smith, and S.R. Guilard), pp. 93-121. Elsevier Science.
Dailey, H.A., Dailey, T.A., Wu, C.K., Medlock, A.E., Wang, K.F., Rose, J.P., and Wang,
B.C. 2000. Ferrochelatase at the millennium: Structures, mechanisms and [2Fe2S] clusters. Cell. Mol. Life. Sci. 57: 1909-1926.
Dailey, H.A., Finnegan, M.G., and Johnson, M.K. 1994a. Human ferrochelatase is an
iron-sulfur protein. Biochemistry 33: 403-407.
Dailey, H.A., and Fleming, J.E. 1983. Bovine ferrochelatase. Kinetic analysis of
inhibition by N-methylprotoporphyrin, manganese, and heme. J. Biol. Chem. 258:
11453-11459.
Dailey, H.A., Jones, C.S., and Karr, S.W. 1989. Interaction of free porphyrins and
metalloporphyrins with mouse ferrochelatase. A model for the active site of
ferrochelatase Biochim. Biophys. Acta 999: 7-11.
Dailey, H.A., and Karr, S.W. 1983. Purification and characterization of murine
protoporphyrinogen oxidase. Biochemistry 26: 2697-2701.
Dailey, H.A., and Lascelles, J. 1974. Ferrochelatase activity in wild-type and mutant
strains of Spirillum itersonii. Solubilization with chaotropic reagents. Arch.
Biochem. Biophys. 160: 523-529.
Dailey, T.A., and Dailey, H.A. 1996b. Human protoporphyrinogen oxidase: Expression,
purification, and characterization of the cloned enzyme. Protein Sci. 5: 98-105.
Dailey, T.A., and Dailey, H.A. 2002. Identification of [2Fe-2S] clusters in microbial
ferrochelatases. J. Bacteriol. 184: 2460-2464.
Dailey, T.A., Dailey, H.A., Meissner, P., and Prasad, A.R.K. 1995. Cloning, sequence
and expression of mouse protoporphyrinogen oxidase. Arch. Biochem. Biophys.
324: 379-384.

169

Dailey, T.A., Meissner, P., and Dailey, H.A. 1994b. Expression of a cloned
protoporphyrinogen oxidase. J. Biol. Chem. 269: 813-815.
Dailey, T.A., Woodruff, J.H., and Dailey, H.A. 2005. Examination of mitochondrial
protein targeting of haem synthetic enzymes: in vivo identification of three
functional haem-responsive motifs in 5-aminolaevulinate synthase Biochem. J.
386: 381-386.
Dandekar, T., Stripecke, R., Gray, N.K., Goossen, B., Constable, A., Johansson, H.E.,
and Hentze, M.W. 1991. Identification of a novel iron-responsive element in
murine and human erythroid delta-aminolevulinic acid synthase mRNA. EMBO J.
10: 1903-1909.
Davies, R.C., and Neuberger, A. 1979. Control of 5-aminolaevulinate synthetase activity
in Rhodopseudomonas spheroides. Binding of pyridoxal phosphate to 5aminolaevulinate synthetase. Biochem. J. 177: 661-671.
de Verneuil, H., Aitken, G., and Nordmann, Y. 1978. Familial and sporadic porphyria
cutanea: two different diseases. Hum. Genet. 44: 145-151.
de Verneuil, H., Deybach, J.C., Phung, N., Da Silva, V., and Nordmann, Y. 1983a. Study
of anaesthetic agents for their ability to elicit porphyrin biosynthesis in chick
embryo liver. Biochem. Pharmacol. 32: 1011-1018.
de Verneuil, H., Geronimi, F., Lamrissi-Garcia, I., Richard, E., Moreau-Gaudry, F., and
Morey, M. 2003. Congenital erythropoietic porphyria and gene therapy in
erythropoietic porphyrias. J. Eur. Acad. Derm. Vener. 17: 61.
de Verneuil, H., Grandchamp, B., Beaumont, C., Picat, C., and Nordmann, Y. 1986.
Uroporphyrinogen decarboxylase structural mutant (Gly281----Glu) in a case of
porphyria. Science 234: 732-734.
de Verneuil, H., Grandchamp, B., and Nordmann, Y. 1980. Some kinetic properties of
human red cell uroporphyrinogen decarboxylase. Biochim. Biophys. Acta 611:
174-186.
de Verneuil, H., Sassa, S., and Kappas, A. 1983b. Purification and properties of
uroporphyrinogen decarboxylase from human erythrocytes. A single enzyme
catalyzing the four sequential decarboxylations of uroporphyrinogens I and III. J.
Biol. Chem. 258: 2454-2460.
DeLeo, V.A., Poh-Fitzpatrick, M., Mathews-Roth, M., and Harber, L.C. 1976.
Erythropoietic protoporphyria. 10 years experience. Am. J. Med. 60: 8-22.

170

Delfau-Larue, M.H., Martasek, P., and Grandchamp, B. 1994. Coproporphyrinogen
oxidase: gene organization and description of a mutation leading to exon 6
skipping. Hum. Mol. Genet. 3: 1325-1330.
Desnick, R.J., and Astrin, K.H. 2002. Congenital erythropoietic porphyria: Advances in
pathogenesis and treatment. Br. J. Haemat. 117: 779-795.
Desnick, R.J., Ostasiewicz, L.T., Tishler, P.A., and Mustajoki, P. 1985. Acute
intermittent porphyria: characterization of a novel mutation in the structural gene
for porphobilinogen deaminase. Demonstration of noncatalytic enzyme
intermediates stabilized by bound substrate. J. Clin. Invest. 76: 865-874.
Deybach, J.C., da Silva, V., Grandchamp, B., and Nordmann, Y. 1985. The
mitochondrial location of protoporphyrinogen oxidase. Eur. J. Biochem. 149:
431-435.
Deybach, J.C., de Verneuil, H., and Nordmann, Y. 1981. The inherited enzymatic defect
in porphyria variegata. Hum. Genet. 58: 425-428.
Deybach, J.C., Puy, H., Robreau, A.M., Lamoril, J., Da Silva, V., Grandchamp, B., and
Nordmann, Y. 1996. Mutations in the protoporphyrinogen oxidase gene in
patients with variegate porphyria. Hum. Mol. Genet. 5: 407-410.
Dioum, E.M., Rutter, J., Tuckerman, J.R., Gonzalez, G., Gilles-Gonzalez, M.-A., and
McKnight, S.L. 2002. NPAS2: A gas-responsive transcription factor. Science
298: 2385-2387.
Doss, M., Von Tiepermann, R., Schneider, J., and Schmid, H. 1979. New type of hepatic
porphyria with porphobilinogen synthase defect and intermittent acute clinical
manifestation. Klin. Wochenschr. 57: 1123-1127.
Doss, M.O., Stauch, T., Gross, U., Renz, M., Akagi, R., Doss-Frank, M., Seelig, H.P.,
and Sassa, S. 2004. The third case of Doss porphyria (delta-aminolevulinic acid
dehydratase deficiency) in Germany. J. Inher. Metab. Disease 27: 529-536.
Duncan, R., Faggart, M.A., Roger, A.J., and Cornell, N.W. 1999. Phylogenetic analysis
of the 5-aminolevulinate synthase gene Mol. Biol. Evol. 16: 383-396.
Dupuis-Girod, S., Akkari, V., Ged, C., Galambrun, C., Kebaïli, K., Deybach, J.-C.,
Claudy, A., Geburher, L., Philippe, N., de Verneuil, H., et al. 2005. Successful
match-unrelated donor bone marrow transplantation for congenital erythropoietic
porphyria (Günther disease). Eur. J. Pediat. 164: 104-107.
Eftink, M.R., and Ghiron, C.A. 1976. Exposure of tryptophanyl residues in proteins.
Quantitative determination by fluorescence quenching studies. Biochemistry 15:
672-680.
171

Egger, N.G., Goeger, D.E., Payne, D.A., Miskovsky, E.P., Weinman, S.A., and
Anderson, K.E. 2002. Porphyria cutanea tarda: multiplicity of risk factors
including HFE mutations, hepatitis C, and inherited uroporphyrinogen
decarboxylase deficiency. Digest. Dis. Sci. 47: 419-426.
Elder, G.H., and Evans, J.O. 1978a. Evidence that coproporphyrinogen oxidase activity
of rat liver is situated in the intermembrane space of mitochondria. Biochem. J.
172: 345-347.
Elder, G.H., and Evans, J.O. 1978b. A radiochemical method for the measurement of
coproporphyrinogen oxidase and the utilization of substrates other than
coproporphyrinogen III by the enzyme from rat liver. Biochem. J. 169: 205-214.
Elder, G.H., Evans, J.O., Jackson, J.R., and Jackson, A.H. 1978a. Factors determining the
sequence of oxidative decarboxylation of the 2- and 4-propionate substituents of
coproporphyrinogen III by coproporphyrinogen oxidase in rat liver. Biochem. J.
169: 215-223.
Elder, G.H., Lee, G.B., and Tovey, J.A. 1978b. Decreased activity of hepatic
uroporphyrinogen decarboxylase in sporadic porphyria cutanea tarda. N. Engl. J.
Med. 299: 274-278.
Elder, G.H., Tovey, J.A., and Sheppard, D.M. 1983. Purification of uroporphyrinogen
decarboxylase from human erythrocytes. Immunochemical evidence for a single
protein with decarboxylase activity in human erythrocytes and liver. Biochem. J.
215: 45-55.
Elder, G.H., and Worwood, M. 1998. Mutations in the hemochromatosis gene, porphyria
cutanea tarda, and iron overload. Hepatology 27: 289-291.
Erskine, P.T., Coates, L., Butler, D., Youell, J.H., Brindley, A.A., Wood, S.P., Warren,
M.J., Shoolingin-Jordan, P.M., and Cooper, J.B. 2003. X-ray structure of a
putative reaction intermediate of 5-aminolaevulinic acid dehydratase. Biochem. J.
373: 733-738.
Erskine, P.T., Coatesa, L., Newboldb, R., Brindleyb, A.A., Staufferc, F., Wooda, S.P.,
Warrenb, M.J., Coopera, J.B., Shoolingin-Jordana, P.M., and Neierc, R. 2001a.
The X-ray structure of yeast 5-aminolaevulinic acid dehydratase complexed with
two diacid inhibitors. FEBS Lett. 503: 196-200.
Erskine, P.T., L. Coates, R. Newbold, A. A. Brindley, F. Stauffer, G. D. E. Beaven, R.
Gill, A. Coker, S. P. Wood, M. J. Warren, et al. 2005. Structure of yeast 5aminolaevulinic acid dehydratase complexed with the inhibitor 5hydroxylaevulinic acid. Acta Cryst. 61: 1222-1226.

172

Erskine, P.T., Newbold, R., Brindley, A.A., Wood, S.P., Shoolingin-Jordan, P.M.,
Warren, M.J., and Cooper, J.B. 2001b. The X-ray structure of yeast 5aminolaevulinic acid dehydratase complexed with substrate and three inhibitors.
J. Mol. Biol. 312: 133-141.
Erskine, P.T., Norton, E., Cooper, J.B., Lambert, R., Coker, A., Lewis, G., Spencer, P.,
Sarwar, M., Wood, S.P., Warren, M.J., et al. 1999. X-ray structure of 5aminolevulinic acid dehydratase from Escherichia coli complexed with the
inhibitor levulinic acid at 2.0 A resolution. Biochemistry 38: 4266-4276.
Erskine, P.T., Senior, N., Awan, S., Lambert, R., Lewis, G., Tickle, I.J., Sarwar, M.,
Spencer, P., Thomas, P., Warren, M.J., et al. 1997. X-ray structure of 5aminolaevulinate dehydratase, a hybrid aldolase. Nat. Struct. Biol. 4: 1025-1031.
Fanica-Gaignier, M., and Clement-Metral, J. 1973. 5-Aminolevulinic-acid synthetase of
Rhodopseudomonas spheroides Y. Kinetic mechanism and inhibition by ATP.
Eur. J. Biochem. 40: 19-24.
Feder, J.N., Gnirke, A., Thomas, W., Tsuchihashi, Z., Ruddy, D.A., Basava, A.,
Dormishian, F., Domingo, R., Ellis, M.C., Fullan, A., et al. 1996. A novel MHC
class I-like gene is mutated in patients with hereditary haemochromatosis. Nat.
Genet. 13: 399-408.
Felix, F., and Brouillet, N. 1990. Purification and properties of uroporphyrinogen
decarboxylase from Saccharomyces cerevisiae. Yeast uroporphyrinogen
decarboxylase. Eur. J. Biochem. 188: 393-403.
Ferreira, G.C. 1994. Mammalian ferrochelatase. Overexpression in Escherichia coli as a
soluble protein, purification and characterization. J. Biol. Chem. 269: 4396-4400.
Ferreira, G.C., Andrew, T.L., Karr, S.W., and Dailey, H.A. 1988. Organization of the
terminal two enzymes of the heme biosynthetic pathway. Orientation of
protoporphyrinogen oxidase and evidence for a membrane complex. J. Biol.
Chem. 263: 3835-3839.
Ferreira, G.C., and Dailey, H.A. 1993. Expression of mammalian 5-aminolevulinate
synthase in Escherichia coli. Overproduction, purification, and characterization.
J. Biol. Chem. 268: 584-590.
Ferreira, G.C., Franco, R., Lloyd, S.G., Pereira, A.S., Moura, I., Moura, J.J., and Huynh,
B.H. 1994. Mammalian ferrochelatase, a new addition to the metalloenzyme
family. J. Biol. Chem. 269: 7062-7065.
Ferreira, G.C., Franco, R., Mangravita, A., and George, G.N. 2002. Unraveling the
substrate-metal binding site of ferrochelatase: An X-ray absorption spectroscopic
study. Biochemistry 41: 4809-4818.
173

Ferreira, G.C., Neame, P.J., and Dailey, H.A. 1993. Heme biosynthesis in mammalian
systems: Evidence of a Schiff base linkage between the pyridoxal 5'-phosphate
cofactor and a lysine residue in 5-aminolevulinate synthase. Protein Sci. 2: 19591965.
Ferreira, G.C., Vajapey, U., Hafez, O., Hunter, G.A., and Barber, M.J. 1995.
Aminolevulinate synthase: Lysine 313 is not essential for binding the pyridoxal
phosphate cofactor but is essential for catalysis. Protein Sci 4: 1001-1006.
Ferris, C.D., Jaffrey, S.R., Sawa, A., Takahashi, M., Brady, S.D., Barrow, R.K., Tysoe,
S.A., Wolosker, H., Baranano, D.E., Dore, S., et al. 1999. Haem oxygenase-1
prevents cell death by regulating cellular iron. Nat. Cell Biol. 1: 152-157.
Floderus, Y., Shoolingin-Jordan, P.M., and Harper, P. 2002. Acute intermittent porphyria
in Sweden. Molecular, functional and clinical consequences of some new
mutations found in the porphobilinogen deaminase gene. Clin. Genet. 62: 288297.
Fodje, M.N., and Al-Karadaghi, S. 2002. Occurrence, conformational features and amino
acid propensities for the π-helix. Protein Eng. 15: 353-358.
Fontanellas, A., Bensidhoum, M., Enriquez de Salamanca, R., Moruno Tirado, A., de
Verneuil, H., and Ged, C. 1996. A systematic analysis of the mutations of the
uroporphyrinogen III synthase gene in congenital erythropoietic porphyria. Eur. J.
Hum. Genet. 4: 274-282.
Fontanellas, A., Frèdèric Mazurier, Marc Landry, Laurence Taine, Carine Morel,
Monique Larou, Jean-Yves Daniel, Xavier Montagutelli, Rafael Enriquez de
Salamanca, and de Verneuil, H. 2000. Reversion of hepatobiliary alterations by
bone marrow transplantation in a murine model of erythropoietic protoporphyria.
Hepatology 32: 73-81.
Fontanellas, A., Mendez M, Mazurier F, Cario-Andre M, Navarro S, Ged C, Taine L,
Geronimi F, Richard E, Moreau-Gaudry F, et al. 2001. Successful therapeutic
effect in a mouse model of erythropoietic protoporphyria by partial genetic
correction and fluorescence-based selection of hematopoietic cells. Gene Ther. 8:
618-626.
Franco, R., Ma, J.G., Lu, Y., Ferreira, G.C., and Shelnutt, J.A. 2000. Porphyrin
interactions with wild-type and mutant mouse ferrochelatase. Biochemistry 39:
2517-2529.
Franco, R., Moura, J.J.G., Moura, I., Lloyd, S.G., Huynh, B.H., Forbes, W.S., and
Ferreira, G.C. 1995. Characterization of the iron-binding site in mammalian
ferrochelatase by kinetic and Mössbauer methods. J. Biol. Chem. 270: 2635226357.
174

Franco, R., Pereira, A.S., Tavares, P., Mangravita, A., Barber, M.J., Moura, I., and
Ferreira, G.C. 2001. Substitution of murine ferrochelatase glutamate-287 with
glutamine or alanine leads to porphyrin substrate-bound variants. Biochem. J.
356: 217-222.
Frank, J., Jugert, F.K., Merk, H.F., Kalka, K., Goerz, G., Anderson, K., Bickers, D.R.,
Poh-Fitzpatrick, M.B., and Christiano, A.M. 2001. A spectrum of novel mutations
in the protoporphyrinogen oxidase gene in 13 families with variegate porphyria. J.
Invest. Derm. 116: 821-823.
Frankenberg, N., Erskine, P.T., Cooper, J.B., Shoolingin-Jordan, P.M., Jahn, D., and
Heinz, D.W. 1999. High resolution crystal structure of a Mg2+-dependent
porphobilinogen synthase. J. Mol. Biol. 289: 591-602.
Frankenberg, N., Moser, J., and Jahn, D. 2003. Bacterial heme biosynthesis and its
biotechnological application. Appl. Microbiol. Biotechnol. 63: 115-127.
Fraunberg, M., Nyronen, T., and Kauppinen, R. 2003. Mitochondrial targeting of normal
and mutant protoporphyrinogen oxidase. J. Biol. Chem. 278: 13376-13381.
Fraunberg, M., Pischik, E., Udd, L., and Kauppinen, R. 2005. Clinical and biochemical
characteristics and genotype-phenotype correlation in 143 Finnish and Russian
patients with acute intermittent porphyria. Medicine (Baltimore) 84: 35-47.
Fraunberg, M., Tenhunen, R., and Kauppinen, R. 2001. Expression and characterization
of six mutations in the protoporphyrinogen oxidase gene among Finnish variegate
porphyria patients. Mol. Med. 7: 320-328.
Fraunberg, M., Timonen, K., Mustajoki, P., and Kauppinen, R. 2002. Clinical and
biochemical characteristics and genotype-phenotype correlation in Finnish
variegate porphyria patients Eur. J. Hum. Genet. 10: 649-657.
Frere, F., Schubert, W.-D., Stauffer, F., Frankenberg, N., Neier, R., Jahn, D., and Heinz,
D.W. 2002. Structure of porphobilinogen synthase from Pseudomonas aeruginosa
in complex with 5-fluorolevulinic Acid suggests a double Schiff-base mechanism.
J. Mol. Biol. 320: 237-247.
Fritsch, C., Lang, K., von Schmiedeberg, S., Bolsen, K., Merk, H., Lehmann, P., and
Ruzicka, T. 1998. Porphyria cutanea tarda. Skin Pharmacol. Appl. Skin Physiol.
11: 321-335.
Fujita, H., Yamamoto, M., Yamagami, T., Hayashi, N., and Sassa, S. 1991.
Erythroleukemia differentiation. Distinctive responses of the erythroid-specific
and the nonspecific δ-aminolevulinate synthase mRNA. J. Biol. Chem. 266:
17494-17502.

175

Furukawa, T., Kohno, H., Tokunaga, R., and Taketani, S. 1995. Nitric oxide-mediated
inactivation of mammalian ferrochelatase in vivo and in vitro: possible
involvement of the iron-sulphur cluster of the enzyme. Biochem. J. 310: 533-538.
Gamble, J.T., Nakatsu, K., and Marks, G.S. 2003. Comparison of the formation of Nalkylprotoporphyrin IX after iteraction of porphyrinogenic xenobiotics with single
cDNA-expressed human P450 enzymes in microsomes prepared from
baculovirus-infected insect cells and human lymphoblastoid cell lines. Drug
Metab. Dispos. 31: 202-205.
Garey, J.R., Franklin, K.F., Brown, D.A., Harrison, L.M., Metcalf, K.M., and Kushner,
J.P. 1993. Analysis of uroporphyrinogen decarboxylase complementary DNAs in
sporadic porphyria cutanea tarda. Gastroenterology 105: 165-169.
Garey, J.R., Labbe-Bois, R., Chelstowska, A., Rytka, J., Harrison, L., Kushner, J., and
Labbe, P. 1992. Uroporphyrinogen decarboxylase in Saccharomyces cerevisiae.
HEM12 gene sequence and evidence for two conserved glycines essential for
enzymatic activity. Eur. J. Biochem. 205: 1011-1016.
Géronimi, F., Richard, E., Lamrissi-Garcia, I., Lalanne, M., Ged, C., Redonnet-Vernhet,
I., Moreau-Gaudry, F., and de Verneuil, H. 2003. Lentivirus-mediated gene
transfer of uroporphyrinogen III synthase fully corrects the porphyric phenotype
in human cells. J. Mol. Med. 81: 310-320.
Gibbs, P.N., Chaudhry, A.G., and Shoolingin-Jordan, P.M. 1985. Purification and
properties of 5-aminolaevulinate dehydratase from human erythrocytes. Biochem.
J. 230: 25-34.
Gibbs, P.N., and Shoolingin-Jordan, P.M. 1986. Identification of lysine at the active site
of human 5-aminolaevulinate dehydratase. Biochem. J. 236: 447-451.
Gibson, K.D., Laver, W.G., and Neuberger, A. 1958. Initial stages in the biosynthesis of
porphyrins. 2. The formation of delta-aminolaevulic acid from glycine and
succinyl-coenzyme A by particles from chicken erythrocytes. Biochem. J. 70: 7181.
Gilles-Gonzalez, M.-A., and Gonzalez, G. 2005. Heme-based sensors: defining
characteristics, recent developments, and regulatory hypotheses. J. Inorg.
Biochem. 99: 1-22.
Goldberg, A., Ashenbrucker, H., Cartwright, G.E., and Wintrobe, M.M. 1956. Studies on
the biosynthesis of heme in vitro by avian erythrocytes. Blood 11: 821-833.
Gollub, E.G., Liu, K.P., Dayan, J., Adlersberg, M., and Sprinson, D.B. 1977. Yeast
mutants deficient in heme biosynthesis and a heme mutant additionally blocked in
cyclization of 2,3-oxidosqualene. J. Biol. Chem. 252: 2846-2854.
176

Gong, J., and Ferreira, G.C. 1995. Aminolevulinate synthase: functionally important
residues at a glycine loop, a putative pyridoxal phosphate cofactor-binding site.
Biochemistry 34: 1678-1685.
Gong, J., Hunter, G.A., and Ferreira, G.C. 1998. Aspartate-279 in aminolevulinate
synthase affects enzyme catalysis through enhancing the function of the pyridoxal
5'-phosphate cofactor. Biochemistry 37: 3509 -3517.
Gong, J., Kay, C.J., Barber, M.J., and Ferreira, G.C. 1996. Mutations at a glycine loop in
aminolevulinate synthase affect pyridoxal phosphate cofactor binding and
catalysis. Biochemistry 35: 14109-14117.
Gora, M., Chacinska, A., Rytka, J., and Labbe-Bois, R. 1996a. Isolation and functional
characterization of mutant ferrochelatases in Saccharomyces cerevisiae.
Biochimie 78: 144-152.
Gora, M., Grzybowska, E., Rytka, J., and Labbe-Bois, R. 1996b. Probing the active-site
residues in Saccharomyces cerevisiae ferrochelatase by directed mutagenesis. J.
Biol. Chem. 271: 11810-11816.
Gouya, L., Deybach, J.C., Lamoril, J., Da Silva, V., Beaumont, C., Grandchamp, B., and
Nordmann, Y. 1996. Modulation of the phenotype in dominant erythropoietic
protoporphyria by a low expression of the normal ferrochelatase allele. Am. J.
Hum. Genet. 58: 292-299.
Gouya, L., Puy, H., Lamoril, J., Da Silva, V., Grandchamp, B., Nordmann, Y., and
Deybach, J.-C. 1999. Inheritance in erythropoietic protoporphyria: A common
wild-type ferrochelatase allelic variant with low expression accounts for clinical
manifestation. Blood 93: 2105-2110.
Gouya, L., Puy, H., Robreau, A.-M., Lyoumi, S., Lamoril, J., Silva, V., Grandchamp, B.,
and Deybach, J.-C. 2004. Modulation of penetrance by the wild-type allele in
dominantly inherited erythropoietic protoporphyria and acute hepatic porphyrias.
Hum. Genet. 114: 256-262.
Gouya, L., Puy, H., Robreau, A.M., Bourgeois, M., Lamoril, J., Da Silva, V.,
Grandchamp, B., and Deybach, J.C. 2002. The penetrance of dominant
erythropoietic protoporphyria is modulated by expression of wild-type FECH.
Nat. Genet. 30: 27-28.
Grandchamp, B., De Verneuil, H., Beaumont, C., Chretien, S., Walter, O., and
Nordmann, Y. 1987. Tissue-specific expression of porphobilinogen deaminase.
Two isoenzymes from a single gene. Eur. J. Biochem. 162: 105-110.
Grandchamp, B., Phung, N., and Nordmann, Y. 1978. The mitochondrial localization of
coproporphyrinogen III oxidase. Biochem. J. 176: 97-102.
177

Granick, S. 1966. The induction in vitro of the synthesis of delta-aminolevulinic acid
synthetase in chemical porphyria: A response to certain drugs, sex hormones and
foreign chemicals. J. Biol. Chem. 241: 1359-1375.
Gray, H.B., and Winkler, J.R. 2005. Long-range electron transfer. Proc. Natl. Acad. Sci.
102: 3534-3539.
Grishin, N.V., Phillips, M.A., and Goldsmith, E.J. 1995. Modeling of the spatial structure
of eukaryotic ornithine decarboxylases. Protein Sci. 4: 1291-1304.
Gross, U., Puy, H., Kuhnel, A., Meissauer, U., Deybach, J.C., Jacob, K., Martasek, P.,
Nordmann, Y., and Doss, M.O. 2002a. Molecular, immunological, enzymatic and
biochemical studies of coproporphyrinogen oxidase deficiency in a family with
hereditary coproporphyria. Cell Mol. Biol. (Noisy-le-grand) 48: 49-55.
Gross, U., Puy, H., Meissauer, U., Lamoril, J., Deybach, J.C., Doss, M., Nordmann, Y.,
and Doss, M.O. 2002b. A molecular, enzymatic and clinical study in a family
with hereditary coproporphyria. J. Inher. Metab. Disease 25: 279-286.
Handschin, C., Lin, J., Rhee, J., Peyer, A.K., Chin, S., Wu, P.H., Meyer, U.A., and
Spiegelman, B.M. 2005. Nutritional regulation of hepatic heme biosynthesis and
porphyria through PGC-1alpha. Cell 122: 505-515.
Hankeln, T., Ebner, B., Fuchs, C., Gerlach, F., Haberkamp, M., Laufs, T.L., Roesner, A.,
Schmidt, M., Weich, B., and Wystub, S. 2005. Neuroglobin and cytoglobin in
search of their role in the vertebrate globin family. J. Inorg. Biochem. 99: 110119.
Hansson, M., Gustafsson, M.C., Kannangara, C.G., and Hederstedt, L. 1997. Isolated
Bacillus subtilis HemY has coproporphyrinogen III to coproporphyrin III oxidase
activity. Biochim. Biophys. Acta. 1340: 97-104.
Hansson, M., and Hederstedt, L. 1992. Cloning and characterization of the Bacillus
subtilis HemEHY gene cluster, which encodes protoheme IX biosynthetic
enzymes. J. Bacteriol. 174: 8081-8093.
Hansson, M., and Hederstedt, L. 1994. Purification and characterisation of a watersoluble ferrochelatase from Bacillus subtilis. Eur. J. Biochem. 220: 201-208.
Harbin, B.M., and Dailey, H.A. 1985. Orientation of ferrochelatase in bovine liver
mitochondria. Biochemistry 24: 366-370.
Hardison, R.C. 1996. A brief history of hemoglobins: Plant, animal, protist, and bacteria.
Proc. Natl. Acad. Sci. 93: 5675-5679.

178

Harper, P., Floderus, Y., Holmstrom, P., Eggertsen, G., and Gafvels, M. 2004.
Enrichment of HFE mutations in Swedish patients with familial and sporadic
form of porphyria cutanea tarda. J. Intern. Med. 255: 684-688.
Hart, G.J., and Battersby, A.R. 1985. Purification and properties of uroporphyrinogen III
synthase (co-synthetase) from Euglena gracilis. Biochem. J. 232: 151-160.
Hart, G.J., Leeper, F.J., and Battersby, A.R. 1987. J. Chem. Soc. Chem. Commun.: 17621765.
Hart, G.J., Miller, A.D., and Battersby, A.R. 1988. Evidence that the pyrromethane
cofactor of hydroxymethylbilane synthase (porphobilinogen deaminase) is bound
through the sulphur atom of a cysteine residue. Biochem. J. 252: 909-912.
He, Y., Alam, S.L., Proteasa, S.V., Zhang, Y., Lesuisse, E., Dancis, A., and Stemmler,
T.L. 2004. Yeast frataxin solution structure, iron binding, and ferrochelatase
interaction. Biochemistry 43: 16254 -16262.
Helliwell, J.R., Nieh, Y.P., Habash, J., Faulder, P.F., Raftery, J., Cianci, M., Wulff, M.,
and Hadener, A. 2003. Time-resolved and static-ensemble structural chemistry of
hydroxymethylbilane synthase. Faraday Discuss. 122: 131-144; discuss. 171-190.
Hentze, M.W., Muckenthaler, M.U., and Andrews, N.C. 2004. Balancing acts: molecular
control of mammalian iron metabolism. Cell 117: 285-297.
Hift, R.J., Meissner, D., and Meissner, P.N. 2004. A systematic study of the clinical and
biochemical expression of variegate porphyria in a large South African family.
Br. J. Dermatol. 151: 465.
Hift, R.J., and Meissner, P.N. 2005. An analysis of 112 acute porphyric attacks in Cape
Town, South Africa: Evidence that acute intermittent porphyria and variegate
porphyria differ in susceptibility and severity. Medicine (Baltimore) 84: 48-60.
Higuchi, M., and Bogorad, L. 1975. The purification and properties of uroporphyrinogen
I synthases and uroporphyrinogen III cosynthase. Interactions between the
enzymes. Ann. N.Y. Acad. Sci. 244: 401-418.
Hornberger, U., Liebetanz, R., Tichy, H.V., and Drews, G. 1990. Cloning and sequencing
of the hemA gene of Rhodobacter capsulatus and isolation of a deltaaminolevulinic acid-dependent mutant strain. Mol. Gen. Genet. 221: 371-378.
Hu, S., Smith, K.M., and Spiro, T.G. 1996. Assignment of protoheme resonance Raman
spectrum by heme labeling in myoglobin. J. Am. Chem. Soc. 118: 12638 -12646.
Humphrey, W., Dalke, A., and Schulten, K. 1996. VMD - Visual Molecular Dynamics. J.
Mol. Graphics 14: 33-38.
179

Hunter, G.A., and Ferreira, G.C. 1999a. Lysine-313 of 5-aminolevulinate synthase acts as
a general base during formation of the quinonoid reaction intermediates.
Biochemistry 38: 3711-3718.
Hunter, G.A., and Ferreira, G.C. 1999b. Pre-steady-state reaction of 5-aminolevulinate
synthase. Evidence for a rate-determining product release. J. Biol. Chem. 274:
12222-12228.
Jackson, A.H., Ferramola, A.M., Sancovich, H.A., Evans, N., Matlin, S.A., Ryder, D.J.,
and Smith, S.G. 1976. Hepta- and hexa-carboxylic porphyrinogen intermediates
in haem biosynthesis. Ann. Clin. Res. 8: 64-69.
Jaffe, E.K. 1995. Porphobilinogen synthase, the first source of heme's asymmetry. J.
Bioenerg. Biomembr. 27: 169-179.
Jaffe, E.K. 2003. An unusual phylogenetic variation in the metal ion binding sites of
porphobilinogen synthase. Chem. Biol. 10: 25-34.
Jaffe, E.K. 2004a. The porphobilinogen synthase catalyzed reaction mechanism.
Bioorganic Chemistry 32: 316-325.
Jaffe, E.K. 2004b. The porphobilinogen synthase catalyzed reaction mechanism. Bioorg.
Chem. 32: 316-325.
Jaffe, E.K. 2005. Morpheeins - a new structural paradigm for allosteric regulation. Trends
Biochem. Sci. 30: 490-497.
Jaffe, E.K., and Hanes, D. 1986. Dissection of the early steps in the porphobilinogen
synthase catalyzed reaction. Requirements for Schiff's base formation. J. Biol.
Chem. 261: 9348-9353.
Jaffe, E.K., Martins, J., Li, J., Kervinen, J., and Dunbrack, R.L., Jr. 2001. The molecular
mechanism of lead inhibition of human porphobilinogen synthase. J. Biol. Chem.
276: 1531-1537.
Johansson, A., Nowak, G., Möller, C., Blomberg, P., and Harper, P. 2004. Adenoviralmediated expression of porphobilinogen deaminase in liver restores the metabolic
defect in a mouse model of acute intermittent porphyria. Mol. Ther. 10: 337-343.
John, R.A. 1995. Pyridoxal phosphate-dependent enzymes. Biochim. Biophys. Acta 1248:
81-96.
Johnson, A., and Jones, O.T.G. 1964. Enzymatic formation of haems and other
metalloporphyrins. Biochim. Biophys. Acta 93: 171-173.

180

Jones, M.S., and Jones, O.T.G. 1969. The structural organization of haem synthesis in rat
liver mitochondria. Biochem. J. 113: 507-514.
Jones, M.S., and Jones, O.T.G. 1970. Ferrochelatase of Rhodopseudomonas spheroides.
Biochem. J. 119: 453-462.
Jones, M.S., and Jones, O.T. 1968. Evidence for the location of ferrochelatase on the
inner membrane of rat liver mitochondria. Biochem. Biophys. Res. Commun. 31:
977-982.
Jones, R.M., and Jordan, P.M. 1993. Purification and properties of the uroporphyrinogen
decarboxylase from Rhodobacter sphaeroides. Biochem. J. 293: 703-712.
Jover, R., Hoffmann, F., Scheffler-Koch, V., and Lindberg, R.L.P. 2000. Limited heme
synthesis in porphobilinogen deaminase-deficient mice impairs transcriptional
activation of specific cytochrome P450 genes by phenobarbital. Eur. J. Biochem.
267: 7128-7137.
Juknat, A.A., Seubert, A., Seubert, S., and Ippen, H. 1989. Studies on uroporphyrinogen
decarboxylase of etiolated Euglena gracilis Z. Eur. J. Biochem. 179: 423-428.
Kalsbeck, W.A., Ghosh, A. Pandey, K.P., Smith, K.M., Bocian, D.F. 1995. Determinants
of the vinyl stretching frequency in protoporphyrins. Implications for cofactorprotein interactions in heme proteins. J. Am. Chem. Soc 117: 10959-10968.
Kannangara, C.G., Gough, S.P., Bruyant, P., Hoober, J.K., Kahn, A., and von Wettstein,
D. 1988. tRNAGlu as a cofactor in δ-aminolevulinate biosynthesis: steps that
regulate chlorophyll synthesis. Trends Biochem. Sci. 13: 139-143.
Kaplan, M., Hammerman, C., and Maisels, M.J. 2003. Bilirubin genetics for the
nongeneticist: Hereditary defects of neonatal bilirubin conjugation. Pediatrics
111: 886-893.
Karlberg, T., Lecerof, D., Gora, M., Silvegren, G., Labbe-Bois, R., Hansson, M., and AlKaradaghi, S. 2002. Metal binding to Saccaromyces cerevisiae ferrochelatase.
Biochemistry 41: 13499 -13506.
Karr, S.R., and Dailey, H.A. 1988. The synthesis of murine ferrochelatase in vitro and in
vivo. Biochem. J. 254: 799-803.
Kauppinen, R. 2005. Porphyrias. The Lancet 365: 241-252.
Kawanishi, S., Seki, Y., and Sano, S. 1983. Uroporphyrinogen decarboxylase.
Purification, properties, and inhibition by polychlorinated biphenyl isomers. J.
Biol. Chem. 258: 4285-4292.

181

Kervinen, J., Jaffe, E.K., Stauffer, F., Neier, R., Wlodawer, A., and Zdanov, A. 2001.
Mechanistic basis for suicide inactivation of porphobilinogen synthase by 4,7dioxosebacic acid, an inhibitor that shows dramatic species selectivity.
Biochemistry 40: 8227-8236.
Kikuchi, G., and Hayashi, N. 1981. Regulation by heme of synthesis and intracellular
translocation of delta-aminolevulinate synthase in the liver. Mol. Cell. Biochem.
37: 27-41.
Klemm, D.J., and Barton, L.L. 1987. Purification and properties of protoporphyrinogen
oxidase from an anaerobic bacterium, Desulfovibrio gigas. J. Bacteriol. 169:
5209-5215.
Koch, M., Breithaupt, C., Kiefersauer, R., Freigang, J., Huber, R., and Messerschmidt, A.
2004. Crystal structure of protoporphyrinogen IX oxidase: a key enzyme in haem
and chlorophyll biosynthesis. EMBO J. 23: 1720-1728.
Kohno, H., Furukawa, T., Yoshinaga, T., Tokunaga, R., and Taketani, S. 1993.
Coproporphyrinogen oxidase. Purification, molecular cloning, and induction of
mRNA during erythroid differentiation. J. Biol. Chem. 268: 21359-21363.
Kohno, H., Okuda, M., Furukawa, T., Tokunaga, R., and Taketani, S. 1994. Site-directed
mutagenesis of human ferrochelatase: Identification of histidine-263 as a binding
site for metal ions. Biochim. Biophys. Acta 1209: 95-100.
Kruse, E., Mock, H.P., and Grimm, B. 1995. Coproporphyrinogen III oxidase from barley
and tobacco - sequence analysis and initial expression studies. Planta 196: 796803.
Kuhnel, A., Gross, U., and Doss, M.O. 2000. Hereditary coproporphyria in Germany:
clinical-biochemical studies in 53 patients. Clin. Biochem. 33: 465-473.
Kundrat, L., Martins, J., Stith, L., Dunbrack, R.L., Jr., and Jaffe, E.K. 2003. A structural
basis for half-of-the-sites metal binding revealed in Drosophila melanogaster
porphobilinogen synthase. J. Biol. Chem. 278: 31325-31330.
Kushner, J.P., Barbuto, A.J., and Lee, G.R. 1976. An inherited enzymatic defect in
porphyria cutanea tarda: decreased uroporphyrinogen decarboxylase activity. J.
Clin. Invest. 58: 1089-1097.
Kutty, R.K., and Maines, M.D. 1981. Purification and characterization of biliverdin
reductase from rat liver. J. Biol. Chem. 256: 3956-3962.
Labbe-Bois, R. 1990. The ferrochelatase from Saccharomyces cerevisiae. Sequence,
disruption, and expression of its structural gene Hem15. J. Biol. Chem. 265: 72787283.
182

Labbe, R.F., Hubbard, N., and Caughey, W.S. 1963. Porphyrin specificity of
ferro:protoporphyrin chelatase from rat liver. Biochemistry 2: 372-374.
Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of
bacteriophage T4. Nature 227: 680-685.
Lamoril, J., Martasek, P., Deybach, J.C., Da Silva, V., Grandchamp, B., and Nordmann,
Y. 1995. A molecular defect in coproporphyrinogen oxidase gene causing
harderoporphyria, a variant form of hereditary coproporphyria. Hum. Mol. Genet.
4: 275-278.
Lamoril, J., Puy, H., Gouya, L., Rosipal, R., Da Silva, V., Grandchamp, B., Foint, T.,
Bader-Meunier, B., Dommergues, J.P., Deybach, J.C., et al. 1998. Neonatal
Hemolytic Anemia Due to Inherited Harderoporphyria: Clinical Characteristics
and Molecular Basis. Blood 91: 1453-1457.
Lamoril, J., Puy, H., Whatley, S.D., Martin, C., Woolf, J.R., Da Silva, V., Deybach, J.C.,
and Elder, G.H. 2001. Characterization of mutations in the CPO gene in British
patients demonstrates absence of genotype-phenotype correlation and identifies
relationship between hereditary coproporphyria and harderoporphyria. Am. J.
Hum. Genet. 68: 1130-1138.
Lander, M., Pitt, A.R., Alefounder, P.R., Bardy, D., Abell, C., and Battersby, A.R. 1991.
Studies on the mechanism of hydroxymethylbilane synthase concerning the role
of arginine residues in substrate binding. Biochem. J. 275: 447-452.
Landis, D.M., and Loeb, L.A. 1998. Random sequence mutagenesis and resistance to 5fluorouridine in human thymidylate synthases. J. Biol. Chem. 273: 25809-25817.
Lange, H., Kispal, G., and Lill, R. 1999. Mechanism of iron transport to the site of heme
synthesis inside yeast mitochondria. J. Biol. Chem. 274: 18989-18996.
Lange, H., Muhlenhoff, U., Denzel, M., Kispal, G., and Lill, R. 2004. The heme synthesis
defect of mutants impaired in mitochondrial iron-sulfur protein biogenesis is
caused by reversible inhibition of ferrochelatase. J. Biol. Chem. 279: 2910129108.
Lash, T.D. 2005. The enigma of coproporphyrinogen oxidase: How does this unusual
enzyme carry out oxidative decarboxylations to afford vinyl groups? Bioorg. Med.
Chem. Lett. 15: 4506-4509.
Lavigne, J.A., Nakatsu, K., and Marks, G.S. 2002. Identification of human hepatic
cytochrome P450 sources of N-alkylprotoporphyrin IX after interaction with
porphyrinogenic xenobiotics, implications for detection of xenobiotic-induced
porphyria in humans. Drug Metab. Dispos. 30: 788-794.

183

Layer, G., Moser, J., Heinz, D.W., Jahn, D., and Schubert, W.-D. 2003. Crystal structure
of coproporphyrinogen III oxidase reveals cofactor geometry of radical SAM
enzymes. EMBO J. 22: 6214-6224.
Layer, G., Verfurth, K., Mahlitz, E., and Jahn, D. 2002. Oxygen-independent
coproporphyrinogen-III oxidase HemN from Escherichia coli. J. Biol. Chem. 277:
34136-34142.
Lecerof, D., Fodje, M., Hansson, A., Hansson, M., and Al-Karadaghi, S. 2000. Structural
and mechanistic basis of porphyrin metallation by ferrochelatase. J. Mol. Biol.
297: 221-232.
Lecerof, D., Fodje, M.N., Alvarez, L.R., Olsson, U., Hansson, A., Sigfridsson, E., Ryde,
U., Hansson , M., and Al-Karadaghi, S. 2003. Metal binding to Bacillus subtilis
ferrochelatase and interaction between metal sites. J. Biol. Inorg. Chem. 8: 452458.
Lee, D.-S., Flachsova, E., Bodnarova, M., Demeler, B., Martasek, P., and Raman, C.S.
2005. Structural basis of hereditary coproporphyria. Proc. Natl. Acad. Sci. 102:
14232-14237.
Lee, J., and Anvret, M. 1991. Identification of the most common mutation within the
porphobilinogen deaminase gene in Swedish patients with acute intermittent
porphyria. Proc. Natl. Acad. Sci. 88: 10912-10915.
Leeper, F.J. 1994. The evidence for a spirocyclic intermediate in the formation of
uroporphyrinogen III by cosynthase. In Ciba Found. Symp., pp. 111-123.
Lermontova, I., Kruse, E., Mock, H.-P., and Grimm, B. 1997. Cloning and
characterization of a plastidal and a mitochondrial isoform of tobacco
protoporphyrinogen IX oxidase. Proc. Natl. Acad. Sci. 94: 8895-8900.
Lesuisse, E., Santos, R., Matzanke, B.F., Knight, S.A.B., Camadro, J.-M., and Dancis, A.
2003. Iron use for haeme synthesis is under control of the yeast frataxin
homologue (Yfh1). Hum. Mol. Genet. 12: 879-889.
Lewis, S.D., Lucas, B.J., Brady, S.F., Sisko, J.T., Cutrona, K.J., Sanderson, P.E.,
Freidinger, R.M., Mao, S.S., Gardell, S.J., and Shafer, J.A. 1998. Characterization
of the two-step pathway for inhibition of thrombin by α-ketoamide transition state
analogs. J. Biol. Chem. 273: 4843-4854.
Li, X., and Nicholl, D. 2005. Development of PPO inhibitor-resistant cultures and crops.
Pest Manag. Sci. 61: 277-285.

184

Liang, J., Edelsbrunner, H., and Woodward, C. 1998. Anatomy of protein pockets and
cavities: Measurement of binding site geometry and implications for ligand
design. Protein Sci. 7: 1884-1897.
Lindberg, R.L.P., Martini, R., Baumgartner, M., Erne, B., Borg, J., Zielasek, J., Ricker,
K., Steck, A., Toyka, K.V., and Meyer, U.A. 1999. Motor neuropathy in
porphobilinogen deaminase–deficient mice imitates the peripheral neuropathy of
human acute porphyria. J. Clin. Invest. 103: 1127-1134.
Lloyd, S.G., Franco, R., Moura, J.J.G., Moura, I., Ferreira, G.C., and Huynh, B.H. 1996.
Functional necessity and physicochemical characteristics of the [2Fe-2S] cluster
in mammalian ferrochelatase. J. Am. Chem. Soc. 118: 9892 -9900.
Louie, G.V., Brownlie, P.D., Lambert, R., Cooper, J.B., Blundell, T.L., Wood, S.P.,
Malashkevich, V.N., Hädener, A., Warren, M.J., and Shoolingin-Jordan, P.M.
1996. The three-dimensional structure of Escherichia coli porphobilinogen
deaminase at 1.76-Å resolution. Proteins Struct. Funct. Genet. 25: 48-78.
Louie, G.V., Brownlie, P.D., Lambert, R., Cooper, J.B., Blundell, T.L., Wood, S.P.,
Warren, M.J., Woodcock, S.C., and Jordan, P.M. 1992. Structure of
porphobilinogen deaminase reveals a flexible multidomain polymerase with a
single catalytic site. Nature 359: 33-39.
Lu, Y., Sousa, A., Franco, R., Mangravita, A., Ferreira, G.C., Moura, I., and Shelnutt,
J.A. 2002. Binding of protoporphyrin IX and metal derivatives to the active site of
wild-type mouse ferrochelatase at low porphyrin-to-protein ratios. Biochemistry
41: 8253-8262.
Lundvall, O., and Weinfeld, A. 1968. Studies of the clinical and metabolic effects of
phlebotomy treatment in porphyria cutanea tarda. Acta Med. Scand. 184: 191-199.
Macieira, S., Martins, B.M., and Huber, R. 2003. Oxygen-dependent
coproporphyrinogen-III oxidase from Escherichia coli: one-step purification and
biochemical characterisation. FEMS Microbiol. Lett. 226: 31-37.
Magnus, I., Jarrett, A., Prankerd, T., and Rimington, C. 1961. Erythropoietic
protoporphyria: a new porphyria syndrome with solar urticaria due to
protoporphyrinaemia. Lancet 2: 448-451.
Maines, M.D., and Gibbs, P.E.M. 2005. 30 some years of heme oxygenase: From a
"molecular wrecking ball" to a "mesmerizing" trigger of cellular events. Biochem.
Biophys. Res. Comm. 338: 568-577.
Mallis, R.J., Brazin, K.N., Fulton, D.B., and Andreotti, A.H. 2002. Structural
characterization of a proline-driven conformational switch within the Itk SH2
domain. Nat. Struct. Biol. 9: 900-905.
185

Manelia, M.H., Corrigalla, A.V., Klumpb, H.H., Davidsa, L.M., Kirscha, R.E., and
Meissner, P.N. 2003. Kinetic and physical characterisation of recombinant wildtype and mutant human protoporphyrinogen oxidases. Biochim. Biophys. Acta
1650: 10-21.
Marks, G.S., McCluskey, S.A., Mackie, J.E., Riddick, D.S., and James, C.A. 1988.
Disruption of hepatic heme biosynthesis after interaction of xenobiotics with
cytochrome P-450. FASEB J. 2: 2774-2783.
Martasek, P. 1998. Hereditary coproporphyria. Semin. Liver Dis. 18: 25-32.
Martasek, P., Camadro, J.M., Delfau-Larue, M.-H., Dumas, J., Montagne, J.J., de
Verneuil, H., Labbe, P., and Grandchamp, B. 1994. Molecular cloning,
sequencing, and functional expression of a cDNA encoding human
coproporphyrinogen oxidase. Proc. Natl. Acad. Sci. 91: 3024-3028.
Martasek, P., Camadro, J.M., Raman, C.S., Lecomte, M.C., Le Caer, J.P., Demeler, B.,
Grandchamp, B., and Labbe, P. 1997. Human coproporphyrinogen oxidase.
Biochemical characterization of recombinant normal and R231W mutated
enzymes expressed in E. coli as soluble, catalytically active homodimers. Cell
Mol. Biol. (Noisy-le-grand) 43: 47-58.
Martins, B.M., Grimm, B., Mock, H.-P., Huber, R., and Messerschmidt, A. 2001. Crystal
structure and substrate binding modeling of the uroporphyrinogen-III
decarboxylase from Nicotiana tabacum. Implications for the catalytic mechanism.
J. Biol. Chem. 276: 44108-44116.
Maruno, M., Furuyama, K., Akagi, R., Horie, Y., Meguro, K., Garbaczewski, L.,
Chiorazzi, N., Doss, M.O., Hassoun, A., Mercelis, R., et al. 2001. Highly
heterogeneous nature of delta-aminolevulinate dehydratase (ALAD) deficiencies
in ALAD porphyria. Blood 97: 2972-2978.
Marzocchi, M.P., and Smulevich, G. 2003. Relationship between heme vinyl
conformation and the protein matrix in peroxidases. J. Raman Spectrosc. 34: 725–
736.
Mathews-Roth, M.M. 1993. Carotenoids in erythropoietic protoporphyria and other
photosensitivity diseases. Ann. N.Y. Acad. Sci. 691: 127-138.
Mathews-Roth, M.M. 1998. Treatment of the cutaneous porphyrias. Clin. Dermatol. 16:
295-298.
Mathews-Roth, M.M., and Rosner, B. 2002. Long-term treatment of erythropoietic
protoporphyria with cysteine. Photodermatol. Photoimmunol. Photomed. 18: 307309.

186

Mathews, M.A.A., Schubert, H.L., Whitby, F.G., Alexander, K.J., Schadick, K.,
Bergonia, H.A., Phillips, J.D., and Hill, C.P. 2001. Crystal structure of human
uroporphyrinogen III synthase. EMBO J. 20: 5832-5839.
Matringe, M., Camadro J.M., Labbe, P., and Scalla, R. 1989. Protoporphyrinogen oxidase
as a molecular target for diphenyl ether herbicides. Biochem. J. 260: 231-235.
Mauzerall, D., and Granick, S. 1958. Porphyrin biosynthesis in erythrocytes. III.
Uroporphyrinogen and its decarboxylase. J. Biol. Chem. 232: 1141-1162.
Medlock, A.E., and Dailey, H.A. 1996. Human coproporphyrinogen oxidase is not a
metalloprotein. J. Biol. Chem. 271: 32507-32510.
Medlock, A.E., and Dailey, H.A. 2000. Examination of the activity of carboxyl-terminal
chimeric constructs of human and yeast ferrochelatases. Biochemistry 39: 74617467.
Mehrany, K., Drage, L.A., Brandhagen, D.J., and Pittelkow, M.R. 2004. Association of
porphyria cutanea tarda with hereditary hemochromatosis. J. Am. Acad. Dermatol.
51: 205-211.
Meissner, P.N., Dailey, T.A., Hift, R.J., Ziman, M., Corrigall, A.V., Roberts, A.G.,
Meissner, D.M., Kirsch, R.E., and Dailey, H.A. 1996. A R59W mutation in
human protoporphyrinogen oxidase results in decreased enzyme activity and is
prevalent in South Africans with variegate porphyria. Nat. Genet. 13: 95-97.
Meissner, P.N., Day, R.S., Moore, M.R., Disler, P.B., and Harley, E. 1986.
Protoporphyrinogen oxidase and porphobilinogen deaminase in variegate
porphyria. Eur. J. Clin. Invest. 16: 257-261.
Melefors, O., Goossen, B., Johansson, H.E., Stripecke, R., Gray, N.K., and Hentze, M.W.
1993. Translational control of 5-aminolevulinate synthase mRNA by ironresponsive elements in erythroid cells. J. Biol. Chem. 268: 5974-5978.
Meyer, U.A., Strand, L.J., Doss, M., Rees, A.C., and Marver, H.S. 1972. Intermittent
acute porphyria--demonstration of a genetic defect in porphobilinogen
metabolism. N. Engl. J. Med. 286: 1277-1282.
Miller, A.D., Hart, G.J., Packman, L.C., and Battersby, A.R. 1988. Evidence that the
pyrromethane cofactor of hydroxymethylbilane synthase (porphobilinogen
deaminase) is bound to the protein through the sulphur atom of cysteine-242.
Biochem. J. 254: 915-918.

187

Miralem, T., Hu, Z., Torno, M.D., Lelli, K.M., and Maines, M.D. 2005. Small
interference RNA-mediated gene silencing of human biliverdin reductase, but not
that of heme oxygenase-1, attenuates arsenite-mediated induction of the
oxygenase and increases apoptosis in 293A kidney cells. J. Biol. Chem. 280:
17084-17092.
Mitchell, L.W., and Jaffe, E.K. 1993. Porphobilinogen synthase from Escherichia coli is
a Zn(II) metalloenzyme stimulated by Mg(II). Arch. Biochem. Biophys. 300: 169177.
Miyamoto, K., Nakahigashi, K., Nishimura, K., and Inokuchi, H. 1991. Isolation and
characterization of visible light-sensitive mutants of Escherichia coli K12. J. Mol.
Biol. 219: 393-398.
Mock, H.P., Trainotti, L., Kruse, E., and Grimm, B. 1995. Isolation, sequencing and
expression of cDNA sequences encoding uroporphyrinogen decarboxylase from
tobacco and barley. Plant Mol. Biol. 28: 245-256.
Morgan, R.R., Da Silva, V., Puy, H., Deybach, J.C., and Elder, G.H. 2002. Functional
studies of mutations in the human protoporphyrinogen oxidase gene in variegate
porphyria. Cell Mol. Biol. (Noisy-le-grand) 48: 79-82.
Morgan, R.R., Errington, R., and Elder, G.H. 2004. Identification of sequences required
for the import of human protoporphyrinogen oxidase to mitochondria. Biochem. J.
377: 281-287.
Morse, D., Sethi, J., and Choi, A.M. 2002. Carbon monoxide-dependent signaling. Crit.
Care Med. 30: S12-17.
Munakata, H., Sun, J.Y., Yoshida, K., Nakatani, T., Honda, E., Hayakawa, S., Furuyama,
K., and Hayashi, N. 2004. Role of the heme regulatory motif in the hememediated inhibition of mitochondrial import of 5-aminolevulinate synthase. J.
Biochem. (Tokyo) 136: 233-238.
Munakata, H., Yamagami, T., Nagai, T., Yamamoto, M., and Hayashi, N. 1993.
Purification and structure of rat erythroid-specific δ-aminolevulinate synthase. J.
Biochem. (Tokyo) 114: 103-111.
Munir, K.M., French, D.C., Dube, D.K., and Loeb, L.A. 1992. Permissible amino acid
substitutions within the putative nucleoside binding site of herpes simplex virus
type 1 encoded thymidine kinase established by random sequence mutagenesis. J.
Biol. Chem. 267: 6584-6589.
Najahi-Missaoui, W., and Dailey, H.A. 2005. Production and characterization of
erythropoietic protoporphyric heterodimeric ferrochelatases. Blood 106: 10981104.
188

Nakahashi, Y., Taketani, S., Okuda, M., Inoue, K., and Tokunaga, R. 1990. Molecular
cloning and sequence analysis of cDNA encoding human ferrochelatase.
Biochem. Biophys. Res. Commun. 173: 748-755.
Nakahigashi, K., Nishimura, K., Miyamoto, K., and Inokuchi, H. 1991. Photosensitivity
of a protoporphyrin-accumulating, light-sensitive mutant (visA) of Escherichia
coli K-12. Proc. Natl. Acad. Sci. 88: 10520-10524.
Nandi, D.L. 1978a. Delta-aminolevulinic acid synthase of Rhodopseudomonas
spheroides. Binding of pyridoxal phosphate to the enzyme. Arch. Biochem.
Biophys. 188: 266-271.
Nandi, D.L. 1978b. Mode of binding of pyridoxal phosphate to 5-aminolevulinate
synthase. Z. Naturforsch. 33: 1003-1005.
Nandi, D.L. 1978c. Studies on δ-aminolevulinic acid synthase of Rhodopseudomonas
spheroides. Reversibility of the reaction, kinetic, spectral, and other studies
related to the mechanism of action. J. Biol. Chem. 253: 8872-8877.
Nandi, D.L., Baker-Cohen, K.F., and Shemin, D. 1968. Delta-Aminolevulinic Acid
Dehydratase of Rhodopseudomonas spheroides. I. Isolation and properties. J.
Biol. Chem. 243: 1224-1230.
Nandi, D.L., and Shemin, D. 1977. Quaternary structure of delta-aminolevulinic acid
synthase from Rhodopseudomonas spheroides. J. Biol. Chem. 252: 2278-2280.
Napier, I., Ponka, P., and Richardson, D.R. 2005. Iron trafficking in the mitochondrion:
novel pathways revealed by disease. Blood 105: 1867-1874.
Narita, S., Tanaka, R., Ito, T., Okada, K., Taketani, S., and Inokuchi, H. 1996. Molecular
cloning and characterization of a cDNA that encodes protoporphyrinogen oxidase
of Arabidopsis thaliana. Gene 182: 169-175.
Navarro, S., del Hoyo, P., Campos, Y., Abitbol, M., Moran-Jimenez, M.-J., GarciaBravo, M., Ochoa, P., Grau, M., Montagutelli, X., Frank, J., et al. 2005. Increased
mitochondrial respiratory chain enzyme activities correlate with minor extent of
liver damage in mice suffering from erythropoietic protoporphyria. Exp.
Dermatol. 14: 26-33.
Nemeria, N., Yan, Y., Zhang, Z., Brown, A.M., Arjunan, P., Furey, W., Guest, J.R., and
Jordan, F. 2001. Inhibition of the Escherichia coli pyruvate dehydrogenase
complex E1 subunit and its tyrosine 177 variants by thiamin 2-thiazolone and
thiamin 2-thiothiazolone diphosphates. Evidence for reversible tight-binding
inhibition. J. Biol. Chem. 276: 45969-45978.

189

Neuberger, A., and Tait, G.H. 1964. Studies on the biosynthesis of porphyrin and
bacteriochlorophyll by Rhodopseudomonas spheroides. 5. Zinc-protoporphyrin
chelatase. Biochem. J. 90: 607-616.
Nishimura, K., Nakayashiki, T., and Inokuchi, H. 1993. Cloning and sequencing of the
hemE gene encoding uroporphyrinogen III decarboxylase (UPD) from
Escherichia coli K-12. Gene 133: 109-113.
Nishimura, K., Nakayashiki, T., and Inokuchi, H. 1995a. Cloning and identification of
the hemG gene encoding protoporphyrinogen oxidase (PPO) of Escherichia coli
K-12. DNA Res. 2: 1-8.
Nishimura, K., Taketani, S., and Inokuchi, H. 1995b. Cloning of a human cDNA for
protoporphyrinogen oxidase by complementation in vivo of a hemG mutant of
Escherichia coli. J. Biol. Chem. 270: 8076-8080.
Nordmann, Y., Grandchamp, B., de Verneuil, H., Phung, L., Cartigny, B., and Fontaine,
G. 1983. Harderoporphyria: a variant hereditary coproporphyria. J. Clin. Invest.
72: 1139-1149.
Nordmann, Y., and Puy, H. 2002. Human hereditary hepatic porphyrias. Clinica Chimica
Acta 325: 17-37.
Nordmann, Y., Puy, H., Da Silva, V., Simonin, S., Robreau, A.M., Bonaiti, C., Phung,
L.N., and Deybach, J.C. 1997. Acute intermittent porphyria: Prevalence of
mutations in the porphobilinogen deaminase gene in blood donors in France. J.
Intern. Med. 242: 213-217.
Norris, P.G., Nunn, A.V., Hawk, J.L., and Cox, T.M. 1990. Genetic heterogeneity in
erythropoietic protoporphyria: a study of the enzymatic defect in nine affected
families. J. Invest. Dermatol. 95: 260-263.
Nunn, A.V., Norris, P., Hawk, J.L., and Cox, T.M. 1988. Zinc chelatase in human
lymphocytes: detection of the enzymatic defect in erythropoietic protoporphyria.
Anal. Biochem. 174: 146-150.
Ohgari, Y., Sawamoto, M., Yamamoto, M., Kohno, H., and Taketani, S. 2005.
Ferrochelatase consisting of wild-type and mutated subunits from patients with a
dominant-inherited disease, erythropoietic protoporphyria, is an active but
unstable dimer. Hum. Mol. Genet. 14: 327-334.
Omata, Y., Sakamoto, H., Higashimoto, Y., Hayashi, S., and Noguchi, M. 2004.
Purification and characterization of human uroporphyrinogen III synthase
expressed in Escherichia coli. J. Biochem. (Tokyo) 136: 211-220.

190

Osborne, M.J., Schnell, J., Benkovic, S.J., Dyson, H.J., and Wright, P.E. 2001. Backbone
dynamics in dihydrofolate reductase complexes: role of loop flexibility in the
catalytic mechanism. Biochemistry 40: 9846-9859.
Otterbein, L.E., and Choi, A.M.K. 2000. Heme oxygenase: colors of defense against
cellular stress. Am. J. Physiol. Lung Cell. Mol. Physiol. 279: L1029-1037.
Park, S., Gakh, O., O'Neill, H.A., Mangravita, A., Nichol, H., Ferreira, G.C., and Isaya,
G. 2003. Yeast frataxin sequentially chaperones and stores iron by coupling
protein assembly with iron oxidation. J. Biol. Chem. 278: 31340-31351.
Parthasarathi, N., Hansen, C., Yamaguchi, S., Spiro, T.G. 1987. Metalloporphyrin core
size resonance Raman marker bands revisited: implications for the interpretation
of hemoglobin photoproduct Raman frequencies. J. Am. Chem. Soc. 109: 38653871.
Pawliuk, R., Bachelot, T., Wise, R.J., Mathews-Roth, M.M., and Leboulch, P. 1999.
Long-term cure of the photosensitivity of murine erythropoietic protoporphyria by
preselective gene therapy. Nat. Med. 5: 768-773.
Pawliuk, R., Tighe, R., Wise, R.J., Mathews-Roth, M.M., and Leboulch, P. 2005.
Prevention of murine erythropoietic protoporphyria-associated skin
photosensitivity and liver disease by dermal and hepatic ferrochelatase. J. Invest.
Dermatol. 124: 256-262.
Pesce, A., Bolognesi, M., Bocedi, A., Ascenzi, P., Dewilde, S., Moens, L., Hankeln, T.,
and Burmester, T. 2002. Neuroglobin and cytoglobin. Fresh blood for the
vertebrate globin family. EMBO Rep. 3: 1146-1151.
Phillips, J.D., Parker, T.L., Schubert, H.L., Whitby, F.G., Hill, C.P., and Kushner, J.P.
2001. Functional consequences of naturally occurring mutations in human
uroporphyrinogen decarboxylase. Blood 98: 3179-3185.
Phillips, J.D., Whitby, F.G., Kushner, J.P., and Hill, C.P. 1997. Characterization and
crystallization of human uroporphyrinogen decarboxylase. Protein Sci. 6: 13431346.
Phillips, J.D., Whitby, F.G., Kushner, J.P., and Hill, C.P. 2003. Structural basis for
tetrapyrrole coordination by uroporphyrinogen decarboxylase. EMBO J. 22:
6225-6233.
Phillips, J.D., Whitby, F.G., Warby, C.A., Labbe, P., Yang, C., Pflugrath, J.W., Ferrara,
J.D., Robinson, H., Kushner, J.P., and Hill, C.P. 2004. Crystal structure of the
oxygen-dependant coproporphyrinogen oxidase (hem13p) of Saccharomyces
cerevisiae. J. Biol. Chem. 279: 38960-38968.

191

Pischik, E., Mehtälä, S., and Kauppinen, R. 2005. Nine mutations including three novel
mutations among Russian patients with acute intermittent porphyria. Hum. Mut.
26: 496.
Podvinec, M., Handschin, C., Looser, R., and Meyer, U.A. 2004. Identification of the
xenosensors regulating human 5-aminolevulinate synthase. Proc. Natl. Acad. Sci.
101: 9127-9132.
Pompliano, D.L., Peyman, A., and Knowles, J.R. 1990. Stabilization of a reaction
intermediate as a catalytic device: definition of the functional role of the flexible
loop in triosephosphate isomerase. Biochemistry 29: 3186-3194.
Ponka, P. 1997. Tissue-specific regulation of iron metabolism and heme synthesis:
distinct control mechanisms in erythroid cells. Blood 89: 1-25.
Ponka, P. 1999. Cell biology of heme. Am. J. Med. Sci. 318: 241.
Porra, R.J., and Falk, J.E. 1964. The enzymic conversion of coproporphyrinogen III into
protoporphyrin IX. Biochem J 90: 69-75.
Porra, R.J., and Jones, O.T.G. 1963a. Studies on ferrochelatase. 1. Assay and properties
of ferrochelatase from a pig liver mitochondrial extract. Biochem. J. 87: 181-185.
Porra, R.J., and Jones, O.T.G. 1963b. Studies on ferrochelatase. 2. An investigation of the
role of ferrochelatase in the biosynthesis of various haem prosthetic groups.
Biochem. J. 87: 186-192.
Porra, R.J., and Ross, B.D. 1965. Haem synthase and cobalt porphyrin synthase in
various micro-organisms. Biochem. J. 94: 557-562.
Porra, R.J., Vitols, K.S., Labbe, R.F., and Newton, N.A. 1967. Studies on ferrochelatase.
The effects of thiols and other factors on the determination of activity. Biochem.
J. 104: 321-327.
Poss,

K.D., and Tonegawa, S. 1997. Heme oxygenase
mammalian iron reutilization. PNAS 94: 10919-10924.

1 is

required

for

Poulos, T.L. 2005. Structural biology of heme monooxygenases. Biochem. Biophys. Res.
Comm. 338: 337-345.
Prasad, A.R.K., and Dailey, H.A. 1995. Effect of cellular location on the function of
ferrochelatase. J. Biol. Chem. 270: 18198-18200.
Proulx, K.L., and Dailey, H.A. 1992. Characteristics of murine protoporphyrinogen
oxidase. Protein Sci. 1: 801-809.

192

Puy, H., Deybach, J.C., Lamoril, J., Robreau, A.M., Da Silva, V., Gouya, L.,
Grandchamp, B., and Nordmann, Y. 1997. Molecular epidemiology and diagnosis
of PBG deaminase gene defects in acute intermittent porphyria. Am. J. Hum.
Genet. 60: 1373-1383.
Raich, N., Romeo, P.H., Dubart, A., Beaupain, D., Cohen-Solal, M., and Goossens, M.
1986. Molecular cloning and complete primary sequence of human erythrocyte
porphobilinogen deaminase. Nucleic Acids Res. 14: 5955-5968.
Rich, P.R. 2003. The molecular machinery of Keilin's respiratory chain. Biochem. Soc.
Trans. 31: 1095-1105.
Richard, E., Robert, E., Cario-Andre, M., Ged, C., Geronimi, F., Gerson, S.L., de
Verneuil, H., and Moreau-Gaudry, F. 2004. Hematopoietic stem cell gene therapy
of murine protoporphyria by methylguanine-DNA-methyltransferase-mediated in
vivo drug selection. Gene Ther. 11: 1638-1647.
Riddle, R.D., Yamamoto, M., and Engel, J.D. 1989. Expression of δ-aminolevulinate
synthase in avian cells: separate genes encode erythroid-specific and nonspecific
isozymes. Proc. Natl. Acad. Sci. 86: 792-796.
Risheg, H., Chen, F.-P., and Bloomer, J.R. 2003. Genotypic determinants of phenotype in
North American patients with erythropoietic protoporphyria. Mol. Genet. Metab.
80: 196-206.
Roberts, A.G., Whatley, S.D., Nicklin, M., Worwood, J.J., Pointon, C.S., and Elder, G.H.
1997. The frequency of hemochromatosis-associated alleles is increased in British
patients with sporadic porphyria cutanea tarda. Hepatology 25: 159-161.
Rodgers, K.R. 1999. Heme-based sensors in biological systems. Curr. Opion.Chem. Biol.
3: 158-167.
Romeo, G., and Levin, E.Y. 1969. Uroporphyrinogen III cosynthetase in human
congenital erythropoietic porphyria. Proc. Natl. Acad. Sci. 63: 856-863.
Romeo, G., and Levin, E.Y. 1971. Uroporphyrinogen decarboxylase from mouse spleen.
Biochim. Biophys. Acta 230: 330-341.
Romeo, P.H., Raich, N., Dubart, A., Beaupain, D., Pryor, M., Kushner, J., Cohen-Solal,
M., and Goossens, M. 1986. Molecular cloning and nucleotide sequence of a
complete human uroporphyrinogen decarboxylase cDNA. J. Biol. Chem. 261:
9825-9831.

193

Rosipal, R., Lamoril, J., Puy, H., Da Silva, V., Gouya, L., De Rooij, F.W., Te Velde, K.,
Nordmann, Y., Martàsek, P., and Deybach, J.-C. 1999. Systematic analysis of
coproporphyrinogen oxidase gene defects in hereditary coproporphyria and
mutation update. Hum. Mut. 13: 44-53.
Rufenacht, U.B., Gouya, L., Schneider-Yin, X., Puy, H., Schafer, B.W., Aquaron, R.,
Nordmann, Y., Minder, E.I., and Deybach, J.C. 1998. Systematic analysis of
molecular defects in the ferrochelatase gene from patients with erythropoietic
protoporphyria. Am. J. Hum. Genet. 62: 1341-1352.
Rufenacht, U.B., Gregor, A., Gouya, L., Tarczynska-Nosal, S., Schneider-Yin, X., and
Deybach, J.-C. 2001. New missense mutation in the human ferrochelatase gene in
a family with erythropoietic protoporphyria: Functional studies and correlation of
genotype and phenotype. Clin. Chem. 47: 1112-1113.
Sadlon, T.J., Dell, rsquo, Oso, T., Surinya, K.H., and May, B.K. 1999. Regulation of
erythroid 5-aminolevulinate synthase expression during erythropoiesis. Int. J.
Biochem. Cell Biol. 31: 1153-1167.
Sams, H., Kiripolsky, M.G., Bhat, L., and Stricklin, G.P. 2004. Porphyria cutanea tarda,
hepatitis C, alcoholism, and hemochromatosis: a case report and review of the
literature. Cutis 73: 188-190.
Sano, S. 1966. 2,4-bis-beta-hydroxypropionic acid. Deuteroporphyrinogen IX, a possible
intermediate between coproporphyrinogen III and protoporphyrin IX. J. Biol.
Chem. 241: 5276-5283.
Sano, S., and Granick, S. 1961. Mitochondrial coproporphyrinogen oxidase and
protoporphyrin formation. J. Biol. Chem. 236: 1173-1180.
Sarkany, R.P.E. 2001. The management of porphyria cutanea tarda. Clin. Exp. Dermatol.
26: 225-232.
Sasarman, A., Letowski, J., Czaika, G., Ramirez, V., Nead, M.A., Jacobs, J.M., and
Morais, R. 1993. Nucleotide sequence of the hemG gene involved in the
protoporphyrinogen oxidase activity of Escherichia coli K12. Can. J. Microbiol.
39: 1155-1161.
Sazanovich, I.V., Galievsky, V.A., van Hoek, A., Schaafsma, T.J., Malinovskii, V.L.,
Holten, D., and Chirvony, V.S. 2001. Photophysical and structural properties of
saddle-shaped free base porphyrins: Evidence for an "orthogonal" dipole moment.
J. Phys. Chem. B. 105: 7818-7829.

194

Schmidt, A., Sivaraman, J., Li, Y., Larocque, R., Barbosa, J., Smith, C., Matte, A.,
Schrag, J.D., and Cygler, M. 2001. Three-dimensional structure of 2-amino-3ketobutyrate CoA ligase from Escherichia coli complexed with a PLP-substrate
intermediate: inferred reaction mechanism. Biochemistry 40: 5151-5160.
Schmitt, C., Gouya, L., Malonova, E., Lamoril, J., Camadro, J.-M., Flamme, M., Rose,
C., Lyoumi, S., Da Silva, V., Boileau, C., et al. 2005. Mutations in human CPO
gene predict clinical expression of either hepatic hereditary coproporphyria or
erythropoietic harderoporphyria. Hum. Mol. Genet. 14: 3089-3098.
Schmitt, M.P. 1997. Utilization of host iron sources by Corynebacterium diphtheriae:
identification of a gene whose product is homologous to eukaryotic heme
oxygenases and is required for acquisition of iron from heme and hemoglobin. J.
Bacteriol. 179: 838-845.
Schneider-Yin, X., Bogard, C., Rüfenacht, U.B., Puy, H., Nordmann, Y., Minder, E.I.,
and Deybach, J.-C. 2000a. Identification of a prevalent nonsense mutation
(W283X) and two novel mutations in the porphobilinogen deaminase gene of
Swiss patients with acute intermittent porphyria. Hum. Hered. 50: 247-250.
Schneider-Yin, X., Gouya, L., Dorsey, M., Rufenacht, U., Deybach, J.-C., and Ferreira,
G.C. 2000b. Mutations in the iron-sulfur cluster ligands of the human
ferrochelatase lead to erythropoietic protoporphyria. Blood 96: 1545-1549.
Schneider-Yin, X., Gouya, L., Meier-Weinand, A., Deybach, J.-C., and Minder, E.I.
2000c. New insights into the pathogenesis of erythropoietic protoporphyria and
their impact on patient care. Eur. J. Pediatr. 159: 719-725.
Schneider-Yin, X., Hergersberg, M., Goldgar, D.E., Rufenacht, U.B., Schuurmans, M.M.,
Puy, H., Deybach, J.C., and Minder, E.I. 2002. Ancestral founder of mutation
W283X in the porphobilinogen deaminase gene among acute intermittent
porphyria patients. Hum. Hered. 54: 69-81.
Schoenfeld, R.A., Napoli, E., Wong, A., Zhan, S., Morin, D., Buckpitt, A.R., Taroni, F.,
Lonnerdal, B., Ristow, M., Puccio, H., et al. 2005. Frataxin deficiency alters heme
pathway transcripts and decreases mitochondrial heme metabolites in mammalian
cells. Hum. Mol. Genet.: Epub ahead of print.
Scholnick, P.L., Hammaker, L.E., and Marver, H.S. 1972. Soluble delta-aminolevulinic
acid synthetase of rat liver. II. Studies related to the mechanism of enzyme action
and hemin inhibition. J. Biol. Chem. 247: 4132-4137.
Schubert, H.L., Raux, E., Matthews, M.A., Phillips, J.D., Wilson, K.S., Hill, C.P., and
Warren, M.J. 2002. Structural diversity in metal ion chelation and the structure of
uroporphyrinogen III synthase. Biochem. Soc. Trans. 30: 595-600.

195

Schwartz, C.J., Djaman, O., Imlay, J.A., and Kiley, P.J. 2000. The cysteine desulfurase,
IscS, has a major role in in vivo Fe-S cluster formation in Escherichia coli. Proc.
Natl. Acad. Sci. 97: 9009-9014.
Sedlak, T.W., and Snyder, S.H. 2004. Bilirubin benefits: Cellular protection by a
biliverdin reductase antioxidant cycle. Pediatrics 113: 1776-1782.
Seehra, J.S., Jordan, P.M., and Akhtar, M. 1983. Anaerobic and aerobic
coproporphyrinogen III oxidases of Rhodopseudomonas spheroides. Mechanism
and stereochemistry of vinyl group formation. Biochem. J. 209: 709-718.
Segel, I.H. 1975. In Enzyme kinetics: behavior and analysis of rapid equilibrium and
steady state enzyme systems, pp. 564-565. John Wiley, New York.
Sellers, V.M., and Dailey, H.A. 1997. Expression, purification, and characterization of
recombinant mammalian ferrochelatase. Methods Enzymol. 281: 378-387.
Sellers, V.M., Dailey, T.A., and Dailey, H.A. 1998a. Examination of ferrochelatase
mutations that cause erythropoietic protoporphyria. Blood 91: 3980-3985.
Sellers, V.M., Johnson, M.K., and Dailey, H.A. 1996. Function of the [2Fe-2S] cluster in
mammalian ferrochelatase: A possible role as a nitric oxide sensor. Biochemistry
35: 2699-2704.
Sellers, V.M., Wang, K.-F., Johnson, M.K., and Dailey, H.A. 1998b. Evidence that the
fourth ligand to the [2Fe-2S] cluster in animal ferrochelatase is a cysteine.
Characterization of the enzyme from Drosophila melanogaster. J. Biol. Chem.
273: 22311-22316.
Sellers, V.M., Wu, C.K., Dailey, T.A., and Dailey, H.A. 2001. Human ferrochelatase:
characterization of substrate-iron binding and proton-abstracting residues.
Biochemistry 40: 9821-9827.
Shady, A.A., Colby, B.R., Cunha, L.F., Astrin, K.H., Bishop, D.F., and Desnick, R.J.
2002. Congenital erythropoietic porphyria: identification and expression of eight
novel mutations in the uroporphyrinogen III synthase gene. Br. J. Haematol. 117:
980-987.
Shemin, D., and Kikuchi, G. 1958. Enzymatic synthesis of sigma-aminolevulinic acid.
Ann. NY Acad. Sci. 75.
Shemin, D., and Russell, C.S. 1953. Delta-amminolevulinic acid, its role in the
biosynthesis of porphyrins and purines. J. Am. Chem. Soc. 75: 4873-4874.

196

Shi, Z., and Ferreira, G.C. 2003. A continuous anaerobic fluorimetric assay for
ferrochelatase by monitoring porphyrin disappearance. Anal. Biochem. 318: 1824.
Shi, Z., and Ferreira, G.C. 2004. Probing the active site loop motif of murine
ferrochelatase by random mutagenesis. J. Biol. Chem. 279: 19977-19986.
Shin, D.H., Roberts, A., Jancarik, J., Yokota, H., Kim, R., Wemmer, D.E., and Kim, S.H. 2003. Crystal structure of a phosphatase with a unique substrate binding
domain from Thermotoga maritima. Protein Sci. 12: 1464-1472.
Shipovskov, S., Karlberg, T., Fodje, M., Hansson, M.D., Ferreira, G.C., Hansson, M.,
Reimann, C.T., and Al-Karadaghi, S. 2005. Metallation of the transition-state
inhibitor N-methyl mesoporphyrin by ferrochelatase: Implications for the catalytic
reaction mechanism. J. Mol. Biol. 352: 1081-1090.
Shoolingin-Jordan, P.M. 1991. Biosynthesis of Tetrapyrroles. Elsevier, New York.
Shoolingin-Jordan, P.M., Al-Abass, A., McNeill, L.A., Sarwar, M., and Butler, D. 2003a.
Human porphobilinogen deaminase mutations in the investigation of the
mechanism of dipyrromethane cofactor assembly and tetrapyrrole formation.
Biochem. Soc. Trans. 31: 731-735.
Shoolingin-Jordan, P.M., Al-Daihan, S., Alexeev, D., Baxter, R.L., Bottomley, S.S.,
Kahari, I.D., Roy, I., Sarwar, M., Sawyer, L., and Wang, S.F. 2003b. 5Aminolevulinic acid synthase: mechanism, mutations and medicine. Biochim.
Biophys. Acta 1647: 361-366.
Shoolingin-Jordan, P.M., Burton, G., Nordlöv, H., Schneider, M.M., Pryde, L., and Scott,
A.I. 1979. Pre-uroporphyrinogen: a substrate for uroporphyrinogen III cosynthase.
J. Chem. Soc. Chem. Comm.: 204-205.
Shoolingin-Jordan, P.M., and Gibbs, P.N. 1985. Mechanism of action of 5aminolaevulinate dehydratase from human erythrocytes. Biochem. J. 227: 10151020.
Shoolingin-Jordan, P.M., Mgbeje, B.I., Thomas, S.D., and Alwan, A.F. 1988. Nucleotide
sequence for the hemD gene of Escherichia coli encoding uroporphyrinogen III
synthase and initial evidence for a hem operon. Biochem. J. 249: 613-616.
Shoolingin-Jordan, P.M., and Warren, M.J. 1987. Evidence for a dipyrromethane cofactor
at the catalytic site of E. coli porphobilinogen deaminase. FEBS Lett. 225: 87-92.

197

Shoolingin-Jordan, P.M., and Woodcock, S.C. 1991. Mutagenesis of arginine residues in
the catalytic cleft of Escherichia coli porphobilinogen deaminase that affects
dipyrromethane cofactor assembly and tetrapyrrole chain initiation and
elongation. Biochem. J. 280: 445-449.
Sigfridsson, E., and Ryde, U. 2003. The importance of porphyrin distortions for the
ferrochelatase reaction. J. Biol. Inorg. Chem. 8: 272-282.
Simons, T.J.B. 1995. The affinity of human erythrocyte porphobilinogen synthase for Zn
and Pb. Eur. J. Biochem. 234: 178-183.
Smythe, E., and Williams, D.C. 1988. Rat liver uroporphyrinogen III synthase has similar
properties to the enzyme from Euglena gracilis, including absence of a
requirement for a reversibly bound cofactor for activity. Biochem. J. 253: 275279.
Solis, C., Martinez-Bermejo, A., Naidich, T.P., Kaufmann, W.E., Astrin, K.H., Bishop,
D.F., and Desnick, R.J. 2004. Acute intermittent porphyria: Studies of the severe
homozygous dominant disease provides insights into the neurologic attacks in
acute porphyrias. Arch. Neurol. 61: 1764-1770.
Soonawalla, Z.F., Orug, T., Badminton, M.N., Elder, P.G.H., Rhodes, J.M., Bramhall,
S.R., and Elias, E. 2004. Liver transplantation as a cure for acute intermittent
porphyria. Lancet 363: 705-706.
Spencer, P., and Shoolingin-Jordan, P.M. 1993. Purification and characterization of 5aminolaevulinic acid dehydratase from Escherichia coli and a study of the
reactive thiols at the metal-binding domain. Biochem. J. 290: 279-287.
Spencer, P., and Shoolingin-Jordan, P.M. 1995. Characterization of the two 5aminolaevulinic acid binding sites, the A- and P-sites, of 5-aminolaevulinic acid
dehydratase from Escherichia coli. Biochem. J. 305: 151-158.
Srivastava, G., Borthwick, I.A., Maguire, D.J., Elferink, C.J., Bawden, M.J., Mercer, J.F.,
and May, B.K. 1988. Regulation of 5-aminolevulinate synthase mRNA in
different rat tissues. J. Biol. Chem. 263: 5202-5209.
Stark, W.M., Hart, G.J., and Battersby, A.R. 1986. Synthetic studies on the proposed
spiro intermediate for biosynthesis of the natural porphyrins: Inhibition of
cosynthetase. J. Chem. Soc. Chem. Comm. 6: 465-467.
Stojeba, N., Carole, M., Jeanpierre, C., Perrot, F., Hirth, C., Pottecher, T., and Deybach,
J.-C. 2004. Recovery from a variegate porphyria by a liver transplantation. Liver
Transplant. 10: 935-938.

198

Straka, J.G., Bloomer, J.R., and Kempner, E.S. 1991. The functional size of
ferrochelatase determined in situ by radiation inactivation. J. Biol. Chem. 266:
24637-24641.
Straka, J.G., and Kushner, J.P. 1983. Purification and characterization of bovine hepatic
uroporphyrinogen decarboxylase. Biochemistry 22: 4664-4672.
Susa, S., Daimon, M., Ono, H., Li, S., Yoshida, T., and Kato, T. 2003. The long, but not
the short, presequence of human coproporphyrinogen oxidase is essential for its
import and sorting to mitochondria. Tohoku J. Exp. Med. 200: 39-45.
Tait, G.H. 1973. Aminolaevulinate synthetase of Micrococcus denitrificans. Purification
and properties of the enzyme, and the effect of growth conditions on the enzyme
activity in cells. Biochem. J. 131: 389-403.
Taketani, S. 2005. Acquisition, mobilization and utilization of cellular iron and heme:
endless findings and growing evidence of tight regulation. Tohoku J. Exp. Med.
205: 297-318.
Taketani, S., Kakimoto, K., Ueta, H., Masaki, R., and Furukawa, T. 2003. Involvement of
ABC7 in the biosynthesis of heme in erythroid cells: interaction of ABC7 with
ferrochelatase. Blood 101: 3274-3280.
Taketani, S., Nakahashi, Y., Osumi, T., and Tokunaga, R. 1990. Molecular cloning,
sequencing, and expression of mouse ferrochelatase. J. Biol. Chem. 265: 1937719380.
Taketani, S., Tanaka-Yoshioka, A., Masaki, R., Tashiro, Y., and Tokunaga, R. 1986.
Association of ferrochelatase with Complex I in bovine heart mitochondria.
Biochim. Biophys. Acta 883: 277-283.
Taketani, S., and Tokunaga, R. 1981. Rat liver ferrochelatase. Purification, properties,
and stimulation by fatty acids. J. Biol. Chem. 256: 12748-12753.
Taketani, S., and Tokunaga, R. 1982. Purification and substrate specificity of bovine
liver-ferrochelatase. Eur. J. Biochem 127: 443-447.
Tan, D., Harrison, T., Hunter, G.A., and Ferreira, G.C. 1998. Role of arginine 439 in
substrate binding of 5-aminolevulinate synthase. Biochemistry 37: 1478 -1484.
Tang, X.D., Xu, R., Reynolds, M.F., Garcia, M.L., Heinemann, S.H., and Hoshi, T. 2003.
Haem can bind to and inhibit mammalian calcium-dependent Slo1 BK channels.
Nature 425: 531-535.

199

Tangeras, A. 1986. Effect of decreased ferrochelatase activity on iron and porphyrin
content in mitochondria of mice with porphyria induced by griseofulvin. Biochim.
Biophys. Acta 882: 77-85.
Tenhunen, R., Marver, H.S., and Schmid, R. 1969. Microsomal heme oxygenase.
Characterization of the enzyme. J. Biol. Chem. 244: 6388-6394.
Thompson, J.D., Higgins, D.G., and Gibson, T.J. 1994. CLUSTAL W: improving the
sensitivity of progressive multiple sequence alignment through sequence
weighting, position-specific gap penalties and weight matrix choice. Nucleic
Acids Res. 22: 4673-4680.
Thunell, S., and Harper, P. 2000. Porphyrins, porphyrin metabolism, porphyrias. III.
Diagnosis, care and monitoring in porphyria cutanea tarda--suggestions for a
handling programme. Scand. J. Clin. Lab. Invest. 60: 561-579.
Todd, D.J. 1994. Erythropoietic protoporphyria. Br. J. Dermatol. 131: 751-766.
Troup, B., Hungerer, C., and Jahn, D. 1995. Cloning and characterization of the
Escherichia
coli
hemN
gene
encoding
the
oxygen-independent
coproporphyrinogen III oxidase. J. Bacteriol. 177: 3326-3331.
Tsai, S.F., Bishop, D., and Desnick, R.J. 1987. Purification and properties of
uroporphyrinogen III synthase from human erythrocytes. J. Biol. Chem. 262:
1268-1273.
Tsai, S.F., Bishop, D.F., and Desnick, R.J. 1988. Human uroporphyrinogen III synthase:
molecular cloning, nucleotide sequence, and expression of a full-length cDNA.
Proc. Natl. Acad. Sci. 85: 7049-7053.
Tschudy, D.P., Valsamis, M., and Magnussen, C.R. 1975. Acute intermittent porphyria:
clinical and selected research aspects. Ann. Intern. Med. 83: 851-864.
Tukey, R.H., and Strassburg, C.P. 2000. Human UDP-Glucuronosyltransferases:
Metabolism, Expression, and Disease. Ann. Rev. Pharm. Toxicol. 40: 581-616.
Uchida, T., Sato, E., Sato, A., Sagami, I., Shimizu, T., and Kitagawa, T. 2005. COdependent activity-controlling mechanism of heme-containing CO-sensor protein,
neuronal PAS domain protein 2. J. Biol. Chem. 280: 21358-21368.
Ugulava, N.B., Gibney, B.R., and Jarrett, J.T. 2000. Iron-sulfur cluster interconversions
in biotin synthase: dissociation and reassociation of iron during conversion of
[2Fe-2S] to [4Fe-4S] clusters. Biochemistry 39: 5206-5214.

200

Ugulava, N.B., Sacanell, C.J., and Jarrett, J.T. 2001. Spectroscopic changes during a
single turnover of biotin synthase: destruction of a [2Fe-2S] cluster accompanies
sulfur insertion. Biochemistry 40: 8352-8358.
Urban-Grimal, D., Volland, C., Garnier, T., Dehoux, P., and Labbe-Bois, R. 1986. The
nucleotide sequence of the HEM1 gene and evidence for a precursor form of the
mitochondrial 5-aminolevulinate synthase in Saccharomyces cerevisiae. Eur. J.
Biochem. 156: 511-519.
Venkateshrao, V., Yin, J., Jarzcki, A.A., Schultz, P.G., and Spiro, T.G. 2004. Porphyrin
distortion during affinity maturation of a ferrochelatase antibody, monitored by
resonance Raman spectroscopy. J. Am. Chem. Soc. 126: 16361-16367.
Volland, C., and Felix, F. 1984. Isolation and properties of 5-aminolevulinate synthase
from the yeast Saccharomyces cerevisiae. Eur. J. Biochem. 142: 551-557.
Volland, C., and Urban-Grimal, D. 1988. The presequence of yeast 5-aminolevulinate
synthase is not required for targeting to mitochondria. J. Biol. Chem. 263: 82948299.
Wang, K.-F., Dailey, T.A., and Dailey, H.A. 2001. Expression and characterization of the
terminal heme synthetic enzymes from the hyperthermophile Aquifex aeolicus.
FEMS Microbiol. Lett. 202: 115-119.
Warnick, G.R., and Burnham, B.F. 1971. Regulation of porphyrin biosynthesis.
Purification and characterization of delta-aminolevulinic acid synthase. J. Biol.
Chem. 246: 6880-6885.
Warren, M.J., Cooper, J.B., Wood, S.P., and Shoolingin-Jordan, P.M. 1998. Lead
poisoning, haem synthesis and 5-aminolaevulinic acid dehydratase. Trends
Biochem. Sci. 23: 217-221.
Warren, M.J., and Shoolingin-Jordan, P.M. 1988. Investigation into the nature of
substrate binding to the dipyrromethane cofactor of Escherichia coli
porphobilinogen deaminase. Biochemistry 27: 9020-9030.
Watanabe, N., Hayashi, N., and Kikuchi, G. 1983. Delta-Aminolevulinate synthase
isozymes in the liver and erythroid cells of chicken. Biochem. Biophys. Res.
Commun. 113: 377-383.
Weaver, T.M. 2000. The π−helix translates structure into function. Protein Sci. 9: 201206.
Wegele, R., Tasler, R., Zeng, Y., Rivera, M., and Frankenberg-Dinkel, N. 2004. The
heme oxygenase(s)-phytochrome system of Pseudomonas aeruginosa. J. Biol.
Chem. 279: 45791-45802.
201

Whatley, S.D., Mason, N.G., Khan, M., Zamiri, M., Badminton, M.N., Missaoui, W.N.,
Dailey, T.A., Dailey, H.A., Douglas, W.S., Wainwright, N.J., et al. 2004.
Autosomal recessive erythropoietic protoporphyria in the United Kingdom:
prevalence and relationship to liver disease. J. Med. Genet. 41: e105-.
Whatley, S.D., Puy, H., Morgan, R.R., Robreau, A.M., Roberts, A.G., Nordmann, Y.,
Elder, G.H., and Deybach, J.C. 1999. Variegate porphyria in Western Europe:
identification of PPOX gene mutations in 104 families, extent of allelic
heterogeneity, and absence of correlation between phenotype and type of
mutation. Am. J. Hum. Genet. 65: 984-994.
Whitby, F.G., Phillips, J.D., Kushner, J.P., and Hill1, C.P. 1998. Crystal structure of
human uroporphyrinogen decarboxylase. EMBO J. 17: 2463–2471.
Whiting, M.J., and Elliott, W.H. 1972. Purification and properties of solubilized
mitochondrial delta-aminolevulinic acid synthetase and comparison with the
cytosol enzyme. J. Biol. Chem. 247: 6818-6826.
Whiting, M.J., and Granick, S. 1976. Delta-Aminolevulinic acid synthase from chick
embryo liver mitochondria. I. Purification and some properties. J. Biol. Chem.
251: 1340-1346.
Williams, J.W., and Morrison, J.F. 1979. The kinetics of reversible tight-binding
inhibition. Methods Enzymol. 63: 437-467.
Wiman, Ã., Floderus, Y., and Harper, P. 2003a. Novel mutations and phenotypic effect of
the splice site modulator IVS3-48C in nine Swedish families with erythropoietic
protoporphyria. J. Hum. Genet. 48: 70-76.
Wiman, Ã., Harper, P., and Floderus, Y. 2003b. Nine novel mutations in the
protoporphyrinogen oxidase gene in Swedish families with variegate porphyria.
Clin. Genet. 64: 122-130.
Wingert, R.A., Galloway, J.L., Barut, B., Foott, H., Fraenkel, P., Axe, J.L., Weber, G.J.,
Dooley, K., Davidson, A.J., Schmidt, B., et al. 2005. Deficiency of glutaredoxin 5
reveals Fe-S clusters are required for vertebrate haem synthesis. Nature 436:
1035-1039.
Wittenberg, J.B., and Wittenberg, B.A. 2003. Myoglobin function reassessed. J. Exp.
Biol. 206: 2011-2020.
Witty, M., Jones, R.M., Robb, M.S., Jordan, P.M., and Smith, A.G. 1996. Subcellular
location of the tetrapyrrole synthesis enzyme porphobilinogen deaminase in
higher plants: an immunological investigation. Planta 199: 557-564.

202

Woodcock, S.C., and Jordan, P.M. 1994. Evidence for participation of aspartate-84 as a
catalytic group at the active site of porphobilinogen deaminase obtained by sitedirected mutagenesis of the hemC gene from Escherichia coli. Biochemistry 33:
2688-2695.
Wu, C.K., Dailey, H.A., Rose, J.P., Burden, A., Sellers, V.M., and Wang, B.C. 2001. The
2.0 Å structure of human ferrochelatase, the terminal enzyme of heme
biosynthesis. Nat. Struct. Biol. 8: 156-160.
Wu, W.H., Shemin, D., Richards, K.E., and Williams, R.C. 1974. The quaternary
structure of delta-aminolevulinic acid dehydratase from bovine liver. Proc. Natl.
Acad. Sci. 71: 1767-1770.
Wyckoff, E.E., Phillips, J.D., Sowa, A.M., Franklin, M.R., and Kushner, J.P. 1996.
Mutational analysis of human uroporphyrinogen decarboxylase. Biochim.
Biophys. Acta 1298: 294-304.
Xu, K., Delling, J., and Elliott, T. 1992. The genes required for heme synthesis in
Salmonella typhimurium include those encoding alternative functions for aerobic
and anaerobic coproporphyrinogen oxidation. J. Bacteriol. 174: 3953-3963.
Xu, W., Warner, C.A., and Desnick, R.J. 1995. Congenital erythropoietic porphyria:
identification and expression of 10 mutations in the uroporphyrinogen III synthase
gene. J. Clin. Invest. 95: 905-912.
Yamamoto, M., Fujita, H., Watanabe, N., Hayashi, N., and Kikuchi, G. 1986. An
immunochemical study of delta-aminolevulinate synthase and deltaaminolevulinate dehydratase in liver and erythroid cells of rat. Arch. Biochem.
Biophys. 245: 76-83.
Yin, J., Andryski, S.E., Beuscher IV, A.E., Stevens, R.C., and Schultz, P.G. 2003.
Structural evidence for substrate strain in antibody catalysis. Proc. Natl. Acad.
Sci. 100: 856-861.
Yoon, T., and Cowan, J.A. 2003. Iron-Sulfur cluster biosynthesis. Characterization of
frataxin as an iron donor for assembly of [2Fe-2S] clusters in ISU-type proteins.
J. Am. Chem. Soc. 125: 6078-6084.
Yoon, T., and Cowan, J.A. 2004. Frataxin-mediated Iron Delivery to Ferrochelatase in
the Final Step of Heme Biosynthesis. J. Biol. Chem. 279: 25943-25946.
Yoshinaga, T., and Sano, S. 1980. Coproporphyrinogen oxidase. I. Purification,
properties, and activation by phospholipids. J. Biol. Chem. 255: 4722-4726.

203

Zagorec, M., Buhler, J.M., Treich, I., Keng, T., Guarente, L., and Labbe-Bois, R. 1988.
Isolation, sequence, and regulation by oxygen of the yeast HEM13 gene coding
for coproporphyrinogen oxidase. J. Biol. Chem. 263: 9718-9724.
Zhang, L., and Guarente, L. 1995. Heme binds to a short sequence that serves a
regulatory function in diverse proteins. EMBO J. 14: 313-320.
Zhang, Y., Lyver, E.R., Knight, S.A.B., Lesuisse, E., and Dancis, A. 2005. Frataxin and
mitochondrial carrier proteins, Mrs3p and Mrs4p, cooperate in providing iron for
heme synthesis. J. Biol. Chem. 280: 19794-19807.
Zhou, S., Zong, Y., Ney, P.A., Nair, G., Stewart, C.F., and Sorrentino, B.P. 2005.
Increased expression of the Abcg2 transporter during erythroid maturation plays a
role in decreasing cellular protoporphyrin IX levels. Blood 105: 2571-2576.
Zhu, H., Bilgin, M., Bangham, R., Hall, D., Casamayor, A., Bertone, P., Lan, N., Jansen,
R., Bidlingmaier, S., Houfek, T., et al. 2001. Global analysis of protein activities
using proteome chips. Science 293: 2101-2105.
Zhu, W., Wilks, A., and Stojiljkovic, I. 2000. Degradation of heme in Gram-negative
bacteria: the product of the hemO gene of Neisseriae is a heme oxygenase. J.
Bacteriol. 182: 6783-6790.

204

Appendices

205

Appendix 1: The primary sequence of the mature form of wild-type murine
ferrochelatase. The porphyrin-binding loop motif is underlined.

TTKPQAQPERRKPKTGILMLNMGGPETLGEVQDFLQRLFLDRDLMTLPIQNKLAPFIAKR
RTPKIQEQYRRIGGGSPIKMWTSKQGEGMVKLLDELSPATAPHKYYIGFRYVHPLTEEAI
EEMERDGLERAIAFTQYPQYSCSTTGSSLNAIYRYYNEVGQKPTMKWSTIDRWPTHPLLI
QCFADHILKELNHFPEEKRSEVVILFSAHSLPMSVVNRGDPYPQEVGATVHKVMEKLGYP
NPYRLVWQSKVGPVPWLGPQTDEAIKGLCERGRKNILLVPIAFTSDHIETLYELDIEYSQ
VLAQKCGAENIRRAESLNGNPLFSKALADLVHSHIQSNKLCSTQLSLNCPLCVNPVCRKT
KSFFTSQQL
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